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Abstract 
 
This thesis consists of four chapters. The first contains a literature review of the 
isolation, previous total syntheses, biological activity and structure activity relationships 
of lactacystin and its analogues. Chapter two discusses our work towards the total 
synthesis of lactacystin and its analogues starting from three different amino acids. 
Chapter three contains the experimental details of our work, and the final chapter 
contains the details of our work on the biological testing of some of our advanced 
intermediates towards deoxylactacystin. 
 
Our synthetic approach towards lactacystin and its analogues starts from a simple amino 
acid derivative; using different amino acid derivatives as starting material, the C5 
position is easily altered. The starting material is then advanced to a suitable diester for 
Dieckmann cyclization to form the lactam core found in the natural product. 
 
The next key step in our approach follows Mander’s acylation protocol to form the C5 
quaternary centre using methyl cyanoformate to install a methyl ester group in a 
selective manner. This step results in the fully functionalized core of lactacystin. 
 
At this stage we had two possible routes. First, we investigated the reduction of the 
ketone at C6 followed by attempted decarboxylation at C7; this route ultimately proved 
unsuccessful. The second route inverted the reaction order; performing the 
decarboxylation at C7 first followed by attempts to reduce the ketone at C6. The 
reduction was unsuccessful and so a thiomethyl derivative was employed to allow the 
ketone to be successfully reduced followed by removal of the thiomethyl group using 
Raney nickel. 
 
Chapter four has been written as a stand-alone chapter. Four advanced intermediates 
towards deoxylactacystin were chosen to undergo biological testing. Compounds were 
tested for their anti-proliferative effects against the HL-60 cell line using an MTS assay 
and their ability to inhibit the chymotrypsin-like activity in the 20S proteasome. 
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1.0 Introduction  
 
Lactacystin 1 is a microbial metabolite first isolated by Ōmura et al. in 1991 from 
Streptomyces sp. OM-6519.1, 2 The microbial metabolites were screened to determine if 
they could induce differentiation of the Neuro 2A (mouse neuroblastoma) cell line. 
Lactacystin was found to induce neurite outgrowth and inhibit cell proliferation in the 
Neuro 2A cell line as well as inhibiting growth in the osteosarcoma cell line in humans.3 
Its effect on Neuro 2A cell lines was found to mimic the action of neurotrophic factors 
(NTF). NTFs are responsible for the maintenance and survival of nerve cells, without 
which the nervous system cannot function correctly, and nerve-related diseases such as 
Alzheimer’s and Parkinson’s can occur as a result. 
 
 
Figure 1. Lactacystin 
 
In 1994 Fenteany et al. studied the activity of lactacystin analogues to determine which 
structural features were essential for biological activity.3 They found that the activity 
could be greatly affected by the groups on the γ-lactam ring. The groups and 
stereochemistry at the C5, C6 and C7 positions including the configuration of the C9 
carbon are important. Modifications can result in partial or complete loss of activity. In 
contrast the N-acetyl-L-cysteine (NAC) moiety was found to play no part in the activity 
and this group could be changed with no effect on activity. It was also found that the 
inactive compounds do not compete with the action of lactacystin. They observed that 
the analogues that are most active in cell cycle progression and neurite outgrowth all 
have the potential to form β-lactones. 
 
Not long after, Schreiber4 carried out labeling studies to identify the specific cellular 
target of lactacystin. Tritium-labeled lactacystin was used and the 20S proteasome was 
identified as the target. The study tested a series of lactacystin analogues and found that 
1
2
N
H
3
45
6
OH
7
8
O 9
O
10
S
11
12
CO2H
NHAc
HO
1
	 	 Introduction		
	 2	
the key to activity was the electrophilic carbonyl group at the C4 position. The C4 
carbonyl group of the thioester in lactacystin and the β-lactone analogue were found to 
be the reactive electrophiles. Hydrolysis of the lactacystin thioester resulted in the 
corresponding acid, a compound which showed no biological activity. 
 
1.1 Mechanistic Studies into the Action of Lactacystin 
 
Dick et al. described the mechanism of proteasome inhibition by lactacystin.5 Following 
the discoveries by Fenteany and Schreiber,3, 4 they were able to show that lactacystin 
underwent hydrolysis in aqueous solution, at pH 8, to form NAC and the dihydroxy acid 
3 through the β-lactone intermediate 2. They discovered that proteasome inhibition is 
not caused by lactacystin but the β-lactone, also known as omuralide, exclusively. At 
pH 6.3, lactacystin is stable but also inactive as a proteasome inhibitor.  
 
Further in vitro studies showed that lactacystin itself cannot permeate through cell 
walls, but the β-lactone derivative can. The efficiency of lactacystin as a proteasome 
inhibitor is thus dependent on its ability to form the β-lactone 2. Once inside the cell the 
β-lactone can undergo several reactions, shown in Scheme 1.6 Hydrolysis can occur to 
form the inactive dihydroxy acid 3, it can react with glutathione (GSH) to form 
lactathione, which is analogous to lactacystin and can reform the β-lactone, and finally 
it can acylate the threonine residue in the proteasome, resulting in inhibition.  
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Scheme 1. Mechanism of action of lactacystin in cells.6 
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1.1.1 The 20S Proteasome 
 
Figure 2. The 20S proteasome. 
 
The 20S proteasome (Figure 2) was found to be the specific cellular target of 
lactacystin and its derivatives.4 Lactacystin was found to inhibit the trypsin-like 
(proteases that cleave peptide bonds in the position following a positively charged 
amino acid such as lysine), chymotrypsin-like (the hydrophobic nature of the S1 pocket 
makes it specific for medium to large hydrophobic residues) and peptidylglutamyl-
peptide hydrolysing (cleavage of peptide bonds in the position following acidic or 
branched-chain amino acids) activity in the enzyme complex.4 The trypsin- and 
chymotrypsin-like activity are both irreversibly inhibited by lactacystin. 
 
The 20S proteasome is a large (~700 kD) protein complex.7 It is cylindrical in shape 
with a hollow center. It is made up of a stack of 4 doughnut-shaped rings, each 
consisting of 7 protein subunits, stacked on top of each other. The two outer rings 
consist of α-type subunits while the inner rings contain β-type subunits. The 20S 
proteasome is capped by 19S proteasomes at either end to make up the whole 26S 
proteasome unit. A crystal structure of the 20S proteasome can be seen below (Figure 
3). 
 
 
 
Thr
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Figure 3. A crystal structure of the 20S proteasome.8 
 
The proteasome is essential in regulating many processes within the cell, including 
cellular function and homeostasis.9 The ubiquitin proteasome pathway (UPP, Figure 4) 
is responsible for the majority of intracellular protein degradation. This is important for 
cell growth and survival, for both healthy and tumour cells. 
 
There are two stages to the UPP. The first stage, ubiquitin tagging, occurs when the 
ubiquitin-activating enzyme E1 covalently binds ubiquitin; the ubiquitin is then 
transferred to the ubiquitin-conjugating enzyme E2. Finally, the E3 ubiquitin ligase 
transfers the ubiquitin to the target protein. The second stage, proteolytic degradation, 
occurs when the ubiquitin-tagged proteins are transported to the proteasome. 
Polyubiquitin chains are produced by conjugation of ubiquitin moieties and act as a 
signal to target the protein for degradation. Different polyubiquitin chain lengths result 
in different functions, one of which is protein degradation. The ubiquitin molecules are 
removed and the protein is fed into the proteasome where it is broken down into small 
peptide units. 
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Figure 4. The ubiquitin proteasome pathway.10  
 
Inhibition of the proteasome stops the process of protein degradation, thereby inducing 
apoptosis.9 If cancer cells can be specifically targeted for proteasome inhibition, these 
cells will undergo apoptosis leaving behind only healthy cells. Proteasome inhibition is 
a key strategy for anti-cancer therapy and is of great interest in current research. 
 
Lactacystin, or rather the β-lactone, acts by acylating the amino terminal threonine 
residue of one of the β-type protein subunits of the 20S proteasome.8 The hydroxyl 
group on the threonine attacks the carbonyl moiety of the lactone, resulting in ring 
opening and the formation of an ester linkage between the proteasome and lactacystin. 
Hydrogen bonding can also be observed between the hydroxyl group formed from the 
lactone ring opening and the amine of the threonine residue, Scheme 2. 
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Scheme 2. Deactivation of the 20S proteasome by acylation of a terminal threonine 
residue.8 
 
1.1.2 Structure Activity Relationship (SAR) Studies 
 
Although early work had touched on the importance of structure and stereochemistry in 
the biological activity of lactacystin, it was Corey who in 1999 completed the most 
comprehensive SAR study to date.11 
 
The relative stereochemistry at the C5 and C6 positions are important for the formation 
of the β-lactone. The C5 hydroxyisobutyl group and the stereochemistry of the hydroxyl 
group at the C9 position are important for binding in the hydrophobic pocket of the 
lactacystin-proteasome complex. This was shown using X-ray crystallography by Groll 
et al.7 As stated above, the NAC moiety is not important to the activity of lactacystin. 
  
In 1998 the Corey group designed a new enantioselective synthesis that would allow 
functionalization of an advanced intermediate enabling the generation of a variety of 
analogues.12 They first studied the effect of replacing the isopropyl moiety at C9 with 
other lipophilic groups, such as ethyl (Scheme 3) and propyl (Scheme 4), while leaving 
the hydroxyl group also at C9 in place.  
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Reagents and Conditions: a) 1. Vinylmagnesium bromide, TMSCl, THF, −40 °C; 2. TFA/H2O (4:1), 50 
°C, 4 h; b) LiOH, THF/H2O (1:1). 23 °C, 0.5 h; c) 1. BOPCl, Et3N, CH2Cl2, 23 °C, 0.5 h; 2. CAN, 
CH3CN/H2O (3:1), 23 °C, 1 h, 35% (5 steps); d) H2, Pd/C (10%), EtOH, 2 h, >99%. 
Scheme 3. 
 
The advanced intermediate 4 was prepared in 6 steps from dimethyl methylmalonate.12 
A Grignard addition onto 4 in tetrahydrofuran in the presence of trimethylsilyl chloride 
followed by desilylation afforded the allylic alcohol 5. Saponification of the methyl 
ester to form the dihydroxy acid followed by β-lactonization using bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOPCl) and triethylamine and removal of the p-
methoxybenzyl group using ceric ammonium nitrate (CAN) led to the formation of β-
lactone 7 in 35% yield over 5 steps. The hydrogenation of 7 afforded the corresponding 
C9-ethyl analogue 8 in >99% yield.  
 
The synthesis of analogues 14 and 15 follows a similar route (Scheme 4): a chromium-
catalysed addition of allyl and methylallyl bromide to 4, followed again by a 
saponification reaction, β-lactonization and p-methoxybenzyl group removal, resulted 
in compounds 12 and 13, respectively. The catalytic hydrogenation of 12 and 13 
afforded the corresponding omuralide analogues, 14 and 15. 
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Reagents and Conditions: a) 1. CrCl3(cat.), Mn(0), TMSCl, THF, 23 °C, 12 h, 50%; 2. 5% HF/CH3CN, 
23 °C, 4 h, 96%; 3. LiOH, THF/H2O (1:1). 23 °C, 2 h, 93%; 4. BOPCl, Et3N, CH2Cl2, 23 °C, 1 h, 95%; b) 
CAN, CH3CN/H2O (3:1), 23 °C, 1 h, 65%; c) H2, Pd/C (10%), EtOH, 23 °C, 2 h, 99%. 
Scheme 4.  
 
The synthesis of analogue 16 (R=H, Table 1) was completed by reduction of the 
aldehyde group of 4 to the corresponding alcohol followed by saponification, β-
lactonization and p-methoxybenzyl group removal as described above. The C9-phenyl 
analogue 17 was prepared in a route analogous to the one used to prepare 7 and 8 using 
a Grignard addition to introduce the desired functionality. 
 
In the studies below (Tables 1-3),11 the different analogues’ ability to inhibit the 
proteasome was tested by measuring the rates of inhibition of chymotrypsin-like 
peptidase activity using purified 20S proteasome from a bovine brain. Investigations 
into the effect of functionalization at C9 (Table 1) supported Schrieber’s early work. 
Even subtle changes to the group, using a slightly larger or smaller group than the 
original isopropyl, resulted in great loss of activity. When replaced with a much smaller 
group, for example just a proton (16), the activity was dramatically reduced. When 
replaced with a much larger group, as in the case of the C9-phenyl analogue 17, a 
complete lack of inhibition was observed. 
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Table 1. Kinetics of inhibition by C9 functionalized β-lactone analogues of lactacystin. 
 
Compound Analogue Structure kassoc (M−1s−1) 
2 R = CH(CH3)2 3059 ± 478 
7 R = CH=CH2 188 ± 11 
8 R = C2H5 290 ± 12 
16 R = H 9.7 ± 6.2 
17 R = C6H5 No inhibition 
12 R = CH2CH=CH2 255 ± 40 
13 R = CH2C(CH3)=CH2 64.7 ± 2.2 
14 R = CH2CH2CH3 192 ± 35 
15 R = CH2CH(CH3) 2 17.4 ± 2.4 
 
 
The effect of other substituents at the C5 position was also studied (Table 2). With a 
ketone in place of the C9 hydroxyl moiety in lactacystin, a complete lack of inhibition 
was observed. The importance of the stereochemistry at the C9 position was also 
confirmed: the activity is dramatically reduced when the stereochemistry is inverted. 
Interestingly, in the case of both C9 and C5 functionalization, the inhibition was at its 
highest when lactacystin was used, and no modification led to any improvement. 
 
Table 2. Kinetics of inhibition by C5 functionalized β-lactone analogues of lactacystin. 
 
Compound Analogue Structure kassoc (M−1s−1) 
2 
R =  
3059 ± 478 
18 R = C(O)CH(CH3)2 No inhibition 
19 
R =  
65 ± 9.6 
20 R = CH2CH(CH3)2 235 ± 16 
21 R = CH=C(CH3)2 98 ± 5 
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The importance of the C7 substituent was also investigated in relation to proteasome 
inhibition (Table 3). Scheme 5 shows the synthetic route to a variety of analogues 
where functionalization was achieved by the early addition of different alkenes. 
Reaction of the alkene with the aldehyde of 22 using a magnesium-catalysed anti-aldol 
approach gave 24.13 Hydrogenation of 24 followed by cyclization and deprotection of 
the primary alcohol gave the bicyclic compound 25. The dihydroxy acid 26 was 
prepared over three steps and then converted into the corresponding β-lactone 27 using 
BOPCl. Again, the ability to inhibit the proteasome was tested by measuring the rates of 
inhibition of chymotrypsin-like peptidase activity.  
 
 
Reagents and Conditions: a) 1. MgI2, CH2Cl2, −20 °C – 0 °C; 2. K2CO3, MeOH, 23 °C, 75-80% (2 
steps); b) 1. H2, Pd/C (10%), EtOH, (i-Pr)2NEt (cat.), 23 °C, 30 h; 2. MeOH, 55 °C, 20 h; 3. 5% 
HF/CH3CN, 23 °C, 24 h, 76-84% (3 steps); c) 1. DMSO, (COCl)2, Et3N, CH2Cl2, −78 °C; 2. NaClO2, 
NaH2PO4, t-BuOH/2-Me-2-butene, 23 °C, 0.5 h; 3. HS(CH2)3SH, 2% HCl (g), CF3CH2OH, 50 °C, 7 h, 
65-75% (3 steps); d) BOPCl, Et3N, CH2Cl2, 23 °C, >90%. 
Scheme 5. 
 
In contrast with the already optimized C5 and C9 substituents, variations at the C7 
group have yielded compounds with increased activity. When the methyl group was 
replaced with a proton (compound 29), the activity dropped dramatically. However, 
when three of the analogues where the substituent was larger than a methyl group were 
tested, the inhibitory activity more than doubled. Interestingly, the C7-ethyl substituent 
(compound 28) is found in salinosporamide B, an analogue of another naturally 
occurring proteasome inhibitor that shares the same core structure and mode of action as 
lactacystin.  
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Table 3. Kinetics of inhibition by C7 functionalized β-lactone analogues of lactacystin. 
 
Compound Analogue Structure kassoc (M−1s−1) 
2 R = CH3 3059 ± 478 
28 R = CH2CH3 6679 ± 553 
29 R = H 450 ± 77 
30 R = CH2C6H5 2227 ± 180 
31 R = (CH2)3CH3 7275 ± 466 
32 R = CH(CH3)2 8465 ± 1572 
 
 
In conclusion, it is clear to see that Nature has nearly optimized lactacystin’s structure 
for proteasome inhibition. The combined studies into the functionalization of the C5 
and C9 positions clearly demonstrate this. There is however scope for improvement at 
the C7 position for a novel proteasome inhibitor to be designed to achieve increased 
activity.			
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1.1.3 Previous Syntheses of Lactacystin 
 
1.1.3.1 The Corey Syntheses 
 
Corey and Reichard reported the first total synthesis of lactacystin in 1992.14 
Lactacystin was successfully synthesized in 6% yield over 13 steps from 33 (Scheme 
6).  
 
 
Reagents and Conditions: a) LDA, LiBr, iso-butyraldehyde, THF, −78 °C, 51%; b) MeOH, TfOH, 80 
°C, 91%; c) TBSCl, imidazole, DMF, 23 °C, 97%; d) TsOH, (CH2O)n, benzene, 96%; e) 1. LiBH4/THF, 
MeOH, 23 °C; 2. DMSO, (COCl)2, Et3N, CH2Cl2, −78 °C, 85%; f) LDA, 2,6-dimethylphenylpropionate, 
THF, −78 °C, 48%; g) H2, Pd/C, EtOH, 23 °C, 87%; h) 1. 5% HF/CH3CN, 23 °C, 90%; 2. DMSO, 
(COCl)2, Et3N, CH2Cl2, −78 °C, 73%; 3. NaClO2 NaH2PO4, t-BuOH, 2-methyl-2-butene, 23 °C, >95%; i) 
1,3-propanedithiol, 2% HCl/CF3CH2OH, 50 °C, >95%; j) N-acetylcysteine allyl ester, BOPCl, Et3N, 
CH2Cl2, 23 °C, 79%; k) Pd(Ph3P)4, HCO2H, Et3N, THF, 23 °C, 84%. 
Scheme 6.  
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To begin, N-benzylserine methyl ester was converted into the cis-oxazolidine derivative 
33, which was isolated as a mixture of diastereoisomers in a 9:1 ratio. An aldol 
condensation of 33 with iso-butyraldehyde gave the oxazolidine 34 in excellent 
diastereoisomeric purity (>98%) after recrystallization from pentane. Lithium bromide 
was found to be essential as low yields and poor selectivity were observed in its 
absence. The oxazolidine ring-opening, followed by the silyl protection of the primary 
alcohol, gave compound 36. The formation of a new oxazolidine 37 proceeded using 
formaldehyde in 96% yield. Reduction of the ester moiety followed by a re-oxidation 
gave aldehyde 22. The aldol condensation with 2,6-dimethylphenylpropionate under 
Pirrung-Heathcock anti-aldol conditions15 resulted in the formation of oxazolidine 38 as 
the major diastereoisomer. The bicyclic lactam 39 was obtained by catalytic 
hydrogenation of 38. Desilylation followed by the oxidation of the primary alcohol gave 
the acid 40. The acid-catalysed transfer of methylene to 1,3-propanedithiol was used to 
ring-open the oxazolidine resulting in the dihydroxy acid 3 in 95% yield. The final steps 
included a reaction with N-acetylcysteine to introduce the NAC side chain; deallylation 
of 41 afforded lactacystin. 
 
The attractive feature in this total synthesis, apart from a good overall yield, is how few 
purification steps requiring chromatography are needed. However, as mentioned above, 
the main drawback of this synthesis was the poor selectivity of the aldol condensation 
of 22. During the transition state of the reaction of aldehyde 22 with 2,6-
dimethylphenylpropionate under Pirrung-Heathcock anti-aldol conditions, the benzyl 
and isopropyl groups of the oxazoline ring are cis to each other. The re and si faces are 
not sterically different enough to induce a stereoselective attack of the aldehyde 
carbonyl moiety (Figure 5).16 
 
 
Figure 5.  
  
 
O
N
Ph
OR
O
Hsi re
	 	 Introduction		
	 15	
Investigations were then carried out to improve the selectivity. Corey used the 
methodology developed by Braun that utilised a chiral zirconium enolate of 2-siloxy-
1,2,2-triphenylpropionate.17 When the (R)-zirconium enolate was used, aldehyde 22 was 
converted into four diastereoisomeric products in a 32:2:2:1 ratio. The required 
diastereoisomer for the natural product, with a (6S,7R) configuration, was isolated as the 
major diastereoisomer in 80% yield. Using the (S)-enantiomer of the zirconium enolate, 
attack occurred onto the re face giving the (6R,7S)-diastereoisomer as the major 
product. The hydrogenation of 42 followed by diazomethane treatment and, finally, 
cyclization in methanol gave the reported bicyclic lactam 39 (Scheme 7).16 
 
 
Reagents and Conditions: a) THF, −20 °C, 80%; b) 1. H2, Pd/C; 2. CH2N2; 3. MeOH, 64%. 
Scheme 7.  
 
Although the selectivity was improved, long reaction times and the large excess of the 
zirconium enolate required were not desirable. Unhappy with these limitations, the 
Corey group made further improvement to the reaction, this time employing a 
magnesium-catalysed anti-aldol reaction.13 The chelation of a metal to the nitrogen of 
the N-benzyl and the oxygen of the aldehyde enabled a Mukaiyama-type aldol process 
to occur.  
 
The test reactions using the t-butyldimethylsilyl enol ether of ethyl acetate and various 
Lewis acids, such as TiCl4, resulted in no aldol product and decomposition of the 
aldehyde. Reactions with bicoordinate Lewis acids and the t-butyldimethylsilyl enol 
ether of ethyl acetate afforded neither the aldol nor decomposition products. These 
results led the group to believe that the nitrogen of the N-benzyl was too sterically 
hindered to coordinate to the metal. However, MgI2 was then tested and complete 
diastereoselectivity was observed. With optimized conditions in hand, the reaction was 
N
O
O
HO
OTBS
O
N
Bn
CHO
OTBS
O
N
Bn
OTBS
HO O
O
OTMS
Ph
Ph
Ph
O
OTMS
Ph Ph
PhClCp2ZrO
a
b
22 42 39
	 	 Introduction		
	 16	
repeated using the (E)-trimethylsilyl enol ether of methyl propionate (Scheme 8). High 
si selectivity was observed, and the desired anti aldol product 43 was isolated from a 
9:1 mixture of anti/syn diastereoisomers using silica gel chromatography. The 
dihydroxy acid 3 was obtained after oxidation of the primary alcohol followed by acid-
catalysed transfer of methylene to 1,3-propanedithiol to ring-open the oxazolidine. 
 
 
Reagents and Conditions: a) MgI2, CH2Cl2, −20 °C; b) 1. H2, Pd/C, EtOH, DIPEA, 23 °C, 30 h; 2. 
MeOH, 55 °C, 20 h; 3. 5% HF/CH3CN, 23 °C, 24 h, 76%; c) 1. Et3N, DMSO, (COCl)2, CH2Cl2, −78 °C; 
2. NaClO2, NaH2PO4, t-BuOH, 23 °C; 3. 1,3-propanedithiol, HCl, CF3CH2OH, 55 °C, 8 h, 77%. 
Scheme 8.  
 
The selectivity observed could be explained by the low energy transition state that 
resulted from the chelation of MgI+. There is much less steric repulsion in 45 compared 
to other geometries. For example, the antiperiplanar arrangement would show much 
higher steric repulsion (Scheme 9).13 
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Scheme 9. 
 
In 1998, Corey and Nagamitsu reported a different approach to the total synthesis of 
lactacystin.12 The new route was not only shorter but was most impressive due to the 
formation of an advanced intermediate that allowed ready access to various lactacystin 
analogues. The introduction of the isopropyl, or other lipophilic groups, could be 
carried out late in the synthesis. This route employs a blocking group at the C7 position; 
the group chosen was a thiomethyl group: importantly, it is not labile but it is also bulky 
enough to induce stereoselectivity in the hydroxymethylation of 50. 
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Reagents and Conditions: a) 1. PLE, H2O, pH 7.3, 23 °C, 24 h, 97%; 2. Recrystallization of the quinine 
salt, 62%, 95% ee; b) 1. (COCl)2, DMF (cat.), 23 °C, 1 h; 2. PMB-NHCH2CO2Me, Et3N, CH2Cl2, 23 °C, 1 
h, 99%; 3. LDA, THF, −78 °C, 2 h, 93%; c) 1.DBU, THF, −78 °C, then aq. CH2O, −78 °C, 0.5 h, 90%; 2. 
NaBH(OAc)3, HOAc, 23 °C, 1 h, recrystallization, 95%, 99% ee; d) 1. PivCl, pyridine, 23 °C, 10 h, 85%; 
2. TBSOTf, 2,6-lutidine, 23 °C, 12 h, 98%; 3. NaOMe, MeOH, 23 °C, 5 h, 92%; e) 1. Raney Ni, EtOH, 0 
°C, 1 h, 82%; 2. Dess-Martin reagent, CH2Cl2, 23 °C, 1 h, 95%; f) H2C=C(Me)MgBr, TMSCl, THF, −40 
°C, 0.5 h, 97%; g) 1. H2, Pd/C, EtOH, 23 °C, 12 h, 99%; 2. CF3CO2H/H2O (4:1), 50 °C, 4 h, 87%; h) 1. 
LiOH, THF/H2O (1:1), 23 °C, 0.5 h; 2. BOPCl, Et3N, CH2Cl2, 23 °C, 0.5 h, 90%; i) CeIV, CH3CN/H2O 
(3:1), 23 °C, 1 h, 62%. 
Scheme 10.  
 
The achiral thiomethyl derivative 48 was synthesized using dimethyl methylmalonate 
with sodium hydride and MsCl in tetrahydrofuran. The compound 48 was then 
converted to the chiral acid 49 by enantioselective hydrolysis using porcine liver 
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esterase, and the acid 49 was obtained in 95% ee after recrystallization. The Dieckmann 
cyclization precursor was prepared after conversion of acid 49 to the corresponding acyl 
chloride using oxalyl chloride followed by coupling to N-p-methoxybenzylglycinate; 
treatment of the newly formed compound with LDA led to the formation of the γ-
lactam product 50 as a 1:1 mixture of diastereoisomers at the C5 position. The 
hydroxymethylation of lactam 50 proceeded with high stereoselectivity (9:1) as hoped. 
A stereospecific ketone reduction gave the dihydroxy lactam 51 in 86% yield over the 
two steps. TBS protection of the secondary hydroxyl moiety was achieved by selective 
esterification of the primary hydroxyl group followed by silylation of the secondary 
hydroxyl moiety; the cleavage of the ester group was then performed to access the 
primary alcohol. The desulfurization of 52 was achieved in high stereoselectivity (10:1) 
by treatment with Raney nickel. A Dess-Martin periodinane oxidation gave aldehyde 4 
in 78% yield over two steps from 52.18 A Grignard addition onto 4 in the presence of 
TMSCl afforded the desired product 53. Use of TMSCl was vital in this reaction; its 
ability to trap the alkoxide ion prevented a rapid retro-aldol cleavage. The 
hydrogenation and desilylation of 53 followed by the saponification of the methyl ester 
resulted in the intermediate needed for the β-lactonization using BOPCl and 
triethylamine. Finally, the removal of the PMB protecting group using CAN gave 
omuralide 2, which can easily be converted to lactacystin upon treatment with N-
acetylcysteine and triethylamine.  
 
With the advanced intermediate 4 in hand, various Grignard additions could be carried 
out to achieve a range of analogues. This is an efficient, stereocontrolled synthesis that 
is both relatively simple and economic in terms of reagents used. 
 
1.1.3.2 The Ōmura Syntheses 
 
Shortly after the first synthesis by Corey, the Ōmura group reported their route to 
lactacystin.19 Using (2R,3S)-β-hydroxyleucine methyl ester 56 as the starting material, 
lactacystin was successfully synthesized in 13% yield over 10 steps (Scheme 11). The 
treatment of the methyl ester 56 with methyl benzimidate gave the trans-oxazoline 57. 
Following Seebach’s protocol,20 an aldol condensation of 57 and formaldehyde was 
performed giving 58 in 98% de and 85% yield. 
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Reagents and Conditions: a) Ph(MeO)C=NH, 72%; b) LiHMDS, formaldehyde, 85%; c) Moffat 
oxidation; d) 1. (E)-crotyldiisopinocampheylborane, THF, −78 °C; 2. OH−, H2O2, 70% (2 steps); e) 1. O3, 
DMS; 2. NaClO2, NaH2PO4, 56% (2 steps); f) 1. Pd, HCO2NH4; 2. 0.1 M NaOH, 82% (2 steps); g) 
BOPCl, Et3N, N-acetyl-L-cysteine allyl ester, 79%; h) (Ph3P)4Pd, 81%. 
Scheme 11.  
 
The next step, oxidation of the primary alcohol, proved challenging. After unsuccessful 
attempts to obtain the aldehyde 59 using the Swern21 and Parikh-Doering22 oxidations, 
pyridinium chlorochromate (PCC),23 and Dess-Martin periodinane,18 the Moffat 
oxidation provided the desired derivative 59.24 A drawback to this methodology was a 
deformylation reaction occurring during aqueous work-up and silica gel 
chromatography; giving the trans-oxazoline 57. To prevent the deformylation, the 
aldehyde was isolated with a non-aqueous work-up and no further purification. 
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In 1986, Brown and co-workers described an allylboration methodology using (E)-
crotyldiisopincampheylborane.25 The high reactivity of organometallic reagents used in 
the allylation of aldehydes often results in poor levels of both regio- and 
stereoselectivity. Brown developed a new regio- and stereoselective preparation of 
optically active (Z)- and (E)-crotylboranes that was used in the allylation of aldehydes. 
 
When the aldehyde 59 was subjected to the Brown conditions, the desired β-methyl 
homoallylic alcohol 60 was obtained as the major product alongside another 
diastereoisomer in 70% yield in a 4:1 ratio. Other methodologies were found to give 
lower selectivity. The use of the (E)-crotylchromium(II) reagent as described by 
Hiyama26 and (E)-crotylpinacol borane as described by Roush27 both gave the alcohol as 
a mixture of diastereoisomers in a 2:1 ratio. Roush was able to increase the ratio to 3:1 
by using (R,R)-(E)-crotyl tartrate borane.28 Conversion of the alkene to the carboxylic 
acid derivative 61 was achieved in one step using ruthenium(III) chloride and sodium 
periodate; however, low yields (11%) were obtained. The yield was improved using a 
two-step procedure consisting of the ozonolysis of 60, with a reductive work-up using 
dimethylsulfide, followed by a selective oxidation, giving 61 in 56% yield.  
 
Formation of the dihydroxy acid 3 proved difficult: both hydrogenolysis (using Pd/C, 
Pd(OH)2, or palladium black with H2 in methanol) and hydrolysis under acidic 
conditions (heating under reflux in 6 M HCl) were unsuccessful. Fortunately, catalytic 
transfer hydrogenation conditions using palladium black, ammonium formate and acetic 
acid under reflux followed, without purification, by ester hydrolysis using sodium 
hydroxide gave the dihydroxy acid 3 in 79% yield. The transformation of 3 to (+)-
lactacystin was carried out as described by Corey.14 
 
Continuing their investigations, the Ōmura group reported improvements to their 
original synthesis.29 This work focused not only on the total synthesis but also on the 
analysis of the biological activity of lactacystin and analogues. Although improvements 
were made to the synthesis of the 3-hydroxyleucine starting material, the majority of the 
synthesis was unchanged.  
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Several approaches to making 3-hydroxyleucine have been reported, but the methods 
were not considered suitable as they either lacked generality, producing only one of the 
four possible diastereoisomers, or required a chiral non-racemic catalyst.30 These 
limitations were undesirable as multigram quantities were needed for biological 
analysis.  
 
 
Reagents and Conditions: a) PhC(Me)2O2H, Ti(O-i-Pr)4, (+)-DIPT, 82%; b) NaH, BnNCO, THF, reflux, 
2 h; c) NaH, THF, reflux; d) Jones oxidation, 100%; e) 1. 2 M KOH; 2. H2, Pd(OH)2, 98% (2 steps); f) 
CH2N2, 87%; g) KOH, EtOH, 96%; h) 1. 2 M KOH; 2. H2, Pd(OH)2, 98% (2 steps). 
Scheme 12.  
 
The method developed by Ōmura was both simple and concise, using commercially 
available starting materials. This method also required little chromatography, as only 63 
and 65 required purification. They employed a catalytic Sharpless epoxidation31 to give 
63, a benzyl isocyanate-induced epoxide ring-opening to give 64, and the epimerization 
of the oxazolidinone ester 67 as the key steps to (2R, 3S) 3-hydroxyleucine 70. 
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With an improved synthesis of 3-hydroxyleucine available, the dihydroxy acid 3 was 
synthesized following the route described above. Lactacystin and two analogues were 
then prepared (Scheme 13).  
 
 
Reagents and Conditions: a) BOPCl, Et3N, CH2Cl2, 85%; b) Et3N, CH2Cl2, 1: 64%, 74: 89%, 75: 77%. 
Scheme 13.  
 
Departing from Corey’s route, an intramolecular coupling using BOPCl was performed 
on dihydroxy acid 3 in the presence of Et3N to form the β-lactone 2 in 85% yield. 
Interestingly, lactone 2 was converted into (+)-lactacystin using N-acetylcysteine, 
instead of N-acetyl-L-cysteine allyl ester, eliminating the need for a deprotection step. 
Using the same procedure, the novel lactacystin analogues 74 and 75 were prepared 
from the condensation of lactone 2 with thiols 72 and 73, respectively. 
 
1.1.3.3 The Baldwin Synthesis	
 
While the Corey and Ōmura groups were developing their synthetic routes, Baldwin and 
co-workers were also investigating a different approach, Scheme 14.32  
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Reagents and Conditions: a) LDA, MeI, THF, −78 °C, 95%; b) LDA, PhSeBr, THF, −78 °C, 79%; c) 
O3, CH2Cl2, −78 °C, pyridine, RT, 87%; d) TBSOTf, 2,6-lutidine, CH2Cl2, RT, 89%; e) i-PrCHO, SnCl4, 
ether, −78 °C, 55%; f) Ac2O, pyridine, RT, 99%; g) OsO4, N-methylmorpholine N-oxide, aq. acetone, RT, 
87%; h) N,N’-thiocarbonyldiimidazole, THF, RT, 91%; i) Bu3SnH, AIBN, toluene, reflux, 94%; j) 2 M 
NaOH/MeOH (1:3), 0-3 °C, 94%; k) H2, Pd/C, HCl, MeOH, RT, 87%; l) Et3SiCl, pyridine, Ac2O, RT, 
89%; m) 40% HF, CH3CN, RT, 91%; n) Jones’ reagent, acetone, 0 °C to RT, 91%; o) 0.2 M NaOH, RT, 
quant.; p) (R)-N-acetylcysteine allyl ester, BOPCl, Et3N, DCM, RT, 60%; q) Pd(PPh3)4, HCO2HNEt3, 
THF, RT, 88%. 
Scheme 14.  
 
Using (R)-glutamic acid as the starting material, the bicyclic oxazolidine 76 was 
prepared over three steps. A sequence of methylation followed by selenenylation and 
ozonolysis led to the unsaturated bicyclic oxazolidine derivative 77. Treatment of 77 
with TBSOTf and 2,6-lutidine gave the siloxypyrrole intermediate 78 as a crystalline 
solid in 89% yield. Aldol reaction of 78 and isobutyraldehyde resulted in the formation 
of the major isomer 79 and the corresponding secondary alcohol epimer in a 9:1 ratio. 
Acylation of the free hydroxyl group followed by dihydroxylation, using osmium 
tetroxide and N-methylmorpholine N-oxide, gave the diol 80 as a single diastereoisomer 
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in 87% yield. Removal of the tertiary hydroxyl was achieved using the Barton-
McCombie deoxygenation reaction through the formation of a thiocarbamate followed 
by radical decarboxylation using Bu3SnH and AIBN as the radical initiator. The method 
was not diastereoselective and resulted in a 1:1 mixture of epimers. Treatment of the 
diastereoisomeric mixture with 0.5 M NaOH in MeOH resulted in removal of the acetyl 
group and epimerization at the C6 position to give the desired syn-isomer 81 (syn:anti, 
73:10). 
 
Hydrogenolysis of 81 resulted in the cleavage of the oxazolidine moiety, giving the key 
lactam core of lactacystin. A sequence of selective protections and deprotections of the 
primary and secondary alcohol groups afforded primary alcohol 82. Using an excess of 
the Jones’ reagent, the primary alcohol was converted to the corresponding carboxylic 
acid. Finally, deprotection of the secondary alcohol groups gave the dihydroxy acid 3 in 
91% yield. In conclusion, the Baldwin group successfully completed the synthesis of 
lactacystin from 76 in 17 steps and 8% overall yield. 
 
1.1.3.4 The Chida Synthesis	
 
In 1995, Chida et al. reported work on the total synthesis of (+)-lactacystin from D-
glucose (Scheme 15).33 3-Deoxy-1,2-O-isopropylidene-3-C-methyl-α-D-allofuranose 
83 was chosen as the starting material. It is a known compound prepared over four steps 
from diacetone-D-glucose.34 
 
Treatment of 83 with dibutyltin oxide and benzyl bromide followed by oxidation of the 
secondary alcohol using Jones’ reagent led to the formation of 84. A Wittig reaction 
was used on 84 to give the corresponding alkene as a 1:1 mixture of diastereoisomers. 
The diastereoisomeric mixture was subjected to a DIBAL reduction to form the allylic 
alcohol in 90% yield. Treatment of the allylic alcohol with trichloroacetonitrile and 
sodium hydride in diethyl ether afforded the trichloroacetimidate 85, which was, 
without purification, heated in toluene at 150 °C for 89 h. Overman rearrangement35 led 
to the formation of product 86 as an inseparable mixture of diastereoisomers in a 4.8:1 
ratio.  
 
	 	 Introduction		
	 26	
 
Reagents and Conditions: a) See ref. 34; b) Bu2SNO, toluene, reflux, then BnBr, CsF, DMF, RT; c) 
Jones’ reagent (CrO3 in dil. H2SO4) acetone, 0 °C; d) Ph3P=CHCO2Et, toluene, 60 °C; e) DIBAL-H, 
CH2Cl2, −15 °C; f) trichloroacetonitrile, NaH (60 mol%), Et2O, RT; g) toluene, heat at 150 °C (in a sealed 
tube), 89 h; h) TFA/H2O (3:2), 0 °C; i) NaIO4, MeOH/H2O (1:1), RT; j) NaBH4, MeOH, 0 °C; k) tert- 
butyldimethylsilyl trifluoromethanesulfonate, 2,6-lutidine, CH2Cl2, RT; l) Na, Liq. NH3-THF, −78 °C; m) 
Me2SO, DCC, TFA, pyridine, benzene, RT; n) iPrMgBr, THF −20 °C to RT; o) TFA/H2O (4:1), 50 °C; p) 
O3, CH2Cl2, −78 °C, then Me2S; q) NaClO2, NaH2PO4, HOSO2NH2, tert-butanol/ H2O, RT. 
Scheme 15.  
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Hydrolysis under acidic conditions of the diastereoisomeric mixture resulted in the 
corresponding lactol in 72% yield after silica gel chromatography. A periodate 
oxidation led to oxidative cleavage followed by cyclization to form the pyrrolidine 87. 
A Jones oxidation to form the corresponding lactam followed by a sodium borohydride 
reduction to remove both the N-trichloroacetyl and O-formyl protecting groups gave 88. 
 
Silyl protection of the secondary alcohol followed by debenzylation gave 89. A Moffat 
oxidation afforded the aldehyde 90, which was then used in the next step without 
purification. Grignard addition using isopropylmagnesium bromide in THF resulted in a 
mixture of diastereoisomers at the C9 position. The desired diastereoisomer 91 was 
isolated in 35% yield. Deprotection of the secondary alcohol of 91 with aqueous 
trifluoroacetic acid gave 92. Formation of the dihydroxy acid 3 was achieved by 
ozonolysis to form an aldehyde moiety followed by selective oxidation to give the 
corresponding carboxylic acid. The synthesis of (+)-lactacystin was then completed 
following Corey’s methodology.14 
 
The main drawback of this route was the poor selectivity of the Grignard addition onto 
aldehyde 90 leading to the formation of alcohol 91 in 35% yield. Indeed, the presence 
of unwanted diastereoisomers is not desirable in total synthesis. However, the oxidation 
of the unwanted diastereoisomer 93 followed by a reduction using triisobutylaluminium 
in CH2Cl2 at 0 °C gave the desired isomer 91 as the major product (70% yield) 
alongside 93 in 7% yield, Scheme 16. 
 
		
Reagents and Conditions: a)Me2SO, DCC, TFA, pyridine, benzene, RT; b) triisobutylaluminium, 
CH2Cl2-hexane, 0 °C, 91: 70%, 93: 7%. 
Scheme 16.  
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1.1.3.5 The Panek Synthesis	
 
The Panek synthesis is similar to that of the Ōmura group.36 Although both syntheses 
share the oxazoline 57 as a common intermediate, their approaches were slightly 
different. Panek and co-workers performed an asymmetric aminohydroxylation of (p-
bromophenyl)-4-methyl-2-pentenoate, 94, under Sharpless conditions followed by 
reaction with CbzNNaCl to give 95 in excellent ee (above 99%) after recrystallization. 
Transesterification to form the methyl ester followed by removal of the Cbz protecting 
group under catalytic hydrogenation conditions afforded 56. The trans-oxazoline 
intermediate 57 was then formed upon treatment of 56 with trimethylorthobenzoate and 
p-toluenesulfonic acid. This is a much shorter and more efficient route to the trans-
oxazoline 57 than that reported by Ōmura.29 The next two steps to intermediate 59 were 
achieved as described above in Scheme 11. 
 
Another key step of the Panek route is the anti-selective crotylation reaction of 59 in the 
presence of TiCl4 to give 97 in high selectivity and yields of 50-60%. Ozonolysis of 97 
in the presence of sodium chlorite led to the formation of known intermediate 61, which 
allowed Panek and co-workers to complete the synthesis of lactacystin employing 
literature procedures.12, 29 
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Reagents and Conditions: a) K2[OsO2(OH)4] (5 mol%), (DHQ)2AQN (5 mol%), CbzNNaCl, nPrOH, 
H2O, RT, 4 h, 60%; b) 1. Ti(OiPr)4, MeOH, RT; 2. H2, 10% Pd/C, MeOH, 100% (2 steps); c) PhC(OMe)3, 
p-TsOH, DME, reflux, 4 h, 85%; d) LiHMDS, formaldehyde, 85%; e) Moffat [O]; f) TiCl4, −78 °C to –35 
°C, 60%; g) 1. O3, DMS; 2. NaClO2, NaH2PO4, 90% (2 steps); h)1. Pd, HCO2NH4; 2. 0.1 M NaOH, 82% 
(2 steps); 3. BOPCl, Et3N, 80% (3 steps); i) N-acetyl-L-cysteine allyl ester, Et3N, CH2Cl2, RT, 70%. 
Scheme 17. 
 
1.1.3.6 The Pattenden Synthesis	
 
Pattenden et al. reported a different route to the total synthesis of lactacystin employing 
a radical-mediated approach to give the lactam core, Scheme 18.37 2-Ethynylpropenol 
was submitted to Sharpless epoxidation conditions,31 and the corresponding chiral 
epoxide 99 was obtained in 66% yield and 86% ee.  Conversion of the epoxide to the 
oxazoline followed by the protection of the primary alcohol using TBSOTf gave 100, 
and its absolute stereochemistry was confirmed using X-ray crystallography. Treatment 
of 100 with 1 M hydrochloric acid resulted in the ring-opening of the oxazoline to give 
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the amino alcohol 101 as the hydrochloride salt. Without purification, 101 was reacted 
with 2-bromopropionyl chloride to give the amide 102 as a mixture of diastereoisomers 
in a 1:1 ratio. The primary alcohol moiety was then converted into the corresponding 
aldehyde using Dess-Martin periodinane followed by further oxidation to the carboxylic 
acid; finally, an esterification reaction using trimethylsilyldiazomethane gave methyl 
ester 103 in 62% yield over three steps. 
 
The radical-mediated 5-exo-dig cyclization was achieved when the bromoamide 103 
was treated with Bu3SnH-AIBN in toluene under reflux.38 The lactam 104 was isolated 
using silica gel chromatography in 60% yield as a mixture of epimers at the C7 position 
in a 2:1 ratio. 
 
Ozonolysis of 104 with a reductive work-up using dimethyl sulfide gave 105 as a 
mixture of diastereoisomers in a 2:1 ratio. Unfortunately, attempts to epimerize the C7 
centre were unsuccessful. The group then decided to employ a strategy reported by 
Corey that made use of a thiomethyl derivative.12 Corey had already shown that Raney 
nickel could be used in desulfurization in a selective manner.  The mixture of epimers 
was treated with S-methyl-p-toluenethiosulfonate to form the thiomethyl derivative 106 
in high diastereoisomeric excess (87:13). The addition was determined to be anti to the 
bulky CH2OTBS group at the C5 position.  
 
Diastereoselective ketone reduction of 106 was achieved using zinc borohydride, giving 
107 in 79% yield. The TBS protection of the resulting secondary alcohol followed by p-
methoxybenzyl protection and selective deprotection of the primary alcohol gave the 
advanced intermediate 52 reported by Corey. 
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Reagents and Conditions: a) L-(+)-DIPT, Ti(OiPr)4, cumene peroxide, CH2Cl2, −10 °C, 66%; b) 
Cl3CCN, DBU, 0 °C, 66%; c) Et2AlCl, CH2Cl2, 0 ° to RT, 78%; d) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C to 
RT, 97%; e) 1 M HCl, THF, RT; f) CH3CH(Br)COCl, NaHCO3, CH2Cl2, RT, 76% (2 steps); g) Dess-
Martin periodinane, CH2Cl2, 0 °C; h) NaClO4, NaH2PO4, t-BuOH, 2-methyl-2-butene, RT; i) Me3SiCHN2, 
MeOH-benzene, RT, 62%; j) Bu3SnH, AIBN, toluene, reflux, 60%; k) O3, MeOH, −78 °C, 15 min then 
Me2S, −78 °C to RT, 75%; l) p-MeC6H4SO2Me, Et3N, CH2Cl2, RT, 78%; m) Zn(BH4)2, (4.4 M in THF), 0 
°C, 79%; n) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C to RT, 80%; o) PMBBr, NaH, DMF, 0 °C to RT, 73%; 
p) HF-pyridine, THF, RT to 40 °C, 89%.  
Scheme 18. 
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1.2 Other Proteasome Inhibitors 
 
There are many classes of proteasome inhibitors; these include, but are not limited to, 
flavonoids, triterpenoids, β-lactones, peptides boronates and syrbactins.39 Bortezomib, a 
peptide boronate, was the first proteasome inhibitor to be used in clinical trials for the 
treatment of multiple myeloma and is now fully approved by the Food and Drug 
Administration (FDA) in the USA and the European Medicines Agency (EMA). 
Bortezomib inhibits the chymotrypsin-like activity of the 26S proteasome and binds 
covalently and reversibly to the β5 residue in the core 20S proteasome.40 
 
 
Figure 6. Bortezomib 
 
Lactacystin is one of the β-lactone class of inhibitors (Figure 7). The inhibitors of this 
class also share other structural features similar to those of lactacystin that have shown 
to be important in SAR studies of lactacystin’s ability to inhibit the 20S proteasome. 
 
 
 
N
N
N
H
O H
N
O
B
OH
OH
108
	 	 Introduction		
	 33	
 
 
Figure 7. The structures of other β-lactone proteasome inhibitors.  
 
Salinosporamide A 109 has proved a popular synthetic target due to its high potency, 
and is discussed in detail below. PS-519 is a novel proteasome inhibitor with structural 
similarities to both omuralide and salinosporamide.  The cinnabaramides A-G were also 
isolated from a strain of Streptomyces and share the same cyclohexenyl moiety found in 
salinosporamide A.41 Oxazolomycin A, as well as having structural similarities to 
lactacystin, is the parent member of a family of compounds (including KSM-2690 B1) 
showing antibacterial, antiviral and antitumour activity. The first total synthesis of 
oxazolomycin A was reported by the Hatakeyama group in 2011.42 
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1.2.1 The Salinosporamides 
 
After lactacystin, the most commonly studied member of this lactam-based proteasome 
inhibitor family is salinosporamide A. It is a particularly interesting compound as its 
high potency as an anti-cancer agent meant it reached Phase I human clinical trials for 
the treatment of multiple myeloma only three years after its discovery in 2003. 
 
 
Figure 8.  Salinosporamide A 
 
In 2003, Feling and co-workers reported the isolation of salinosporamide A 109 from 
the CNB-392 strain of the bacterium Salinospora tropica.43 Unlike lactacystin, 
salinosporamide A is naturally occurring in its β-lactone form. The key structural 
differences are the cyclohexenyl group that replaces the isopropyl group at C9, the 
replacement of the proton with a methyl group at C6 and the chloroethyl chain replacing 
the methyl group at C7. Salinosporamides A-K have been isolated and all have slightly 
different functional groups around the same core bicyclic ring structure. 
Salinosporamide A binds to the 20S proteasome in a similar way to omuralide but has 
been found to be more effective as a proteasome inhibitor than omuralide.44 
 
 
Scheme 19. The binding of salinosporamide A to the 20S proteasome. 
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1.2.2 Previous Syntheses of Salinosporamide A 
 
1.2.2.1 The Corey Synthesis	
 
There have been many reported syntheses of salinosporamide A. As in the case of 
lactacystin, the first of these was by the Corey group in 2004, Scheme 20.45 
 
 
Reagents and Conditions: a) p-TsOH, toluene, reflux, 12 h, 80%; b) LDA, THF, HMPA, −78 °C, 
ClCH2OBn, 4 h, 69%; c) NaCNBH3, AcOH, 40 °C, 12 h, 90%; d) 1. TMSCl, Et2O, 23 °C, 12 h; 2. 
Acryloyl chloride, i-Pr2Net, CH2Cl2, 1 h, 0 °C, then H+, Et2O, 23 °C, 1 h, 96%; e) Dess-Martin 
periodinane, 23 °C, 1 h, 96%; f) 1. Quinuclidine, DME, 0 °C, 7 d, 90%; 2. BrCH2Si(CH3)2Cl, Et3N, 
DMAP, CH2Cl2, 0 °C, 30 min, 95%; g) Bu3SnH, AIBN, benzene, reflux, 8 h, 89%; h) 1. Pd/C, EtOH, H2 
(1 atm), 18 h, 95%; 2. Dess-Martin periodinane, 23 °C, 1 h, 95%; i) THF, −78 °C, 5 h, 88%; j) KF, 
KHCO3, H2O2, THF/MeOH (1:1), 23 °C, 18 h, 92%; k) CAN, MeCN/H2O (3:1), 0 °C, 1 h, 83%; l) 1. 3 M 
LiOH/THF (3:1), 5 °C, 4 d; 2. BOPCl, pyridine, CH2Cl2, 23 °C, 1 h; 3. Ph3PCl2MeCN, pyridine, 23 °C, 1 
h, 65% (3 steps). 
Scheme 20. 
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Acylation of (S)-threonine methyl ester using 4-methoxybenzoyl chloride afforded the 
amide 110. Cyclization of 110 to form the oxazoline 111 was achieved upon reflux in 
toluene with p-toluenesulfonic acid. Deprotonation of 111 with LDA followed by 
alkylation of the resulting enolate with chloromethyl benzyl ether allowed the formation 
of 112 in 69% yield. The tertiary stereocentre formed in this reaction has the same 
absolute configuration as the natural product. Reduction of 112 with sodium 
cyanoborohydride cleaves the oxazoline, giving 113 in 90% yield. Formation of 114 
was achieved over two steps: alcohol 113 was first converted to the corresponding TMS 
ether using trimethylsilyl chloride and triethylamine; then, N-acylation using acryloyl 
chloride and acidic work-up using aqueous hydrochloric acid to remove the TMS group 
led to the formation of 114. 
 
The formation of the lactam was achieved through a well-designed sequence that also 
established the desired stereochemistry at the C5 and C6 positions. A Dess-Martin 
periodinane oxidation gave the keto amide ester 115, which was then cyclized under 
Baylis-Hillman aldol conditions. Cyclization resulted in a mixture of diastereoisomers 
at the C6 position in a 9:1 ratio. Silylation of the desired diastereoisomer gave 116, 
which was then transformed into the bicyclic compound 117 using a radical-mediated 
cyclization using tributyltin hydride and AIBN. Cleavage of the benzyl ether was 
achieved under standard hydrogenation conditions using Pd/C. A Dess-Martin 
periodinane oxidation was used again, to form the aldehyde 118 in 95% yield. 
 
The introduction of the 2-cyclohexenyl group was achieved by addition of 2-
cyclohexenylzinc chloride 119. Synthesis of 2-cyclohexenylzinc chloride was achieved 
using a palladium-catalysed 1,4-addition of tributyltin hydride to 1,3-cyclohexadiene to 
give 2-cyclohexenyl-tri-n-butyltin which underwent transmetallation using n-
butyllithium and zinc chloride to give the desired 2-cyclohexenylzinc chloride. The 
reaction of 2-cyclohexenylzinc chloride with 118 in THF at –78 °C gave 120 in 88% 
yield. Oxidation of 120 under Tamao-Fleming conditions gave the triol 121 in 92% 
yield. 
 
The next three steps of the synthesis follow literature reported by the Corey group in the 
synthesis of lactacystin. CAN was used to remove the p-methoxybenzyl group, the 
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methyl ester was saponified using lithium hydroxide, and β-lactonization was achieved 
using BOPCl. Finally, the reaction with triphenylphosphine dichloride in acetonitrile-
pyridine gave the natural product salinosporamide A in 14% yield over 17 steps. 
 
1.2.2.2 The Ōmura Synthesis	
 
After Corey, other groups reported the total synthesis of salinosporamide A, including 
the Ōmura group in 2008.46 Unlike Corey and other subsequent researchers, such as 
Romo and Danishefsky, who all install the cyclohexene ring in the same way at a late 
stage in the synthesis,47, 48 Ōmura and co-workers reported a new approach to construct 
the cyclohexene ring in the early stages of their synthesis, Scheme 21. 
 
The aldehyde starting material 122 was converted over multiple steps into the 
carbamate 123. The precursor to the cyclohexene moiety was then introduced at this 
early stage. Simultaneous installation of the C5 and C6 stereogenic centres was 
achieved by an aldol reaction between the aldehyde 123 and cyclohexanone, and the 
reaction quenched with benzoyl chloride. The large diastereoisomeric ratio (20:1) 
observed in 125 was achieved due to formation of the highly chelated intermediate 124. 
This reaction was also attempted using Corey’s methodology: 2-cyclohexenylzinc 
chloride was added to the aldehyde 123; however, low diastereoselectivity was 
observed.45 
 
Conversion of the cyclohexanone moiety to the corresponding cyclohexene proved 
more difficult than the group envisaged. Reduction of an enol triflate using palladium 
chemistry, the Shapiro reaction, and a reduction-dehydration procedure were attempted 
but unsuccessful. Finally, they settled on a method that utilized a cyclic sulfate 
intermediate 126, which, after elimination, gave the required cyclohexene moiety. 
 
The construction of the γ-lactam core was achieved over multiple steps via the bicyclic 
compound 127. Ring-opening of the lactone gave the core lactam ring which was then 
subjected to multiple protection and deprotection reactions, β-lactonization and 
chlorination reactions to give salinosporamide A. Although a relatively long route, the 
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ability to stereoselectively construct the cyclohexene ring at an early stage is the most 
interesting feature of this synthesis. 
 
 
Reagents and Conditions: a) 1. Ph3P+CH3Br−, NaHMDS, THF, RT, 97%; 2. i-TsOH·H2O, MeOH, RT, 
82%; 3. Lipase vinyl acetate, i-Pr2O, RT; 4. TBDPSCl, imidazole, DMF, RT, 94%, 97% ee (2 steps); 5. 
K2CO3, MeOH, RT; 6. MEMCl, i-Pr2Net, CH2Cl2, RT, 94% (2 steps); 7. TBAF, THF, RT; 8. NaH, 
THF/DMF, then PMBCl, RT, 97% (2 steps); 9. OsO4, NMO, acetone/H2O, RT; 10. NaIO4, MeOH/H2O, 
RT, 92% (2 steps); b) LDA, cyclohexanone, THF, −78 °C; c) BzCl, 79%; d) 1. NaBH4, CeCl3·7H2O, 
MeOH, RT; 2. K2CO3, MeOH, RT, 95% (2 steps); 3. SOCl2, pyridine, CH2Cl2, RT; 4. RuCl3, NaIO4, 
MeCN/CCl4/H2O, RT, 94% (2 steps); e) 1. DBU, toluene, 100 °C; 2. TsOH·H2O, dioxane, RT, 97% (2 
steps); 2. NaH, THF/EtOH, RT; 3. (COCl)2, DMSO, Et3N, CH2Cl2, −78 °C, 92% (2 steps); 4. MeMgBr, 
THF, −78 °C; 2. Dess-Martin periodinane, CH2Cl2, RT, 100% (2 steps); 5. CAN, MeCN/H2O, 0 °C, 92%; 
6. LiHMDS, THF, −78 °C, then chloroacetyl chloride, 63%; f) 1. SmI2, LiCl, benzyloxyacetaldehyde, 
THF, −78 °C, 83%; 2. MsCl, Et3N, Me3N·HCl, toluene, RT; 3. NaOH, MeOH/H2O, 0 °C, 81% (2 steps); 
4. LiEt3BH, THF, 0 °C, 77%; g) 1. TESCl, NaI, MeCN, 0 °C, 100%; 2. TESOTf, 2,6-lutidine, CH2Cl2, 
−78 °C, 48%; 3. HF·pyridine, THF, 0 °C, 90%; 4. Dess-Martin periodinane, CH2Cl2, RT; 2. NaClO2, 2-
methyl-2-butene, Na2HPO4, t-BuOH/H2O, RT; 5. Li, NH3, t-BuOH/THF, −78 °C; 6. BOPCl, 
pyridine/CH2Cl2, RT; 7. Ph3PCl2, pyridine/MeCN, RT, 48% (5 steps); 8. HF·pyridine, THF, RT, 84%. 
Scheme 21. 
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1.3 Previous Work in the Page Group 
 
Investigations within the group began focusing on the construction of the lactam core of 
lactacystin. One of the key steps was the use of a Dieckmann cyclization to obtain the 
core. The synthesis of the unprotected cyclization precursor 130 proceeded without 
difficulty; however, the protection of the amide moiety proved challenging, Scheme 
22.49 
 
 
Reagents and Conditions: a) 1. NaOH; 2. Ethyl malonyl chloride, CH2Cl2, 57%; b) potassium ethyl 
malonate, DCC, Et3N, aq. MeCN, 81%; c) Boc2O, Et3N, DMAP, CH2Cl2, 131: 15%, 132: 13%, 133: 11%. 
Scheme 22. 
 
The use of di-tert-butyl dicarbonate resulted in a mixture of both N- and C-Boc products 
131, 132 and 133, in low yields. Compounds 132 and 133 were both subjected to 
Dieckmann cyclization conditions; unfortunately, the desired products were not 
isolated. A possible solution to avoid the formation of the C-Boc product would be the 
introduction of a methyl group at the C7 position prior to the Boc protection, Scheme 
23.  
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Reagents and Conditions: a) 1. KOH, EtOH, 24 h, RT, 87%; 2. glycine ethyl ester, DCC, Et3N, CH2Cl2, 
82%; b) Boc2O, DMAP, MeCN, RT, 136: 60%, 137: 11%. 
Scheme 23. 
 
Compound 135 was prepared over two steps from methylmalonate diethyl ester in 71% 
yield. The use of di-tert-butyl dicarbonate with triethylamine and DMAP as a catalyst in 
dichloromethane gave compounds 136 and 137 in 30% and 18% yields, respectively. 
Changing the solvent to acetonitrile and removing the triethylamine led to the formation 
of the desired N-Boc product 136 as the major compound in 60% yield alongside a 
small amount of 137 (11%). Compounds 135, 136 and 137 were all subjected to a 
number of cyclization conditions: the desired products were not observed and, instead, 
transesterification occurred, complex mixtures were formed and in some cases the 
starting material was recovered. 
 
Cyclization of the unprotected Dieckmann cyclization precursor 130 gave the lactam 
138 in 70% yield, Scheme 24. Compound 138 was insoluble in common organic 
solvents, and attempts were made to further functionalize the amide nitrogen to increase 
solubility. Again, the Boc protection did not proceed as desired and the trisubstituted 
pyrrole 139 was isolated in 14% yield 
 
 
Reagents and Conditions: a) Na/MeOH, toluene, reflux, 70%; b) Boc2O, Et3N, DMAP, MeCN, RT, 
14%. 
Scheme 24. 
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Attempts were then made to alkylate lactam 138 at the C3 position using methyl iodide, 
Scheme 25. The use of tetrabutylammonium fluoride (TBAF) both as a base and phase 
transfer catalyst solved the problem of insolubility mentioned above, and the methylated 
product 140 was obtained in 82% yield. With the presence of the quaternary centre at 
the C3 position preventing aromatization to the pyrrole, the reaction with di-tert-butyl 
dicarbonate and DMAP in acetonitrile gave the N-Boc protected lactam 141 in 76% 
yield alongside trace amounts of 142. 
 
 
Reagents and Conditions: a) TBAF, THF, MeI, RT, 82%; b) Boc2O, DMAP, MeCN, RT, 141: 76%. 
Scheme 25. 
 
Introduction of the functionality at the C5 position was the next step. Acylation was 
investigated using a variety of bases under different conditions (Table 4).49 Although 
most methods proved unsuccessful, the desired product 143 was obtained in 10% yield 
when ethylcyanoformate was used. A possible reason for the low yields observed was 
thought to be the steric hindrance caused by the Boc group. 
 
Table 4. Investigations into the acylation of 141.  
 
Conditions R 143 144 
LDA, THF, −78 °C Cl 10% 12% 
LiHMDS, THF, −78 °C Cl - - 
t-BuOK, THF, −78 °C Cl - 35% 
t-BuOK, THF, −78 °C OEt - - 
KH, benzene, reflux OEt - - 
LDA, THF, −78 °C CN 10% - 
N
H
O
O
MeO2C
N
H
O
O
Me
MeO2C
N
O
O
Me
MeO2C
N
OBoc
O
Me
MeO2C
Boc Boc
a b
138 140 141 142
N
O
O
Me
MeO2C
Boc
R
O
OEt
N
O
O
Me
MeO2C
Boc
N
O
O
Me
MeO2C
Boc
CO2Et
OEt
O
141 143 144
	 	 Introduction		
	 42	
With multiple problems arising from the use of Boc as a protecting group, 
investigations were then focused on groups which would be both smaller and less likely 
to lead to C-acylation. N-Benzyl glycine ethyl ester 145 was chosen as the starting 
material: it can be easily prepared from the condensation of ethyl bromoacetate and 
benzylamine. 
 
 
Reagents and Conditions: a) pyridine, DMAP, CH2Cl2, RT, 24 h, 148: 91%, 149: 95%; b) For 148; 
Na/MeOH, reflux, 88%; c) For 149; NaH, benzene, 6 h, 63%; d) TBAF, MeI, 24 h, 152: 77%, 153: 70%. 
Scheme 26.  
 
Condensation of ethyl malonyl chloride 146 or benzyl malonyl chloride 147 and N-
benzyl glycine ethyl ester 145 led to the formation of the Dieckmann cyclization 
precursors 148 and 149 in 91% and 95% yield, respectively. The Dieckmann cyclization 
of 148 using sodium/methanol under reflux gave 150 in 88% yield. Treatment of 149 
with sodium/benzyl alcohol gave 151 in a low yield of 14%. This methodology was 
improved by using sodium hydride in benzene, which gave 151 in 63% yield.  
 
The next step was to introduce the methyl group at the C7 position. Unfortunately, both 
150 and 151 were poorly soluble in common organic solvents. Attempts at methylation 
using various methods including NaH/MeI, tBuOK/BuOH/MeI and K2CO3/MeI all 
failed to give the desired products. After further investigation, the use of TBAF with 
methyl iodide in THF was found to be successful and gave the methylated products 152 
and 153 in high yields (77% and 70%, respectively). 
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Alkylation of 150 using various electrophiles was then carried out to investigate the 
efficiency of this reaction, Table 5.50 This is also interesting as it suggests this 
methodology could allow access to a variety of lactacystin analogues. 
 
Table 5.  Alkylation of 150 using TBAF (1.2 equiv.) and RI (2 equiv.) in THF. 
 
R Yield (%) 
Me 77 
Et 63 
PhCH2 89 
CH2=CHCH2 60 
PhCH= CHCH2 64 
EtO2 CCH2 46 
 
 
Later work details improvements made to the Dieckmann cyclization step; instead of 
using sodium hydride in benzene as described above, it was found that treatment of 149 
with TBAF in diethyl ether at room temperature gave the tetrabutylammonium salt 155. 
Without purification, treatment of the salt with methyl iodide in THF gave 153 in 73% 
yield from 149, Scheme 27. As well as the desired product, the enol ether regioisomer 
156 was also isolated (153:156, 3.5:1). These milder conditions are much more 
attractive for a synthesis. 
  
 
Reagents and Conditions: a) TBAF, Et2O, RT, 24 h; b) MeI, THF, RT, 24 h, 73%. 
Scheme 27. 
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Another key step in the synthesis is the introduction of the functionality at the C5 
position following Mander’s protocol, Scheme 28. Deprotonation of 153 using lithium 
bis(trimethylsilyl)amide (LiHMDS) in the presence of 1,3-dimethyl-3,4,5,6-tetrahydro-
2(1H)-pyrimidinone (DMPU) generated the corresponding enolate; methyl 
cyanoformate was then added to the solution to give 157 in 75% yield as a 5:1 mixture 
of diastereoisomers. As observed above (Table 4), the use of Mander’s reagent did not 
lead to any competing O-acylation. 
 
 
Reagents and Conditions: a) LiHMDS, DMPU, THF, MeO2CCN, 75%; b) CH3CHCOCl, pyridine, 
CH2Cl2, RT, 24 h, 68%; c) H2, Pd/C, THF, 98%. 
Scheme 28. 
 
Formation of the quaternary centre at the C5 position using isobutyraldehyde under 
various conditions including Mukaiyama’s protocol proved unsuccessful. After the use 
of methyl cyanoformate gave exclusively the C-alkylated product in the previous step, 
attempts were made to alkylate compound 157 using isobutyryl cyanide. Unfortunately, 
the desired alkylated product was not isolated. When isobutyryl chloride was used, only 
the O-acylation product was observed; 158 was isolated in 68% yield. When 158 was 
subjected to hydrogenolysis conditions, the decarboxylated product 159 was obtained in 
98% yield. 
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To prevent the O-acylation, the reaction conditions were modified.51 Treatment of 157 
with sodium hydride in DMF followed by the addition of allyl bromide gave 160 in 
44% yield; no O-allylation was observed. When the reaction was repeated using 
methallyl bromide, the analogous compound 161 was prepared in much higher yield 
(75%). 
 
 
Reagents and Conditions: a) NaH, DMF, allyl bromide, RT, 160: 44%; b) NaH, DMF, methallyl 
bromide, RT, 161: 75%; c) H2, Pd/C, THF, 162: 90%. 
Scheme 29. 
 
When 160 was subjected to standard hydrogenation conditions, the decarboxylation of 
the benzyl ester with concomitant reduction of the double bond occurred to give 162 in 
90% yield. This advanced intermediate contains the complete carbon skeleton of clasto-
lactacystin dihydroxyacid and was achieved after only five steps.51 
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2.0 Results and Discussion 
 
2.1 Retrosynthetic Analysis of Lactacystin and Analogues 
 
Lactacystin and its analogues share the same substituted lactam core, but differ at the 
C5 and C7 positions, allowing us to consider a common retrosynthetic approach. The 
retrosynthetic analysis below (Scheme 1) shows the key steps required for a synthesis 
of lactacystin and its analogues. Using a commercially available amino acid derivative 
as the starting material, the C5 functionality is present from the start, and the use of 
different amino acids allows variation at this position. Key steps include a Dieckmann 
cyclization and a Mander’s acylation to form the lactam ring and the C5 quaternary 
centre, respectively. The use of a range of alkylating agents during the tandem 
Dieckmann cyclization/alkylation should allow the installation of a C7 group that 
differs between the natural products as well as allowing access to novel structures. A 
decarboxylation at the C7 position and the reduction of the ketone moiety at the C6 
position would then be required to give the fully functionalized core found in this class 
of proteasome inhibitors. 
 
 
Scheme 1. 
 
The work presented below details the use of L-leucine, L-serine and L-valine derivatives 
as the starting materials. Work has mainly been focused on the use of L-leucine (which 
will lead to the formation of deoxylactacystin) as it has the iso-butyl group present from 
the start and shares the closet structural similarity to lactacystin. We hope that by using 
a chiral starting material, in this case L-leucine, we can induce the desired 
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stereochemistry at the C5, C6 and C7 positions throughout the synthesis. Indeed, this β-
lactone class of inhibitors is particularly challenging due to the number of stereocentres 
that need to be generated and controlled during the synthesis. 
 
2.2 Synthesis of the Leucine Analogue 
 
2.2.1 Proposed Synthetic Route Towards Deoxylactacystin 
 
Using L-leucine methyl ester hydrochloride 6 as the starting material, we hoped to 
synthesize the advanced intermediate 11 that was reported by Corey in 19991 using the 
route developed by the Page group as described above (Chapter 1).  
 
 
Scheme 2.  
 
2.2.2 Synthesis of the Dieckmann Cyclization Precursor 8 
 
Due to the problems encountered when using the Boc and benzyl protecting groups 
described above, we turned our attention towards the 4-methoxybenzyl moiety as the 
protecting group. Corey reported the use of this group and its easy removal using ceric 
ammonium nitrate in his early approach to the synthesis of lactacystin.2 Compound 7 
can be synthesized in one-pot from commercially available L-leucine methyl ester 
hydrochloride 6 using triethylamine, 4-methoxybenzaldehyde and sodium borohydride 
in methanol; however, low yields (53%) were obtained. The reaction did not afford 
reproducible yields and, at times, resulted in an inseparable mixture of the desired 
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product 7 and p-methoxybenzylalcohol. This result indicated that full conversion to the 
imine 13 was vital before introduction of the reducing reagent. Hence, a two-step 
procedure was investigated.  
 
 
Reagents and Conditions: a) 4-methoxybenzaldehyde, Et3N, NaBH4, MeOH, 53%; b) 4-
methoxybenzaldehyde, acetic acid, toluene, reflux, 100%; c) NaBH3CN, acetic acid, MeOH, 93%. 
Scheme 3. 
 
In order to improve the conversion to the imine, 4-methoxybenzaldehyde and acetic 
acid were heated under reflux in toluene using a Dean-Stark apparatus to give 13, which 
was used without further purification. The use of the Dean-Stark apparatus drove the 
reaction equilibrium to the required imine by removal of water. It is easy to determine 
whether full conversion to the imine has occurred by 1H NMR spectrum analysis of the 
crude product. If the aldehyde starting material is still present a characteristic singlet 
peak can be seen just below 10 ppm. The reduction of 13 was achieved using sodium 
borohydride and acetic acid in methanol; however, compound 7 was isolated in 58% 
yield, a marginal improvement on the method described above. When sodium 
cyanoborohydride, a reducing reagent known to be selective towards imine reduction, 
was used, amine 7 was obtained in 93% yield. Because acetic acid is required to control 
the pH of this reaction, the use of sodium cyanoborohydride can be dangerous as toxic 
hydrogen cyanide gas can be released. Sodium triacetoxyborohydride is often used as a 
safer alternative to sodium cyanoborohydride for imine reductions. It is known that 
sodium borohydride can react with acetic acid to form sodium triacetoxyborohydride; 
this could have occurred in the two-step reductive amination described above. However, 
when the reaction was carried out with commercially available sodium 
triacetoxyborohydride, no reaction occurred and the starting material was recovered. 
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Table 1. Investigation into the reduction of compound 13. 
 
Reaction Conditions Reducing Reagent Yield (%) 
AcOH, MeOH, 0 °C to RT NaBH4 53 
AcOH, MeOH, 0 °C to RT NaBH3CN 93 
MeOH, 0 °C to RT NaBH(OAc)3 S.M. 
 
The Dieckmann cyclization precursor 8 was then synthesized using a peptide coupling 
reaction. There are many peptide coupling reagents reported in the literature; these 
include (but are not limited to) phosphonium reagents (for example: BOPCl, first used 
by Corey to form the lactone moiety in omuralide), uronium reagents (for example: 
HATU, a reagent commonly used in the synthesis of macrocycles), carbodiimide 
reagents (for example, EDAC·HCl) and imidazolium reagents (for example, CDI).3 
 
 
Figure 1. Coupling reagents. 
 
The synthesis of potassium benzyloxycarbonyl acetate 16 required for the peptide 
coupling was achieved over two steps from malonic acid in 72% yield (Scheme 4).4 
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Reagents and Conditions: a) benzyl alcohol, p-TsOH, toluene, reflux, overnight; b) KOH in BnOH (1 
M), 72% (2 steps); c) oxalyl chloride, toluene, 34 °C, 24 h. 
Scheme 4.  
 
We chose to use a commercially available carbodiimide coupling reagent, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC·HCl), due to its ease 
of handling and because the by-product formed is easily removed during work-up as it 
is water-soluble under acidic conditions. The treatment of 7 with potassium 
benzyloxycarbonyl acetate 16, EDAC·HCl, 4-(dimethylamino)pyridine (DMAP) and N-
methylmorpholine (NMM) in dichloromethane gave 8 in 72% yield after silica gel 
chromatography purification. 
 
 
Reagents and Conditions: a) potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, NMM, 
CH2Cl2, 72%.  
Scheme 5.  
 
Room temperature 1H NMR spectrum analysis shows the presence of two rotamers, and 
so a variable-temperature (VT) 1H NMR experiment was carried out in deuteriated 
dimethylsulfoxide (d6-DMSO) at 25, 75 and 100 °C, Figure 2. Analysis of the resulting 
spectra clearly shows the peaks beginning to coalesce as the temperature is increased. 
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Figure 2. Variable temperature 1H NMR spectra of compound 8 at 1: 25 °C, 2: 75 °C 
and 3: 100 °C. 
 
The optimization of this reaction was investigated using methods other than 
carbodiimide coupling. The treatment of potassium benzyloxycarbonyl acetate 16 with 
oxalyl chloride gave the corresponding acid chloride 17 without purification in 
quantitative yield. The addition of the acyl chloride to 7 in the presence of pyridine and 
DMAP gave the Dieckmann precursor 8 in only 58% yield. The coupling reagent 
propane phosphonic acid anhydride, known commercially as T3P®, was also used for 
this reaction.5 The by-products formed from using T3P® are all water-soluble and can be 
easily removed during aqueous work-up, which aids the purification of the desired 
compound. T3P® is also a greener reagent as it is less toxic than the carbodiimide 
reagents. The treatment of 7 with potassium benzyloxycarbonyl acetate 16, N,N-
diisopropylethylamine (DIPEA or Hünig’s base) and T3P® in tetrahydrofuran gave 8 in 
62% yield. 
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Table 2. Synthesis of the Dieckmann cyclization precursor 8 from 7.  
 
Reaction Conditions Coupling Reagent Yield (%) 
16, NMM, DMAP, CH2Cl2 EDAC·HCl 72 
17, pyridine, DMAP, CH2Cl2 None 58 
16, DIPEA, THF` T3P® 62 
 
2.2.3 The Dieckmann Cyclization 
 
The Dieckmann cyclization, also known as the Dieckmann condensation, is a form of 
intramolecular Claisen condensation used to synthesize cyclic β-ketoesters of varying 
ring size. In 1894, Dieckmann reported the reaction of the diesters 18 and 20 with 
sodium in ethanol to give the corresponding cyclic β-ketoesters 19 and 21, 
respectively.6  
 
 
Reagents and Conditions: a) Na, EtOH. 
Scheme 6.  
 
When diester 22 is treated with a base, the ester enolate intermediate 23 is formed 
followed by attack of the enolate onto the other ester moiety to give the cyclic β-
ketoester 25. The rate-determining step of the reaction is the ring formation step, the 
attack of the ester enolate onto the carbonyl of the second ester moiety. 
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Scheme 7. The Dieckmann condensation mechanism.  
 
There are many natural product syntheses in the literature that employ a Dieckmann 
condensation. Grossman and co-workers reported the synthesis of (±)-sacacarin 28 in 
1996 in which a Dieckmann condensation was used to synthesize the second ring 
moiety of the natural product in high yield (90%).7  
 
 
Reagents and Conditions: a) 1. NaOEt, EtOH, reflux; 2. TsOH (cat), EtOH, C6H6-H2O, reflux, 90% (2 
steps). 
Scheme 8. The synthesis of (±)-sacacarin. 
 
In 2003, Covarrubias-Zúñiga reported the synthesis of mycophenolic acid.8 2-Geranyl-
1,3-acetonedicarboxylate 29 was treated with sodium hydride followed by the addition 
of a protected alkynal to form the enolate which then underwent Dieckmann 
condensation to give the substituted aromatic ring of mycophenolic acid 31 in 33% 
yield (Scheme 9). 
 
 
Reagents and Conditions: a) 1. NaH, THF, RT; 2. Protected alkynal, 2 h; 3. HCl 33% (3 steps). 
Scheme 9. The synthesis of mycophenolic acid. 
RO
O
OR
O
RO
O
OR
O
RO O
OR
O
OR
OO
22 23 24 25
n n n n
Me
EtO2C CO2Et
CO2Et
CN
COMe
Me
EtO2C
CO2Et
CN
O
OEt
OO
Me
O
Me
O
a
28 (±)-Sacacarin26 27
MeO2C
R
O
CO2Me
MeO2C
R
O
CO2Me
CHO OPiv
OH
R
CHO
HO
OPiv
O
OMe
OH
Me
MeO
O
O
HO2C
a
Dieckmann
condensation
32 Mycophenolic acid
29   R=geranyl 30   R=geranyl 31   R=geranyl
	 	 Results	and	Discussion		
	 57	
As described above (Chapter 1, Scheme 27), the Page group reported a two-step 
process wherein cyclization occurs first using TBAF in diethyl ether to form the 
tetrabutylammonium salt, followed by the methylation step in tetrahydrofuran to install 
the C7 functionality. Methylation occurs through the enolate intermediate 33 resulting 
in the formation of the two diastereoisomers (±)-34 and (±)-9 in 30 and 29% yield, 
respectively (Scheme 10). Unfortunately, diastereoisomers (±)-34 and (±)-9 are difficult 
to separate using silica gel chromatography because of their similar polarity, leading to 
the isolation of a mixture of (±)-34 and (±)-9 (as well as the pure diastereoisomers). 
 
 
Reagents and Conditions: a) TBAF, Et2O, RT, overnight; b) MeI, THF, RT, overnight, (±)-34: 30%, 
(±)-9: 29% (2 steps). 
Scheme 10.  
 
Disappointingly, the reaction did not appear to be diastereoselective. Due to the 
planarity of enolate intermediate 33, the small size of the methyl group and the bulky 
group at C5 being too far away, the addition does not favour either face, resulting in the 
formation of two diastereoisomers in a 1:1 mixture. Furthermore, specific rotation 
measurements show racemization had occurred at this point. 
 
Unfortunately, we were unable to obtain crystals suitable for X-ray crystallography of 
(±)-34 and (±)-9; however, work within the group yielded crystals of the p-nitro benzyl 
analogue of (±)-34 (Figure 3) allowing us to deduce the relative configuration of (±)-34 
and (±)-9. 
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Figure 3. X-ray crystallographic structure of the p-nitro benzyl analogue of (±)-34. 
 
 The cyclization results in the formation of two stereocentres and if the only enolate 
generated was enolate 33, two non-racemic diastereoisomers would be the only 
products formed. There are three possible explanations for the racemization: either the 
racemization occurs before the cyclization (35), or after the cyclization but before the 
methylation (37), or after the methylation (38); it could also possibly occur during more 
than one step. We do not believe racemization occurs before cyclization; indeed, the 
difference in pKa between the enolisable proton of the amino ester (pKa≈25) and the 
malonyl protons (pKa≈13) leads us to believe racemization should not occur at this 
point. Enolization through the C5 position could occur before or after methylation, as 
methoxide is generated during the cyclization step, so deprotonation at C5 would be 
possible. Interestingly, we were unable to observe any products resulting from the 
methylation at C5. Due to the large excess of methyl iodide used, if enolization 
occurred after methylation at C7 to form 38, we would also expect to see methylation at 
C5. However, if enolization occurs first, selective methylation at C7 may be observed 
because the proton at C7 (pKa≈11) is much more acidic than that at C5 (pKa≈25) 
making 33 the thermodynamically more stable enolate form; hence, the equilibrium 
between 33 and 37 is shifted towards 33.  
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Scheme 11. 
 
This result is not unprecedented; racemization during Dieckmann cyclization has been 
reported previously. In 1990, Poncet and co-workers reported the ‘racemisation during 
the synthesis of tetramic acids via Dieckmann cyclisation’.9 In 1964, Lukas reported the 
total synthesis of holomycin in which a key step was the cyclization of 40 with sodium 
ethoxide to form the racemic lactam (±)-41.10 
 
 
Reagents and Conditions: a) diketene, EtOH, RT; b) NaOEt, EtOH, benzene, reflux. 
Scheme 12.  
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A one-pot tandem Dieckmann cyclization/methylation synthesis was also attempted 
with no notable loss in yield. Treatment of 8 with TBAF and methyl iodide in 
tetrahydrofuran gave the diastereoisomers (±)-34 and (±)-9 in 22% and 39% yield, 
respectively (Scheme 13). When diethyl ether was used instead of tetrahydrofuran, no 
reaction was observed and the starting material was recovered. 
 
 
Reagents and Conditions: a) TBAF, MeI, THF, (±)-34: 22%, (±)-9: 39%. 
Scheme 13. 
 
Although (±)-34 and (±)-9 were isolated in different yields, the 1H NMR spectrum 
analysis of the reaction mixture shows the formation of the diastereoisomers in a 1:1 
ratio, as observed in the two-step procedure.  
 
The formation of unwanted diastereoisomers is never an attractive feature in total 
synthesis as only one has the correct relative stereochemistry required thereby reducing 
the yield of usable material. 
 
2.2.4 The Mander’s Acylation 
 
The next step in our synthesis was the introduction of the C5 functionality that will 
eventually be used to form the β-lactone moiety, found to be essential to the inhibitors’ 
ability to bind to the 20S proteasome. 
 
In 1983, Lewis Mander reported the ‘Regioselective synthesis of β-ketoesters from 
lithium enolates and methyl cyanoformate’ in which he described the treatment of a 
range of ketones with lithium diisopropylamine (LDA), hexamethylphosphoramide 
(HMPA) and methyl cyanoformate in tetrahydrofuran at −78 °C to give the 
corresponding β-ketoesters.11 This method was the first of its kind to allow access to 
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these types of compounds in consistently high yields with complete chemoselectivity. 
This reaction can also be carried out using methyl chloroformate instead of methyl 
cyanoformate.12, 13 
 
 
Reagents and Conditions: a) LDA, THF b) HMPA, methyl cyanoformate. 
Scheme 14. 
 
Older methods such as the reaction with acyl halides or anhydrides often lacked 
selectivity and resulted in a mixture of both the C- and O-alkylated products. Acylation 
of the cyclohexanone enolate 45 gives different ratios of C- and O-alkylated products 
depending on the metal cation and solvent used (Table 3).14 
 
Table 3. A comparison between the C- and O-alkylation when reacting with acetic 
anhydride. 
 
 
Metal Cation Solvent Yield of 46 Yield of 47 
Li+ Dimethoxyethane (DME) 49% 16% 
Mg2+ Diethyl ether 25% 43% 
 
With crystallographic data analysis showing that compound (±)-9 has the desired 
relative stereochemistry, the acylation reaction was carried out following a procedure 
similar to Mander’s (Scheme 15). 
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Reagents and Conditions: a) LiHMDS, DMPU, methyl cyanoformate, THF, −78 °C, 86%. 
Scheme 15.  
 
Compound (±)-9 was treated with LiHMDS (freshly prepared from n-butyl lithium and 
hexamethyldisilazane) in tetrahydrofuran at −78 °C and the reaction mixture stirred for 
one hour. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) and methyl 
cyanoformate were then added. The reaction was stirred at −78 °C for four hours after 
which it was quenched using an aqueous solution of ammonium chloride. The desired 
compound (±)-10 was isolated in 79% yield. Due to the reaction going through an 
enolate intermediate, addition of the methyl ester group could occur from the top or 
bottom face resulting in the formation of diastereoisomers. However, this was not 
observed; analysis of the 1H NMR spectrum confirms that the acylation is 
stereoselective as a single product was observed, and crystallographic data of the 
product obtained from the reduction of the ketone moiety of (±)-10 (Figure 5, 
compound (±)-51) shows that the C5 methyl ester moiety adds to the opposite side of 
the C7 benzyl ester. When we compare the stereochemistry of lactacystin and (±)-10 
(Figure 4) we can see that the correct relative stereochemistry has been achieved. 
 
 
Figure 4. Relative configuration of (±)-10. 
 
Due to the racemization occurring during the Dieckmann cyclization/methylation step 
and the stereoselective nature of the acylation, we thought that the separation of the 
diastereoisomers (±)-34 and (±)-9 might not be necessary. Indeed, (±)-34 and (±)-9 
should lead to the same racemic enolate (±)-38. Then, in theory, if the acylation reaction 
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were not selective, racemic enolate (±)-38 would lead to four possible stereoisomers: 
48, 49, 10 and 50. It is important to note here that compounds 48 and 10, as well as 49 
and 50, are enantiomers, respectively. 
 
 
Scheme 16. Investigation into the Mander’s acylation reaction.  
 
As the acylation is selective, we predicted that compound (±)-34 should behave in the 
same way as (±)-9, and lead to the formation of (±)-10. Indeed, when compound (±)-34 
was subjected to the acylation conditions described above, only compound (±)-10 was 
isolated in 73% yield. NMR and IR spectroscopic and mass spectrometric analysis of 
the product obtained showed the compound isolated from this reaction was the same as 
that isolated from the reaction of (±)-9. To further support this conclusion, the reaction 
was attempted using a mixture of (±)-34 and (±)-9. Unsurprisingly, only one compound 
was isolated from this reaction, compound (±)-10. 
 
When we first started investigating this reaction, the LiHMDS was prepared in situ from 
the reaction of n-butyl lithium and hexamethyldisilazane in tetrahydrofuran at −78 °C 
giving (±)-10 in 79% yield. The yield was increased to 86% when commercially 
available LiHMDS was used. This difference in yield may be due in part to the 
accumulative internal error associated with the preparation of LiHMDS and subsequent 
cannulation of the base into the reaction mixture. In 2013, Pfizer reported the synthesis 
of filibuvir in which they use LiHMDS to perform a Dieckmann cyclization.15 They 
describe how both the source of LiHMDS and the mode of addition of LiHMDS can 
affect the yield of product obtained. They report a difference in yield when using n-
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BuLi or Li metal as the lithium source and a difference in yield when using LiHMDS 
from different suppliers. They stated that they did not know why there was a difference 
and concluded by describing the results as an ‘unexplained LiHMDS source variation’. 
 
Table 4. Investigation into the Mander’s acylation reaction.  
 
Starting Material Base Yield of (±)-10 (%) 
(±)-9 LiHMDS (made in situ) 79 
(±)-34 LiHMDS (made in situ) 73 
Mixture of (±)-9 and (±)-34 LiHMDS (made in situ) 78 
Mixture of (±)-9 and (±)-34 LiHMDS (commercial) 86 
 
 
2.2.5 Steps Towards the Synthesis of (±)-11 
 
At this stage in the synthesis, two routes are possible to obtain the desired intermediate; 
the first possibility involves the reduction of the ketone at C6 followed by 
decarboxylation of the benzyl ester moiety at the C7 position  (Scheme 17, Route A), 
while the second route starts with the decarboxylation of the benzyl ester moiety at the 
C7 position followed by reduction of the ketone at C6 (Scheme 17, Route B). 
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Scheme 17.  
 
2.2.5.1 Route A Towards (±)-11 
 
2.2.5.1.1 Reduction of the Mander’s Reaction Product, (±)-10 
 
 
Reagents and Conditions: a) NaBH4, EtOH, 0 °C to RT, 30 min, 43-57%. 
Scheme 18. 
 
Under standard conditions using sodium borohydride (Scheme 18), compound (±)-51 
was isolated as a single diastereoisomer in yields of 43-57%. Crystallographic studies 
show that the correct relative stereochemistry was achieved when compared to that of 
lactacystin; the hydroxyl moiety, the methyl group and the methyl ester, at the C6, C7 
and C5 positions, respectively, are all on the same side relative to each other. 
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Figure 5. X-ray crystallographic structure of (±)-51.  
 
In an attempt to optimize this reaction, other reducing reagents were screened under 
varying conditions (Table 5).  The use of sodium cyanoborohydride or sodium 
triacetoxyborohyride resulted in full recovery of the starting material. Attempts using 
DIBAL also led to the recovery of the starting material probably due to the bulky nature 
of DIBAL. 
 
The Meerwein-Ponndorf-Verley (MPV) reduction (the reverse reaction, the oxidation of 
the alcohol, is known as the Oppenauer oxidation) is a well-documented reaction that 
uses an excess of aluminium isopropoxide and iso-propyl alcohol to reduce ketones to 
the corresponding alcohols.16 We had hoped to use this reaction as one of its key 
features is its highly diastereoselective nature when applied to rigid cyclic compounds.  
 
 
Scheme 19. The Meerwein-Ponndorf-Verley reduction. 
 
Formation of the aluminium complex occurs at the less hindered face; this then directs 
the subsequent formation of the six-membered transition state and therefore the hydride 
transfer. Unfortunately, this approach was not successful and the starting material was 
N
CO2Bn
MeHO
PMB
O
MeO2C
Lactacystin
N
H
HO
O
O
S
HO2C
AcHN
OH
(±)-51
O
R'
R
(i-PrO)3Al
(i-PrO)2Al
O
H
O
R'
R
O
O
H
R
R'
(i-PrO)2Al
(i-PrO)2Al
O
O
H
R'
R
OH
R'R
H
work up
	 	 Results	and	Discussion		
	 67	
recovered (Table 5, Entries 12 and 13). One of the drawbacks of the MPV reduction is 
that it is greatly affected by steric hindrance; hence, we believe, with a relatively small 
5-membered ring and large groups at the C5 and C7 positions, the steric hindrance was 
too great. 
 
Table 5. Investigation into the reduction of (±)-10. 
 
Entry Reducing Reagent Reactions Conditions Product Yield (%) 
1 NaBH3CN (2 equiv.) Acetic acid, MeOH,  
0 °C – RT, 4 h 
S.M. 100 
2 NaBH3CN (2 equiv.) Acetic acid, MeOH,  
0 °C – RT, 48 h 
S.M. 100 
3 Na(AcO)3BH (10 
equiv.) 
CH2Cl2, 0 °C – RT,  
24 h 
S.M. 100 
4 NaBH4 (2 equiv.) Acetic acid, MeOH,  
0 °C – RT, 4 h 
S.M. 100 
5 NaBH4 (0.7 equiv.) EtOH, −10 °C, 2 h (±)-51  
(±)-52 or (±)-53 
(±)-52 or (±)-53 
42 
29 
10 
6 NaBH4 (2 equiv.) EtOH, 0 °C – RT,  
30 min 
(±)-51 43-57 
7 NaBH4 (0.7 equiv.) EtOH, −20 °C, 1 h (±)-51 51 
8 NaBH4 (0.7 equiv.) EtOH, −10 °C, 1 h (±)-51 54 
9 NaBH4 (0.7 equiv.) EtOH, −10 °C, 30 min S.M. 
(±)-51 
31 
52 
10 DIBAL (1 equiv.) THF, 60 °C, 4 h S.M. 100 
11 DIBAL (2 equiv.) THF, 60 °C, 4 h S.M. 100 
 12 (iPrO)3Al (10 
equiv.) 
i-PrOH, reflux, 24 h S.M. 100 
13 (iPrO)3Al (10 
equiv.) 
i-PrOH, Dean-Stark 
reflux, 24 h 
S.M. 100 
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With all attempts failing when changing the reducing reagent, optimization of the 
reaction conditions using sodium borohydride was carried out. It became clear that both 
reaction time and temperature were significant factors in the success of this reaction. 
 
 
Reagents and Conditions: a) NaBH4, EtOH, −10 °C, 2 h, (±)-51: 42%, (±)-52 or (±)-53: 29%, (±)-52 or 
(±)-53: 10%. 
Scheme 20. 
 
When using sodium borohydride as the reducing reagent at −10 °C for two hours (Table 
5, Entry 5), the desired compound (±)-51 was isolated as the first eluting compound 
after silica gel column chromatography in 42% yield. Two over-reduced products, 
diastereoisomers (±)-52 and (±)-53, were also isolated from the reaction. Although we 
know the structures of (±)-52 and (±)-53, we were unable to determine their relative 
configurations. The second eluting compound was isolated in 29% yield and the third in 
10% yield. As we do not isolate compound (±)-54, we can predict the relative rates of 
the reaction. The formation of (±)-51 must be much faster compared to that of (±)-54; 
however, (±)-54 must then be converted to (±)-53 very quickly (Scheme 20). 
 
 
Reagents and Conditions: a) NaBH4, EtOH, −10 °C, 30 min, (±)-51: 52%, (±)-10: 31%. 
Scheme 21. 
N
CO2Bn
MeO
PMB
O
MeO2C
(±)-10
N
CO2Bn
MeHO
PMB
O
MeO2C
N
MeHO
PMB
O
MeO2C
N
MeHO
PMB
O
MeO2C
OH OHa
N
CO2Bn
MeHO
PMB
O
MeO2C
(±)-54
(±)-51 (±)-52 (±)-53
slow
fast
fast
slow
N
CO2Bn
MeO
PMB
O
MeO2C
(±)-10
N
CO2Bn
MeHO
PMB
O
MeO2C
(±)-51
a
N
CO2Bn
MeO
PMB
O
MeO2C
(±)-10
+
	 	 Results	and	Discussion		
	 69	
Optimization of the conditions using sodium borohydride led to the isolation of the 
product (±)-51 in 52% yield as well as the recovery of starting material (±)-10 in 31% 
yield (Table 5, Entry 9). 
 
Fortunately, this reaction was completely stereoselective. The formation of (±)-54 under 
these conditions is so slow that, when left for only 30 minutes, only one diastereoisomer 
was ever isolated and, as described above, no trace of (±)-54 was ever observed.  
Although this is a positive result, as the correct relative stereochemistry in relation to 
lactacystin (Figure 5) has been achieved, this is an interesting result because hydride 
addition occurs from the opposite face to that which one would predict. The crystal 
structure shows the benzyl ester, iso-butyl and PMB groups all occupying space above 
the ring; we can assume this would be the same for the starting material (±)-10. It 
would, therefore, not be unprecedented to expect the hydride to approach from 
underneath, which is the least sterically hindered face, resulting in the hydroxyl group 
being on the same side as the benzyl ester, iso-butyl and PMB groups. When using 
Newman projections to predict the stereochemistry of the product obtained from 
reduction the hydroxyl group would, again, be expected to form on the same side as the 
benzyl ester, iso-butyl and PMB groups.  
 
 
Figure 6.  The Newman projection for the prediction of the stereoselectivity of the 
ketone reduction. 
 
In 2008, Moloney and co-workers reported the ‘equilibration in bicyclic pyroglutamates 
by ring opening-reclosure’ in which the stereoselective ketone reduction of 55 is 
described using NaBH4 in ethanol or LAH in THF to give the corresponding alcohol 56 
(Scheme 22).17 
O CO2BnMe OH
H
CO2BnMe
angle of attack
HO CO2Bn
MeH
O CO2Mei-Bu OH
H
i-Bu CO2Me
angle of attack
i-Bu OH
HMeO2C
	 	 Results	and	Discussion		
	 70	
 
Reagents and Conditions: a) NaBH4, EtOH, 0 °C, 1 h; b) LiAlH4, THF, −78 °C, 1 h. 
Scheme 22. 
 
They state that the selectivity is achieved by endo-addition of the small hydride 
nucleophile anti- to the lone pair of the nitrogen. In our case the lone pair on the 
nitrogen is on the bottom face and so the hydride will attack from the top face (the same 
face as the benzyl ester, iso-butyl and PMB groups) resulting in the hydroxyl group 
being on the same side as the methyl ester group at C5 and the methyl group at C7. 
 
2.2.5.1.2 Decarboxylation of Compound (±)-51 
 
 
Reagents and Conditions: a) H2, Pd(OH)2/C, THF, quant. 
Scheme 23. 
 
When (±)-51 was treated under hydrogenolysis conditions using palladium hydroxide 
on carbon and a hydrogen balloon the corresponding carboxylic acid (±)-57 was 
isolated in quantitative yield without purification. We had hoped that the treatment of 
(±)-51 under the hydrogenolysis conditions would proceed with concomitant 
decarboxylation due to the presence of the carbonyl moiety in the β position enabling 
formation of the enolate. This was not the case however, and the corresponding 
carboxylic acid (±)-57 was the only product isolated from this reaction. For 
decarboxylation to occur the intermediate must be stabilized through conjugation, 
usually through the enolate. When the ketone of (±)-10 is reduced to a hydroxyl moiety, 
the enolate can no longer be formed. The carbonyl group at C8 is part of an amide 
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moiety and conjugation between the nitrogen atom lone pair and the carbonyl group is 
possibly too strong to allow enolization to proceed through this position. 
 
A literature search shows that this result is not unprecedented. There are many reports 
of the debenzylation of substituted γ-lactams to form the corresponding carboxylic 
acid.18 In 1994, Leonard and co-workers reported ‘a sulfolene-based intramolecular 
Diels-Alder approach to the synthesis of manzamine A’ in which they subject the benzyl 
ester 59 to hydrogenolysis conditions using H2 and 5% Pd/C in diethyl ether, and the 
product obtained is the corresponding carboxylic acid 60.19 
 
 
Reagents and Conditions: a) 1. (Me3Si)2NLi, THF; 2. PhCH2COCN; b) H2, 5% Pd/C, Et2O. 
Scheme 24. 
 
2.2.5.1.2.1 Radical-Mediated Decarbonylation of the Acyl Selenide 
 
As the hydrogenolysis of (±)-51 yielded the carboxylic acid (±)-57 instead of the 
desired (±)-11, methods to achieve the decarboxylation of (±)-57 were investigated. 
First, we decided to carry out the synthesis of an acyl selenide from the carboxylic acid 
(±)-57 followed by a radical-mediated decarbonylation to give the desired advanced 
intermediate (±)-11. 
 
 
Scheme 25.  
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Selenium compounds have many uses in organic synthesis including in radical reactions 
as precursors. The C-Se and Se-H bonds are considered relatively weak, this along with 
the polarizability of the selenium atom makes organoselenides useful compounds for 
radical chemistry.20 
 
 
Scheme 26.  
 
Tributyltin hydride (Bu3SnH), tributylgermanium hydride (Bu3GeH) and 
tris(trimethylsilyl)silane (TTMSS) are commonly used as radical initiators, where the 
precursor is a halide, for example bromides and iodides. Selenide groups, specifically 
phenylselenenyl (PhSe) groups, have been used to replace the halides, and rate studies 
show that abstraction rates with Bu3Sn, Bu3Ge, and primary alkyl (RCH2) radicals 
are comparable to that of the corresponding bromide, but smaller than the corresponding 
iodide by several orders of magnitude.21 
 
Table 6. Reaction constants for the abstraction of PhSe, Br and I. 
Radical Compound Temperature (°C) Rate Constant (M−1s−1) 
RCH2 PhSe-CH2CO2Et 50 1.0 x 105 
RCH2 Br-CH2CO2Et 50 0.7 x 105 
RCH2 I-CH2CO2Et 50 2.6 x 107 
Bu3Sn PhSe-CH2CO2Et 25 1.2 x 108 
Bu3Ge PhSe-CH2CO2Et 25 9.2 x 108 
 
Interestingly, when acyl selenides are used, the abstraction of the phenylselenenyl group 
is faster than when using alkylphenylselenides. The most common reagents for the 
abstraction of the PhSe group from an acyl selenide are Bu3SnH and TTMSS; however, 
Bu3GeH has also been shown to work in the same way. Acyl selenides are easily 
synthesized from the corresponding carboxylic acid. 
 
As well as the abstraction rates, selenenyl groups are a popular choice as they are often 
referred to as ‘radical protective groups’. Indeed, when compared to the halides, they 
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can survive many more synthetic transformations, allowing them to be introduced at a 
much earlier stage of the synthesis if necessary. Another advantage of acyl selenides 
compared to acyl halides is their stability: it is often possible to purify acyl selenides 
using silica gel column chromatography. 
 
Acyl selenides are often used to generate acyl radicals that are then cyclized (Scheme 
27).22 The main drawback of this reaction is the unwanted loss of CO; performing the 
reaction under an atmosphere of CO can easily prevent this. In our proposed route this 
is not a problem, as decarbonylation is required to give the desired product. 
 
 
Reagents and Conditions: a) Bu3P, (PhSe)2, CH2Cl2, 24 h; b) Bu3SnH, AIBN, CO, CH3CN. 
Scheme 27. 
 
In 2005, the Allin group reported the synthesis of the indole alkaloid deplancheine by 
employing the radical-mediated decarbonylation of an acyl selenide (Scheme 28).23 The 
alcohol 61 was oxidized to the carboxylic acid 62, which was then treated with 
diphenyldiselenide and tributylphosphine (TBP) in dichloromethane to give the 
corresponding acyl selenide 63. The radical-mediated decarbonylation of 63 was 
achieved upon treatment with n-Bu3SnH and AIBN as the radical initiator in toluene to 
give 64. 
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Reagents and Conditions: a) 1. IBX, DMSO, RT, 24 h, 70%; 2. Et3N, (Boc)2O, DMAP, THF, RT, 4 h, 
98%; 3. NaClO2, NaH2PO4, 1-methyl-1-cyclohexene, CH3CN, t-BuOH, H2O, 0 °C to RT, 18 h, 83%; b) 
(PhSe)2, PBu3, CH2Cl2, 0 °C to RT, 18 h, 83%; c) n-Bu3SnH, AIBN, toluene, 80 °C, 2 h, 73%. 
Scheme 28. 
 
Following the reported procedure, the carboxylic acid (±)-57 was treated with 
diphenyldiselenide and tributylphosphine in anhydrous dichloromethane at room 
temperature overnight.23 Unfortunately, the desired product was not observed and the β-
lactone (±)-66 was the only product isolated from the complex mixture in a 43% yield. 
IR spectrum analysis shows a stretch at 1842 cm−1 which is a characteristic stretch for 
the C=O functionality of the β-lactone. 
 
 
Reagents and Conditions: a) Bu3P, (PhSe)2, CH2Cl2, 24 h, (±)-66: 43%. 
Scheme 29.  
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At first, this result was surprising as the formation of a trans β-lactone is not possible. 
However, with tributylphosphine present in the reaction mixture, a Mitsunobu-like 
reaction could have occurred. The most common conditions for the Mitsunobu reaction 
use triphenylphosphine (TPP) and diethyl azodicarboxylate; however, in 1999 Tsunoda 
and co-workers reported the use of ‘new Mitsunobu reagents in the C-C bond 
formation’ in which new systems using TMAD-TBP and DHTD-TBP were found to be 
more efficient in the N-alkylation of primary alcohols than the original DEAD-TPP 
system (Figure 7).24 
 
 
Figure 7. Azo-type Mitsunobu reagents. 
 
Scheme 30 describes our proposed mechanism for the formation of the β-lactone (±)-
66. The phosphine is activated upon reaction with diphenyldiselenide, and the 
phosphonium selenide is then attacked by the hydroxyl group. An intramolecular 
lactonization occurs resulting in formation of the β-lactone. 
 
 
Scheme 30. 
 
Consideration of the reverse reaction, the hydrolysis of the β-lactone, and the principle 
of microscopic reversibility can help support the theory described above. Ester 
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hydrolysis most commonly occurs through the base-catalysed acyl cleavage (BAC2) 
mechanism; however, there are some reports of the very rare base-catalysed alkyl 
cleavage (BAL2) mechanism (Scheme 31).25 
 
 
Base-catalysed acyl cleavage (BAC2) mechanism. 
 
 
Base-catalysed alkyl cleavage (BAL2) mechanism. 
Scheme 31.  
 
In 1993, Douglas and co-workers reported their study of the hydrolysis of 18O-methyl 
triphenylacetate: even when conditions designed to halt the BAC2 mechanism were used, 
it was still found to be the predominant mechanism and only about 5% of the reaction 
proceeded through the BAL2 mechanism, indicating that the BAL2 mechanism is 
intrinsically unfavourable.25 In 2013, Casado and co-workers reported the calculated 
energy barriers for the neutral hydrolysis of a series of lactones.26 These energies 
suggested that β-lactones are susceptible to neutral hydrolysis and that some favour the 
BAL2 mechanism. 
 
 
Reagents and Conditions: a) Pyridine, mesyl chloride, CH2Cl2, 5 °C for 40 h then 25 °C for 5 h, 98%; b) 
HBr in acetic acid, CH2Cl2, 25 °C for 6 h then −15 °C for 16 h, 71%; c) H2O, NaHCO3, pH 7.5, 45%. 
Scheme 32.  
 
In 1990 Lenz reported a three-step sequence to form a β-lactone in which the 
configuration of the β-carbon was inverted (Scheme 32).27 The β-lactone was formed 
by conversion of the hydroxyl group into a good leaving group using mesyl chloride 
(MsCl) and triethylamine, followed by cleavage of the benzyl group under 
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hydrogenolysis conditions to give the corresponding carboxylic acid, and finally, an 
intramolecular SN2 reaction initiated by the treatment of the carboxylic acid with base. 
Other groups have since applied this strategic approach to β-lactone formation. In 2006, 
Wu and co-workers employed this methodology in the total synthesis of valilactone 
(Scheme 33).28 
 
 
Reagents and Conditions: a) mesyl chloride, Et3N, CH2Cl2, 0 °C 3 h, 87%; b) Pd(OH)2, H2, 
EtOAc/MeOH, RT, 7 h, 100%; c) K2CO3, THF, RT, 12 h, 71%. 
Scheme 33.  
 
NOESY NMR analysis of compound (±)-66 was performed to support our findings and 
help confirm relative stereochemistry; the NOESY spectrum shows through space 
interactions as opposed to through bond interactions (J-coupling). Through space 
interactions were observed between the methyl group at C7 and the ring proton at C6; 
they are on the same side of the ring, confirming the cis-lactone structure. 
 
 
Figure 8. NOESY spectrum analysis interpretation of (±)-66. 
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2.2.5.1.2.1.1 Silyl Protection 
 
In order to prevent lactonization, protection strategies were investigated. The most 
common reagents for protecting hydroxyl groups are silylating reagents, for example 
triisopropylsilyl chloride (TIPS-Cl) and tert-butyldimethylsilyl chloride (TBDMS-Cl), 
as they are often easily added and removed using fluoride. Under standard conditions, 
treatment of (±)-51 with TIPS-Cl or TBDMS-Cl proved unsuccessful and the starting 
material was recovered. Attempts were made using triisopropylsilyl triflate as it is more 
reactive than its chloride counterpart but the same result was observed. We believe the 
failure of this reaction is due to steric hindrance, the large benzyl ester at C7 and the 
two substituents at C5 prevented the addition of the bulky TIPS and TBDMS groups. 
 
Table 7. Investigation into the protection of the hydroxyl group of (±)-51 and 
subsequent hydrogenolysis. 
 
Protecting Reagent Step 1: Protection Step 2: Hydrogenolysis 
TIPS-Cl Starting material N/A 
TIPS-OTf Starting material N/A 
TBDMS-Cl Starting material N/A 
TMS-Cl (±)-67 (±)-57 
TES-Cl (±)-68 (±)-57 
 
Trimethylsilyl chloride (TMS-Cl) and triethylsilyl chloride (TES-Cl) are not commonly 
used as protecting reagents as the TMS and TES groups are often poorly stable and 
cannot survive other synthetic transformations. As we believed the reason the other silyl 
groups were unsuccessful was due to the groups being too bulky, we decided to test 
both TMS- and TES-Cl. 
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Reagents and Conditions: a) TMSCl, imidazole, DMF, 35 °C, 24 h, quant.; b) TESCl, imidazole, DMF, 
35 °C, 24 h, quant.; c) H2, Pd(OH)2/C, THF, 30 °C. 
Scheme 34.  
 
The use of both the TMS and TES groups was successful and compounds (±)-67 and 
(±)-68 were obtained in quantitative yields without purification. Unfortunately, when 
subjected to the hydrogenolysis conditions, both groups were removed resulting in the 
isolation of compound (±)-57. 
 
In 2008, Stawinski reported work describing hydroxyl protection using N-
methylimidazole and iodine with various silyl chloride protecting groups.29 It was found 
that these conditions not only decreased reaction times but also enabled protection 
where, before, under standard conditions (i.e. not using iodine) protection was 
unsuccessful. This promising work led us to try the Stawinski conditions; however, we 
were only able to recover the starting material. 
 
 
Reagents and Conditions: a) TBDMSCl, imidazole, I2, THF, RT, 24 h. 
Scheme 35.  
 
2.2.5.1.2.1.2  Acetate Protection 
 
The synthesis required a protecting group reagent that was reactive enough and small 
enough while at the same time forming a stable product. The reaction of (±)-51 with 
acetyl chloride in an attempt to form the acetate was unsuccessful. Although seemingly 
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small enough, it did not appear reactive enough under the conditions used and full 
recovery of the starting material was obtained. 
 
 
Reagents and Conditions: a) acetyl chloride, Et3N, DMAP, CH2Cl2, RT, 24 h. 
Scheme 36.  
 
2.2.5.1.2.1.3  Trifluoroacetate Protection 
 
Trifluoroacetic anhydride is a well-documented reagent used in the protection of 
hydroxyl groups.30 Treatment of (±)-51 with trifluoroacetic anhydride and pyridine in 
anhydrous diethyl ether gave the desired compound (±)-70, isolated in 52% yield after 
silica gel column chromatography.  
 
 
Reagents and Conditions: a) (CF3CO)2O, pyridine, Et2O, (±)-70:52%, (±)-71:21%. 
Scheme 37.  
 
Upon purification, a second compound similar in structure to the desired product (±)-70 
was isolated. Compound (±)-71 is the suggested structure for the product isolated as 
supported by 1H NMR, 13C NMR, 19F NMR, IR and MS data. The 1H NMR spectrum of 
the crude product mixture before purification did not show the presence of (±)-71 and 
so this was believed to be a decomposition product caused by the chromatography. To 
prevent this, all subsequent reactions were carried out without purification of (±)-70.  
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Treatment of (±)-70 under hydrogenolysis conditions resulted in the formation of two 
products in a 1.5:1 ratio according to analysis of the 1H NMR spectrum of the crude 
mixture. The first eluting compound was the desired product (±)-72 in 20% yield. (±)-
57 was also isolated from the reaction mixture in 16% yield and was formed by the 
trifluoroacetate protecting group being removed during the reaction. 
 
 
Reagents and Conditions: a) H2, Pd(OH)2/C, THF, 30 °C, (±)-71: 20%, (±)-57: 16%. 
Scheme 38.  
 
Although this route was successful, the yield was unsatisfactory. To improve the route, 
the order of the reactions was inverted to make the carboxylic acid (±)-57 first, and then 
protect the hydroxyl group. Treatment of (±)-57 with trifluoroacetic anhydride gave (±)-
72 in 81% yield (Scheme 39). 
 
 
Reagents and Conditions: a) H2, Pd(OH)2/C, THF, 30 °C, quant.; b) (CF3CO)2O, pyridine, Et2O, 81%. 
Scheme 39.  
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2.2.5.1.2.2 Synthesis of the Acyl Selenide from the Protected 
Carboxylic Acid (±)-72 and Subsequent Radical-Mediated 
Decarbonylation 
 
With (±)-72 in hand, the acyl selenide synthesis was attempted under the conditions 
described above (2.2.5.1.2.1, Scheme 29) in the hope that the protecting group would 
prevent the lactonization reaction.23 This reaction resulted in a complex mixture and, 
although successful, the acyl selenide (±)-65 was isolated in a low yield (31%). The β-
lactone (±)-66 was isolated alongside the desired product in 10% yield. Unfortunately, 
no other products were isolated in significant yield from this reaction and starting 
material was not recovered. 
 
 
Reagents and Conditions: a) Bu3P, (PhSe)2, CH2Cl2, 24 h, (±)-65: 31%, (±)-66: 10%. 
Scheme 40.  
 
Following the procedure reported by Allin in 2005, the acyl selenide (±)-65 was treated 
with tri-n-butyltin hydride and 1,1′-azobis(cyclohexanecarbonitrile) (ABCN) as the 
radical initiator in anhydrous toluene.23 Purification of this product proved extremely 
challenging; 1H NMR analysis of the main fractions isolated after silica gel column 
chromatography showed the extensive presence of tin residues in the samples 
(characteristic peaks due to tin residues were observed from around 0.8-1.7 ppm). 
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Reagents and Conditions: a) n-Bu3SnH, ABCN, toluene, 80 °C, 2 h. 
Scheme 41.  
 
Mixtures containing tin reagents are notoriously hard to purify. The most common 
methodology, partitioning between acetonitrile and hexane, proved unsuccessful in our 
hands. In 2004, Harrowven reported the use of a ‘KF-silica stationary phase for the 
chromatographic removal of tin residues from organic compounds’.31 Although the 
amount of tin residues was significantly reduced using this method, we were unable to 
remove them completely. Other purification methodologies, including stirring the 
mixture with KF overnight before purification, also proved unsuccessful.  
 
With the tin residues causing such problems in purification, tributylgermanium hydride 
and tris(trimethylsilyl)silane were used in the reaction instead of the tributyltin hydride. 
Unfortunately, both methods proved unsuccessful and resulted in complex mixtures, 
neither the desired compound nor starting material being isolated. 
 
The lack of positive results and various problems arising when using the radical-
mediated decarboxylation route led us to investigate alternative decarboxylation 
strategies. 
 
2.2.5.1.2.3 The Barton Decarboxylation 
 
The Barton decarboxylation is another example of a radical-mediated reaction. In 1980, 
Barton reported ‘a new radical decarboxylation reaction for the conversion of 
carboxylic acids into hydrocarbons’ using tributyltin hydride.32 Barton suggested that 
carboxyl radicals could be generated if an efficient alkene-forming radical-mediated 
fragmentation reaction could be achieved (Scheme 42).32  
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Earlier work had shown that, in the steroidal series, the reduction of vicinal 
chlorohydrin esters using tributyltin hydride resulted only in dehalogenation without 
any fragmentation of the intermediate radical. Barton believed that the driving force for 
successful carboxyl radical generation was the formation of a conjugated alkene. 
Decarboxylation would then occur, resulting in another radical species, followed by 
hydrogen atom transfer from tributyltin hydride to give the desired hydrocarbon 
product. 
 
 
Scheme 42. 
 
Later, in 1983, Barton reported ‘new and improved methods for the radical 
decarboxylation of acids’.33 The reaction of N-hydroxypyridine-2-thione with a 
carboxylic acid gives the corresponding ester, which can then undergo a radical 
decarboxylation to form the corresponding alkane upon treatment with tributyltin 
hydride or t-butylmercaptan (Scheme 43). These N-hydroxypyridine-2-thione esters are 
now more commonly referred to as ‘Barton esters’. 
 
 
Scheme 43. 
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There are many natural product syntheses in the literature that employ a Barton 
decarboxylation. (−)-Quinocarcin is an antitumour antibiotic, and, when the Terashima 
group were carrying out structure activity relationship studies, they prepared the 10-
decarboxyquinocarcin analogue employing the Barton decarboxylation methodology 
(Scheme 44).34 The esterification of carboxylic acid 73 was achieved using N-
hydroxypyridine-2-thione with N,N'-dicyclohexylcarbodiimide (DCC) and DMAP in 
benzene. Subjecting the thiohydroxamate ester to Barton radical decarboxylation 
conditions using AIBN and tributyltin hydride resulted in full decarboxylation and 75 
was isolated in 65% yield over the two steps. 
 
 
Reagents and Conditions: a) 2-mercaptopyridine-N-oxide, DCC, DMAP, benzene, reflux; b) n-Bu3SnH, 
AIBN, benzene, reflux, 65% (2 steps); c) 1. 1 M NaOH, MeOH, RT, 98%; 2. AgNO3, MeOH, RT, 81%. 
Scheme 44. 
 
The original method for the Barton decarboxylation employs tributyltin hydride as the 
hydrogen donor and to propagate the radical reaction. Tributylgermanium hydride and 
TTMSS can also be used in the same way. Furthermore, recent methods report the use 
of a photochemical approach. Because of the issues encountered by us when tributyltin- 
and tributylgermanium hydride and TTMSS were used, we decided to employ the 
photochemical approach reported by Ko in 2011 (Scheme 45).35 Ko also reported that 
chloroform could successfully be used as a H-donor instead of tributyltin hydride, 
reducing both the cost and toxicity of such reactions. 
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Scheme 45. 
 
Our approach would involve the conversion of the carboxylic acid into the 
corresponding acyl chloride, followed by addition of 2-mercaptopyridine N-oxide 
sodium salt to form the Barton ester, and finally decarboxylation to give the desired 
intermediate (±)-11 (Scheme 46).  
 
 
Scheme 46. 
 
The carboxylic acid (±)-57 was treated with oxalyl chloride in chloroform and 
dimethylformamide (DMF) to produce the corresponding acyl chloride. The acyl 
chloride solution was then added to a solution of 2-mercaptopyridine N-oxide sodium 
salt in chloroform using a cannula under the irradiation of a UV lamp.  
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Reagents and Conditions: a) (±)-57, oxalyl chloride, 2-mercaptopyridine N-oxide sodium salt, DMF, 
CHCl3; b) (±)-57 or (±)-72, EDAC·HCl, NMM, DMAP, 2-mercaptopyridine N-oxide sodium salt, THF. 
Scheme 47. 
 
Unfortunately, 1H NMR spectrum analysis of the reaction mixture showed the formation 
of the β-lactone (±)-66 as the major product (described above 2.2.5.1.2.1, Scheme 29), 
and the expected signals corresponding to the thiohydroxamate ester were not observed, 
leading us to the believe that the desired product was not formed in the reaction. 
 
Attempts were also made to couple the 2-mercaptopyridine N-oxide sodium salt to the 
carboxylic acid using EDAC·HCl as described in section 2.2.2. This was carried out on 
both the unprotected alcohol (±)-57 and the protected compound (±)-72; however, both 
gave the same result: the major product observed was β-lactone (±)-66. 
 
In the reaction to form the acyl selenide (described above 2.2.5.1.2.1, Scheme 29), we 
suggested that the formation of the β-lactone was due to a Mitsunobu-like reaction 
occurring in the presence of tributylphosphine; however, this is not the case with respect 
to the Barton decarboxylation as there is no phosphine present. In order to form the β-
lactone, the hydroxyl moiety must be converted into a leaving group followed by the 
attack of the carboxylate onto the C6 position to form the lactone moiety (this is still a 
Mitsunobu-like reaction in terms of transformation but not in terms of reagents used).  
 
In the first coupling reaction, with the unprotected (±)-57, the EDAC·HCl may have 
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group, the NMM could then act as a base to deprotonate the acid resulting in an 
intramolecular lactonization to form the β-lactone (Scheme 48). In the second reaction, 
when the hydroxyl was protected with a trifluoroacetate group (compound (±)-72), the 
C6 moiety is already a suitable leaving group and so, again, deprotonation of the acid 
could have resulted in an intramolecular lactonization to form the β-lactone. 
 
 
Scheme 48. 
 
The outcome of the reaction of the β-hydroxy acid (±)-57 with oxalyl chloride was at 
first more confusing. However, if we consider that the acyl chloride did not form and 
instead the oxalyl chloride reacted with the hydroxyl group we can apply the same 
reasoning described above. Oxalyl chloride would react with the hydroxyl moiety, 
creating a suitable leaving group at the C6 position (Scheme 49). 
 
 
Scheme 49. 
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showed that the β-lactone (±)-66 had been formed. After silica gel column 
chromatography the β-lactone (±)-66 was isolated in quantitative yield. 
 
 
Reagents and Conditions: a) oxalyl chloride, DMF, CHCl3, RT, 4 h, (±)-66: quant. 
Scheme 50. 
 
2.2.5.1.2.4 The Krapcho Decarboxylation 
 
In 1967, Krapcho reported the use of sodium cyanide and DMSO to achieve the 
decarboxylation of geminal diesters in one step (Table 8).36 Previously, this type of 
transformation could only be carried out in three steps: saponification to the diacid, 
decarboxylation of the diacid, then finally esterification to give the desired ester. Not 
only did Krapcho’s method reduce the number of synthetic steps, but in so doing yields 
were also increased. 
 
Table 8. Decarboxylation of 1,1-diesters with sodium cyanide in DMSO. 
Reactant Product Yield (%) 
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Since 1967, the scope of this reaction has been thoroughly investigated and the toxic 
sodium cyanide has been replaced by lithium or sodium chloride, now the most 
commonly used reagents for this transformation. An important structural requirement 
for this reaction is the presence of an electron-withdrawing group in the beta position; 
β-ketoesters and malonic esters can both undergo decarboxylation using this method. 
 
The Krapcho decarboxylation has many synthetic applications. Metacycloprodigiosin is 
an immunosuppressive alkaloid, and in 1999, the Fürstner group reported the use of 
Krapcho conditions in their synthesis.37 Treatment of the methyl ester 76 with sodium 
chloride in wet DMSO resulted in the desired decarboxylated product 77 in 91% yield, 
which was then advanced to the desired product, metacycloprodigiosin. 
 
 
Reagents and Conditions: a) NaCl, H2O, DMSO, 180-190 °C, 1.5 h, 91%. 
Scheme 51. 
 
We hoped to use this method to decarboxylate the benzyl ester of (±)-51 at the C7 
position, using the carbonyl group of the amide to form the enolate, and in doing so 
forming benzyl chloride and carbon dioxide as the by-products. One possible problem 
was the presence of the methyl ester group at the C5 position; however, without the 
presence of the β-ketone at C6 we hoped that this group would be left intact. 
 
 
Reagents and Conditions: a) LiCl, DMF, 135 °C, 4 h, (±)-78: 49% and (±)-79: 38%. 
Scheme 52. 
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The β-ketoester (±)-51 was treated with lithium chloride in DMF and heated at 135 °C 
for 4 h.38 After silica gel column chromatography, compounds (±)-78 and (±)-79 were 
isolated in 49% and 38% yield, respectively. 1H NMR spectrum analysis of the crude 
reaction mixture showed that these compounds were formed in a 1:1 ratio. 
Unfortunately, the benzyl and methyl ester and the hydroxyl moiety were removed. 
 
2.2.5.1.2.5 Acid-Catalysed Decarboxylation 
 
As the methods described above were unsuccessful, an acid-catalysed decarboxylation 
was attempted. The mechanism for this reaction can be seen in Scheme 53; the 
intramolecular deprotonation of the carboxylic acid and subsequent loss of CO2 give the 
alkene (±)-80; however, the equilibrium will be shifted towards (±)-11 due to the 
increased stability of the amide, and the acid present in the reaction. 
 
 
Scheme 53. 
 
Treatment of the carboxylic acid (±)-57 with 6 M hydrochloric acid (HCl) and heating 
to reflux resulted in a complex mixture. At first it appeared that the reaction may have 
been successful; IR analysis showed stretches at 1733, 1674 and 3387 cm-1 
corresponding to the carbonyl of the ester and amide, and the hydroxyl moieties (no 
characteristic carboxylic acid stretches were observed), respectively. Mass spectrometry 
data correlates to the desired product (±)-11 with the formula for [M+H]+ as 
[C19H25NO5+H]+ with mass 350.20. Unfortunately, despite multiple purification 
attempts using silica gel column chromatography, we were unable to isolate a single 
product cleanly. 1H NMR spectrum analysis showed at least three compounds had co-
eluted. Without the ability to separate the products, we cannot confirm whether the 
desired product is present. 
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Reagents and Conditions: a) 6 M HCl, H2O, reflux, 4 h. 
Scheme 54. 
 
As the initial results were promising, the reaction was performed with a weaker acid, p-
toluenesulfonic acid (p-TSA), in the hope of preventing any possible decomposition 
caused by using a strong acid such as 6 M HCl. Unfortunately, when this reaction was 
performed under reflux a complex mixture was again formed and no products could be 
isolated; the product described above was not observed in the 1H NMR spectrum of the 
crude mixture. To prevent decomposition, the reaction was repeated under milder 
conditions, at both 80 °C and room temperature; however, in both cases, no reaction 
occurred and the starting material was recovered. 
 
Table 9. Investigation into the acid-catalysed decarboxylation of (±)-57. 
Acid Conditions Result 
6 M HCl Reflux Complex mixture 
p-TSA Reflux Complex mixture 
p-TSA 80 °C Starting material 
p-TSA RT Starting material 
 
2.2.5.2 Route B Towards (±)-11 
 
2.2.5.2.1 Decarboxylation of the Mander’s Reaction Product, (±)-10 
 
With the Route A (Scheme 17) proving so challenging, we decided instead to perform 
the decarboxylation of the benzyl ester moiety at the C7 position followed by reduction 
of the ketone at C6 (Scheme 17, Route B). 
 
The hydrogenolysis of benzyl β-ketoesters using palladium and a hydride source is a 
well-known reaction that results in the corresponding ketone (Scheme 55). There are 
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many examples of this type of reaction in the literature; the most common reaction 
conditions involve using hydrogen gas as the hydride source and catalytic amounts of 
Pd/C.39 
 
 
Reagents and Conditions: a) Pd0, hydride source. 
Scheme 55.  
 
Following route B, when (±)-10 was treated under hydrogenolysis conditions using 
palladium hydroxide on carbon and a hydrogen balloon, debenzylation and 
decarboxylation occurred, but led to a 1:1 mixture of diastereoisomers at the C7 
position, compounds (±)-81 and (±)-82 (Scheme 56).  
 
 
Reagents and Conditions: a) H2, Pd(OH)2/C, THF, 30 °C, >90%. 
Scheme 56.  
 
As described above, this is, again, due to the planarity of the enolate intermediate 
formed during the reaction. The hydrogenolysis results in the removal of the benzyl 
group, and concomitant loss of CO2 occurs via the enolate. Unfortunately, these 
diastereoisomers were inseparable on silica gel column chromatography. It was also 
found that the product was relatively unstable on both silica gel and alumina, and for 
this reason was used without purification in the following step. 
 
The reaction did not afford reproducible yields; hence, work was undertaken to find 
optimal conditions. The reaction outcome can be influenced by both the reaction time 
and temperature. When the reaction time was shorter than 12 hours, 1H NMR spectrum 
analysis of the mixture showed the reaction had not gone to completion. However, we 
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were unable to isolate and characterize any product due to the compounds’ instability on 
both silica gel and alumina. When the reaction time was longer than 72 hours, complete 
decomposition occurred. Temperature also played an important role in this reaction; at 
first, the reaction was carried out at room temperature, which led to irreproducible 
results. As room temperature can vary we decided to remove this variable by keeping 
the reaction at 30 °C. Finally, we settled on the optimized conditions described in 
Scheme 56; using Pd(OH)2/C and under a hydrogen atmosphere using a balloon in 
anhydrous THF at 30 °C. 
 
When the benzyl ester group is removed, the resulting proton at the C7 position is 
relatively acidic as the 1,3-keto-amide moiety in the lactam ring has a pKa similar to 
that of a diester (pKa≈11-13). The compounds (±)-81 and (±)-82 can undergo 
enolization as observed in earlier steps of the synthesis, and this may account for the 
unstable nature of this compound.  While the outcome of the decarboxylation step was 
not the desired one, the reduction of the ketone moiety was attempted on the 
diastereoisomeric mixture in the hope that the corresponding products could be 
separated at a later stage.  
 
2.2.5.2.2 Reduction of the Diastereoisomeric Mixture, (±)-81 and 
(±)-82 
 
The reduction of the ketone at the C6 position proved much more challenging than 
expected. Reduction using sodium borohydride, sodium triacetoxyborohydride and 
sodium cyanoborohydride all proved unsuccessful under a variety of reaction 
conditions. These reactions either resulted in the recovery of the starting material, 
decomposition, complex mixtures or isolation of compounds closely related to the 
desired product. 
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Table 10. Investigation into the reduction of (±)-81 and (±)-82. 
 
Reducing Reagent Conditions Result 
NaBH4 EtOH, 0 °C, 30 min Complex mixture 
NaBH3CN MeOH, 0 °C – RT, 2 h S.M. 
NaBH(OAc)3 Acetic acid, RT, 1 h Unidentified product 
LAH THF, 0 °C, 2 h Decomposition 
LAH THF, −78 °C, 1-2 h Complex mixture 
DIBAL THF, 0 °C, 2 h Complex mixture 
DIBAL THF, −78 °C, 1-2 h Complex mixture 
Red-Al® CH2Cl2, −78 °C, 1-2 h Complex mixture 
 
1H NMR spectrum analysis of the starting material (±)-81 and (±)-82 showed the 
required doublet corresponding to the methyl group at C7, and the lack of this doublet 
peak was immediately clear from the 1H NMR spectrum analysis of the reaction 
mixtures that gave related compounds. The presence of a singlet peak corresponding to 
the methyl group indicated that the C7 position was now a quaternary centre again. 
 
Following the reported procedure, the diastereoisomeric mixture of (±)-81 and (±)-82 
was treated with sodium triacetoxyborohydride in acetic acid at room temperature for 
one hour.40 The desired compound was not isolated but a product closely related to the 
staring material was isolated. In an attempt to determine the structure of the product 
isolated, a combination of 1H NMR, 13C NMR, COSY, HSQC, DEPT and IR 
spectroscopic analysis was used. Unfortunately, the mass spectrometry data did not 
correlate to any predicted structure. Figure 9 below shows the 1H NMR spectrum of the 
compound isolated after reduction of (±)-81 and (±)-82 with sodium 
triacetoxyborohydride. 
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Figure 9.  1H NMR spectrum of the compound isolated after reduction of (±)-81 and 
(±)-82 with sodium triacetoxyborohydride.  
 
Analysis of the 1H NMR spectrum shows that the signal corresponding to the methyl 
group at the C7 position is no longer a doublet and is instead a singlet, indicating that 
the C7 carbon is now quaternary. The signals corresponding to the two methoxy groups, 
the iso-butyl group and the PMB group are all present. 
 
 
Reagents and Conditions: a) NaBH(OAc)3, acetic acid, RT, 1 h. 
Scheme 57. 
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At first, we proposed the structure to be (±)-83; all the signals in the 1H NMR spectrum 
appeared to correlate to this structure (Scheme 57). However, upon analysis of the IR 
spectrum, three carbonyl stretches similar to those in the starting material can be seen. 
A stretch at 3363 cm−1 also indicates the presence of a hydroxyl group. We know 
addition of the hydroxyl to the C7 position is not possible but also that if the ketone at 
C6 had been reduced, we would not see the carbonyl stretch in the IR spectrum or the 
ketone signal in the 13C NMR spectrum at 205.2 ppm. The same logic can be applied to 
the amide moiety; the enol (±)-84 cannot be the product as both the stretch in the IR 
spectrum and the peak in the 13C NMR spectrum are present. Unfortunately, the 
accurate mass spectrometry data did not correlate with any of the theorized structures 
and so, without X-ray crystallographic data, we cannot be certain of the structure of this 
compound. 
 
The use of lithium aluminium hydride (LAH) was also investigated. Although LAH is a 
stronger reducing reagent than the borohydrides mentioned above and can be used to 
reduce esters and amides as well as ketones, we hoped to control this by using low 
temperatures and monitoring the reaction by thin layer chromatography. Both LAH 
powder and LAH in solution (1 M in tetrahydrofuran) were used at temperatures of 0 °C 
and −78 °C. Unfortunately, neither resulted in successful isolation of the desired 
compound. Sodium bis(2-methoxyethoxy)aluminium hydride (Red-Al®) is comparable 
in reactivity to LAH and was also used in an attempt to reduce the ketone but proved 
equally unsuccessful. Di-isobutyl aluminium hydride (DIBAL) is most commonly used 
in the reduction of esters to aldehydes; however, as other reagents had failed, the 
reaction was repeated using a DIBAL solution (1 M in tetrahydrofuran). Unfortunately, 
this was again unsuccessful. In both the Red-Al® and DIBAL reactions, analysis of the 
1H NMR spectra of the reaction mixtures showed similarities to the starting material; 
however, we were unable to purify the compound to a sufficient standard to allow 
structure identification. No starting material was recovered from either reaction. 
 
2.2.5.2.3 The Noyori Asymmetric Hydrogenation Reaction 
 
As a final attempt to reduce the ketone, we employed a strategy using the Noyori 
catalyst for asymmetric hydrogenation. Noyori was joint winner of the Nobel Prize in 
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2001 for his work on asymmetric hydrogenation reactions. In 1987, Noyori reported the 
use of a ruthenium catalyst, RuCl2[(R)-BINAP], in the catalytic asymmetric reduction of 
methyl acetoacetate.41 
 
 
Scheme 58. The catalytic cycle for the Noyori asymmetric hydrogenation. 
 
There are many reported uses of the Noyori asymmetric hydrogenation reaction in total 
synthesis. In 1991, Robinson and co-workers reported the synthesis of the antibiotic (+)-
brefeldin A, wherein the β-ketoester 85 was converted to 86 in 96% yield and high 
enantiomeric ratio (99:1) using Noyori’s approach.42 
 
 
Reagents and Conditions: a) RuCl2·cyclooctadiene, BINAP, H2, MeOH, 50 psi, 80 °C, 6 h, 96%.  
Scheme 59. The synthesis of (+)-brefeldin A. 
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Since Noyori’s original report in 1987, the catalyst has been improved.43 We used the 
commercially available RuCl2[(R)−DM−BINAP][(R)−DAIPEN] catalyst (Figure 10). 
Treatment of (±)-81 and (±)-82 with potassium carbonate and 5 mol% of the ruthenium 
catalyst in a 5:1 mixture of iso-propanol and tetrahydrofuran did not yield the desired 
compound. This reaction was carried out under a hydrogen atmosphere using a balloon 
and also under a pressure of 3 bar, but both sets of reaction conditions led to the same 
products. 
 
 
Figure 10. The RuCl2[(R)−DM−BINAP][(R)−DAIPEN] catalyst. 
 
After purification using silica gel column chromatography two compounds were 
isolated. Our proposed structures for the first eluting compound are either (±)-87 or (±)-
88. The proposed structures have been deduced using NMR, IR and MS data analysis as 
we were unable to obtain any crystals suitable for X-ray crystallographic analysis. IR 
spectrum analysis showed two absorptions corresponding to carbonyl stretches; one at 
1758 cm−1, slightly higher than the characteristic ester or ketone stretches, and one at 
1670 cm−1 representing the amide; there was no signal in the hydroxyl region. The mass 
spectrometry data suggest a possible formula for [M+H]+ as [C21H29NO6+H]+ with mass 
392.21. Both the proposed structures (±)-87 and (±)-88 match this data. 
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Reagents and Conditions: a) RuCl2[(R)−DM−BINAP][(R)−DAIPEN] (5 mol%), IPA:THF (5:1), 3-6 
days.  
Scheme 60.  
 
Unfortunately, we are unable to give a definitive mechanism as to how this reaction 
might proceed to give either of the proposed compounds (±)-87 and (±)-88. In both 
suggested structures, it appears first that the ester group at the C5 position has migrated 
to the C6 position, and secondly that the iso-propanol has acted as a nucleophile in 
some way. 1H NMR spectrum analysis (Figure 11) shows that the splitting pattern 
corresponding to the CH2 of the iso-butyl is now two sets of multiplets, this presumably 
arising from coupling with each other, the CH of the iso-butyl and one other proton (the 
new ring proton at the C5 position). Analysis of the COSY H-H spectrum shows a 
correlation between the multiplets corresponding to the methylene proton and a single 
proton at around 4 ppm; the splitting pattern for this proton is a doublet of doublets and 
represents the ring proton at the C5 position. The signal corresponding to the methyl 
ester is not present, and signals corresponding to the two methyl groups (two doublets at 
around 1.25 ppm) and the methine unit (a multiplet at around 5 ppm) of an iso-propoxy 
moiety are now present. 
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Figure 11.  1H NMR spectrum of the first eluting compound isolated after reduction of 
(±)-81 and (±)-82 with the Noyori catalyst. 
 
The second compound isolated from this reaction was an interesting discovery. The data 
greatly resembled those of the compound isolated from the reduction of (±)-81 and (±)-
82 with sodium triacetoxyborohydride, suggesting that the products from these two 
separate reactions could be diastereoisomers. The IR spectrum showed the same three 
carbonyl and hydroxyl signals at similar frequencies, the mass spectrometry data for 
both reactions showed [M+H]+ peaks at 364.17, and both the 13C NMR spectra showed 
a characteristic ketone signal. A comparison of the 1H NMR spectra for both 
compounds (Figure 12) shows just how similar they are, the only significant difference 
is the peak for the methylene of the iso-butyl group (in the region of 1.9 – 2.3 ppm): 
instead of being two clearly separated doublet of doublets peaks, as the product 
obtained from the sodium triacetoxyborohydride reaction, in the compound isolated 
from the Noyori reaction, these peaks have coalesced (highlighted in Figure 12). The 
data do not give us enough information to assign a structure to this compound. 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.5
f1 (ppm)
3.
09
2.
96
6.
32
0.
97
0.
86
3.
22
0.
96
1.
04
3.
05
1.
00
0.
97
1.
00
2.
02
2.
01
0.
91
0.
92
0.
97
0.
98
1.
24
1.
24
1.
25
1.
25
1.
79
1.
80
1.
80
1.
81
1.
81
1.
82
1.
82
1.
82
1.
83
1.
84
1.
84
1.
85
1.
86
1.
87
1.
88
1.
88
1.
89
1.
90
1.
90
1.
92
3.
72
3.
75
3.
80
4.
02
4.
02
4.
04
4.
04
5.
03
5.
05
5.
06
5.
07
5.
08
5.
47
5.
50
6.
85
6.
87
7.
15
7.
17
	 	 Results	and	Discussion		
	 102	
 
Figure 12.  A comparison between the 1H NMR spectrum after reduction of (±)-81 and 
(±)-82 with 1: sodium triacetoxyborohydride and 2: the Noyori catalyst. 
 
 
2.2.5.2.4 Synthesis of the Thiomethyl Derivative 
 
With the reduction of (±)-81 and (±)-82 proving unsuccessful under a range of 
conditions, a new approach was investigated. Both Corey’s and Pattenden’s syntheses 
of lactacystin are reviewed in detail above (Chapter 1): a thiomethyl derivative is 
employed in their synthetic approaches.2, 40 Corey describes the use of a thiomethyl 
group as both a blocking group and a group to induce stereoselectivity in the 
hydroxymethylation of 89 (Scheme 61). Desulfurization of 91 was achieved in high 
stereoselectivity (10:1) by treatment with Raney nickel. 
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Reagents and Conditions: a) 1. DBU, THF, −78 °C, then aq. CH2O, −78 °C, 0.5 h, 90%; 2. 
NaBH(OAc)3, HOAc, 23 °C, 1 h, recrystallization, 95%, 99% ee; b) 1. PivCl, pyridine, 23 °C, 10 h, 85%; 
2. TBSOTf, 2,6-lutidine, 23 °C, 12 h, 98%; 3. NaOMe, MeOH, 23 °C, 5 h, 92%; c) 1. Raney Ni, EtOH, 0 
°C, 1 h, 82%; 2. Dess-Martin reagent, CH2Cl2, 23 °C, 1 h, 95%. 
Scheme 61. 
 
Pattenden reported the isolation of compound 93 as an inseparable mixture of 
diastereoisomers in a 2:1 ratio (Scheme 62). Interestingly, Pattenden does not mention 
if attempts were made to reduce the ketone 93, and instead uses the findings described 
by Corey to improve the diastereoisomeric ratio. 
 
Reagents and Conditions: a) p-MeC6H4SO2Me, Et3N, CH2Cl2, RT, 78%; b) Zn(BH4)2, (4.4 M in THF), 0 
°C, 79%. 
Scheme 62.  
 
In Pattenden’s procedure compound 93 was treated with S-methyl-p-
toluenethiosulfonate 96 and triethylamine resulting in the formation of a mixture of 
diastereoisomers at the C7 position in a 7:1 ratio; compound 94 was isolated as the 
major diastereoisomer after silica gel column chromatography. Compound 94 was 
reduced using zinc borohydride to give 95 as a single diastereoisomer. Then, following 
the procedure reported by Corey, the thiomethyl group was removed in a stereoselective 
manner using Raney nickel. We hoped to employ the same strategy in our synthetic 
route. 
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Reagents and Conditions: a) CH2Cl2, I2, RT, quant. 
Scheme 63.  
 
Thus, S-methyl-p-toluenethiosulfonate 96 was synthesized following Fujiki’s procedure 
(Scheme 63).44 Treatment of the diastereoisomeric mixture of (±)-81 and (±)-82 with 
(S)-methyl-p-toluenethiosulfonate and triethylamine in dichloromethane resulted in the 
isolation of compounds (±)-97 and (±)-98 as an inseparable mixture of diastereoisomers 
in a 2:1 ratio and 47% yield after silica gel column chromatography. Using a NOESY 
NMR spectrum analysis, compound (±)-98 was found to be the major isomer. While 
Pattenden was able to improve the diastereoisomeric ratio from 2:1 to 87:13, we were 
not as fortunate.  
 
 
Reagents and Conditions: a) p-MeC6H4SO2Me, Et3N, CH2Cl2, RT, (±)-97 and (±)-98: 47%. 
Scheme 64. 
 
 
Figure 13. NOESY spectrum analysis interpretation to assign relative stereochemistry 
to the inseparable mixture of (±)-97 and (±)-98. 
 
Trace amounts of another inseparable mixture of isomers in a 2:1 ratio were also 
isolated from the reaction. In an attempt to assign a structure to the compounds isolated 
a combination of 1H NMR, 13C NMR, COSY, HSQC, DEPT and IR spectra analyses 
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was used. 1H NMR spectrum analysis of the mixture shows a singlet peak at 1.61 ppm 
corresponding to the methyl group at the C7 position, indicating that the C7 carbon is a 
quaternary centre. IR analysis shows absorptions at 3355, 1783, 1747 and 1684 cm-1 
indicating the presences of a hydroxyl group and three carbonyl groups. Unfortunately 
we were unable to assign structures using the data obtain. 
 
2.2.5.2.4.1 Reduction of the Thiomethyl Derivative 
 
Pattenden reported the use of zinc borohydride to reduce the ketone moiety in 94 to give 
the corresponding alcohol 95 in 79% yield (Scheme 62).40 In this case, the 
stereoselectivity is achieved by chelation of the zinc to the oxygen atom of the ketone 
and the sulfur atom of the thiomethyl group resulting in hydride attack from the 
opposite side to the thiomethyl group, i.e. the least hindered face.  
 
Scheme 65 shows how chelation can alter the stereochemistry of the reduction product. 
The chelation of the zinc centre to the oxygen and sulfur atoms causes rotation, and, 
therefore, changes the conformation of the starting material. This conformational 
change means the least hindered face, and so the angle of attack, is now on the opposite 
side with respect to the non-chelated model.  
 
	  
Scheme 65.  
O
Ph
Ph
PhS
H angle of attack
O
Ph
Ph
H
PhS
Zn
angle of attack
OH
HPh
Ph
H
PhS OH
PhH
Ph
H
PhS
Ph
Ph
HO
SPh
Ph
Ph
HO
SPh
Without Chelation With Chelation
	 	 Results	and	Discussion		
	 106	
Although there are many reports of the use of zinc borohydride for stereoselective 
reduction, it is not a common, commercially available reagent.45 Zinc borohydride is 
prepared from commercially available zinc chloride and sodium borohydride in diethyl 
ether. 
 
In contrast, Corey reported the reduction of ketone 89 (after hydroxymethylation) using 
sodium triacetoxyborohydride in acetic acid to give 90 as a single diastereoisomer in 
95% yield.2 The reduction was selective without the need for zinc borohydride. Indeed, 
chelation control is an important factor in selective reductions for acyclic substrates and 
cyclic substrates with similar sized substituents. In Corey’s case, the substituents’ size 
difference is sufficient to induce the desired outcome. As Corey had shown the 
reduction was selective using sodium triacetoxyborohydride, and zinc borohydride is 
not commercially available, we attempted the ketone reduction of the mixture of (±)-97 
and (±)-98 under optimized reduction conditions described above using sodium 
borohydride in ethanol (section 2.2.5.1.1). 
 
 
Scheme 66. 
 
As the starting material is a mixture of two racemic diastereoisomers, if the reduction is 
not selective, a possible four racemic products could be formed (Scheme 66). 1H NMR 
spectrum analysis of the reaction mixture showed the presence of four compounds, in a 
6:6:4:1 ratio approximately. Fortunately, the reduction was successful, and selective, 
and after silica gel column chromatography, only two reduction products, compounds 
(±)-99 and (±)-100, were isolated in 17% and 25% yield, respectively. The other two 
compounds observed in the 1H NMR spectrum of the reaction mixture were the two 
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starting material diastereoisomers, isolated as an inseparable diastereoisomeric mixture 
of (±)-97 and (±)-98 in 23% yield. 
 
 
Reagents and Conditions: a) NaBH4, EtOH, −10 °C, 30 min, (±)-99: 17%, (±)-100: 25% and (±)-97 and 
(±)-98: 23%. 
Scheme 67. 
 
The ratio of diastereoisomers in the starting material (2:1) compared to the ratio of 
recovered starting material diastereoisomers after the reaction (6:1) gives us information 
on the rate of reduction: the minor diastereoisomer is reacting faster than the major 
diastereoisomer. 
 
 
Figure 14. NOESY spectrum analysis interpretation of (±)-99 and (±)-100. 
 
The relative stereochemistry shown in compounds (±)-99 and (±)-100 was assigned 
from NOESY NMR spectrum analysis (Figure 14). Unfortunately, we were unable to 
obtain crystals of these compounds suitable for X-ray crystallography. 
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2.2.5.2.4.2 Desulfurization of the Thiomethyl Derivative 
 
Corey reported the selective desulfurization of 91 using Raney nickel in ethanol at 0 °C 
to give 92 (Scheme 68).2 The product 92 displays opposite configuration of the methyl 
group at the C7 position to that observed in the starting material. It has been suggested 
that the mechanism for desulfurization using Raney nickel may proceed through a 
radical intermediate. This difference in configuration at the C7 position may be due to 
equilibration during the radical process. Due to the structural and configurational 
similarities between compound (±)-99 and Corey’s compound 91, we hoped that a 
similar equilibration process may occur. 
 
 
Reagents and Conditions: a) 1. Raney Ni, EtOH, 0 °C, 1 h, 82%; 2. Dess-Martin reagent, CH2Cl2, 23 
°C, 1 h, 95%. 
Scheme 68. 
 
Unfortunately, treatment of (±)-99 with Raney nickel in ethanol at 0 °C did not give the 
desired product (±)-11, and the starting material was not recovered either. The 1H NMR 
spectrum showed the peak corresponding to the thiomethyl group at 2.16 ppm still 
present. 
 
 
Reagents and Conditions: a) Raney Ni, EtOH, reflux, 4 h. 
Scheme 69. 
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When (±)-99 was treated with Raney nickel in ethanol and heated under reflux for 4 h, 
1H NMR spectrum analysis of the product isolated after silica gel chromatography 
appeared to show the desired compound (±)-11 alongside diastereoisomer (±)-101 as an 
inseparable mixture. These compounds were observed in a 3:1 ratio; however, we were 
unable to determine which diastereoisomer is the major product. A NOESY NMR 
experiment was attempted to assign relative stereochemistry; however, no correlations 
were observed. The diastereoisomeric ratio is, however, large enough to enable us to 
distinguish between the diastereoisomers and assign the 1H NMR spectrum of the major 
product. We were confident that desulfurization had been successful as the 1H NMR 
spectrum clearly showed the signal corresponding to the methyl group at the C7 
position as a doublet, coupling with the new ring proton at the C7 position. The mass 
spectrometry data correlates to the desired product (±)-11 with the formula for [M+H]+ 
as [C19H25NO5+H]+ with mass 350.20. Using a combination of 1H, COSY, 13C, DEPT 
and HSQC NMR, IR and MS data analyses, we believe the desired compound, Corey’s 
intermediate (±)-11, was successfully synthesized. Unfortunately, we were unable to 
separate the diastereoisomers. Although (±)-11 is an advanced intermediate synthesized 
by Corey, unfortunately, no data for the compound was reported. 
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2.3 Synthesis of the Serine Analogue 
 
2.3.1  Proposed Synthetic Route Towards Lactacystin  
 
At the same time as work was being carried out on the leucine analogue, the synthesis 
using a different amino acid starting material, L-serine, was also being investigated. In 
comparison to the leucine derivative, when using serine, the hydroxyl functionality at 
C9 found in lactacystin is present from the beginning. The hydroxyl functionality was 
proven to be very important in structure activity relationship (SAR) studies, and is 
found in many of the lactacystin analogues, for example the salinosporamides and the 
cinnabaramides (Chapter 1). We hoped that, by using serine, our synthetic route would 
allow ready access to these natural products and possible novel analogues with groups 
tailored to give high biological activity. 
 
Using L-serine methyl ester hydrochloride 102 as the starting material, we hoped to 
synthesize the advanced intermediate 90, reported by Corey in 1998, using our route 
developed for the leucine analogue (Scheme 70).2 
 
 
Scheme 70. 
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2.3.2 Synthesis from L-Serine 
 
2.3.2.1 Protection of the Amine with 4-Methoxybenzaldehyde 
 
Esterification of commercially available L-serine with acetyl chloride in methanol gave 
L-serine methyl ester hydrochloride in quantitative yield, without purification. 
 
 
Reagents and Conditions: a) Acetyl chloride, MeOH, reflux, quant.; b) 1. 4-Methoxybenzaldehyde, 
acetic acid, toluene, reflux; 2. NaBH3CN, acetic acid, MeOH. 
Scheme 71. 
 
Using the optimized conditions described above (section 2.2.2), L-serine methyl ester 
hydrochloride was treated with 4-methoxybenzaldehyde and acetic acid in toluene 
under reflux using a Dean-Stark apparatus. Unfortunately, the reaction was not 
successful, decomposition occurred and the imine was not observed when the 1H NMR 
spectrum of the reaction mixture was analysed. L-Serine methyl ester hydrochloride is 
not soluble in toluene and decomposes when heated under reflux in toluene. 
 
 
Reagents and Conditions: a) 4-methoxybenzaldehyde, NaBH3CN, acetic acid, MeOH, 103: 4%. 
Scheme 72. 
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A one-pot procedure was attempted whereby treatment of L-serine methyl ester 
hydrochloride with 4-methoxybenzaldehyde, sodium cyanoborohydride and acetic acid 
in methanol resulted in the formation of three products. The major products observed 
were 4-methoxybenzylalcohol 110 and 1-methoxy-4-(methoxymethyl)benzene 111. The 
desired compound 103 was the minor product, isolated in 4% yield. Unlike the leucine 
derivative, the by-products could be separated from the desired compound 103 using 
silica gel column chromatography. 
 
In 1993, Yoo and co-workers reported the synthesis of PMB protected L-serine methyl 
ester through a one-pot procedure using triethylamine, 4-methoxybenzaldehyde, 
hydrogen and palladium on carbon in methanol.46 Following their procedure, compound 
103 was isolated in 64% yield. As well as increasing the yield of the desired product, 
the only by-product observed in this reaction was 4-methoxybenzylalcohol 110. 
 
 
Reagents and Conditions: a) 4-methoxybenzaldehyde, triethylamine, H2, Pd/C, MeOH, 103: 64%. 
Scheme 73. 
 
Attempts were made to optimize the reaction. The by-product (4-
methoxybenzylalcohol) is formed when full conversion to the imine intermediate is not 
achieved; if full conversion can be achieved (as observed in the case of the leucine 
analogue), the yield of 103 should increase. L-serine methyl ester hydrochloride was 
treated with triethylamine in methanol in the presence of sodium sulfate. After stirring, 
the sodium sulfate was filtered off and the solvent removed under reduced pressure 
before analysis of the resulting material. This reaction was investigated under a range of 
conditions: increasing the reaction time, the use of 4 Å molecular sieves instead of 
sodium sulfate, and changing the solvent to dichloromethane. Under every set of 
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reaction conditions attempted, conversion to the imine was not complete according to 
1H NMR spectrum analysis of the crude reaction mixture. 
 
2.3.2.2 Synthesis of the Dieckmann Cyclization Precursor 
 
2.3.2.2.1 Peptide Coupling to the PMB Protected Amine 
 
Applying the optimized coupling conditions described above (section 2.2.2), compound 
103 was treated with potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP and 
NMM in dichloromethane. Two compounds were isolated from the reaction after silica 
gel column chromatography. The desired compound 104 was isolated in a low yield 
(14%). Compound 112, the result of coupling occurring at both the amine and hydroxyl 
moieties, was isolated as the major product in 31% yield. This result is neither 
unprecedented nor unexpected; there are many reports in the literature of the coupling 
of a carboxylic acid to a hydroxyl moiety in the presence of carbodiimide coupling 
reagents.47 
 
 
Reagents and Conditions: a) potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, NMM, 
CH2Cl2, 104: 14%, 112: 31%. 
Scheme 74.  
 
To prevent coupling to the hydroxyl moiety, a protection strategy was needed. Previous 
work in the group described the attempt at benzyl protection, however, this was found 
to be unsuccessful, and treatment of 103 with benzylbromide and potassium carbonate 
in DMF resulted in the formation of the tertiary amine as the only product. 
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Reagents and Conditions: a) benzylbromide, potassium carbonate, DMF. 
Scheme 75.  
 
As described above in our work on the leucine analogue, the most common reagents 
used to protect hydroxyl moieties are silyl reagents. A possible problem with this route 
is the use of TBAF during the Dieckmann cyclization step (competing reactions 
between removal of the protecting group and cyclization may occur), but we still felt it 
was a worthwhile route to investigate. 
 
 
Reagents and Conditions: a) TIPS-Cl, imidazole, DMF, reflux, 90%; b) potassium benzyloxycarbonyl 
acetate 16, EDAC·HCl, DMAP, NMM, CH2Cl2, 91%. 
Scheme 76.  
 
Treatment of 103 with TIPS-Cl and imidazole in DMF under reflux gave compound 
113 in 90% yield. Subsequent peptide coupling, under optimized conditions, gave the 
tertiary amide 114 in 91% yield. None of the double-coupled product 112 was observed. 
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2.3.2.2.2 Peptide Coupling to L-Serine Methyl Ester Hydrochloride 
 
 
Reagents and Conditions: a) potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, NMM, 
CH2Cl2, 115: 8%, 116: 52%. 
Scheme 77.  
 
The coupling of 16 to the unprotected L-serine methyl ester hydrochloride was also 
investigated. When L-serine methyl ester hydrochloride was subjected to optimized 
peptide coupling conditions, compounds 115 and 116 were isolated in 8% and 52% 
yields, respectively. Interestingly, the major product of this reaction is the opposite to 
that observed above. Coupling occurs preferentially to the nitrogen with only small 
amounts of the bis-coupled compound observed; this may be due to the absence of the 
PMB group making the nitrogen atom much more reactive. 
 
2.3.2.3 The Dieckmann Cyclization  
 
  
Reagents and Conditions: a) TBAF, MeI, THF; b) 1. TBAF, Et2O, RT, overnight; 2. MeI, THF, RT, 
overnight. 
Scheme 78. 
 
Subjecting compound 114 to the optimized one-pot conditions for the Dieckmann 
cyclization proved unsuccessful, resulting in a complex mixture from which nothing 
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also attempted under the original two-step conditions reported by Page, however, it was 
again unsuccessful, and no starting material or desired product was isolated from the 
reaction. 
 
2.3.2.4 The Oxazolidine Approach 
 
 
Scheme 79. 
 
In conjunction with the work described above investigation into a route to 
simultaneously protect the amine and hydroxyl moieties was carried out. We hoped that 
forming the oxazolidine intermediate would not only reduce the number of steps in our 
synthetic route but that it might also have an effect on the ratio of diastereoisomers 
formed in the Dieckmann cyclization. 
 
Following the method reported by Siciliano in 2014, compound 102 was treated with 
camphorsulfonic acid (CSA) and 2,2-dimethoxypropane (DMP) in toluene under 
reflux.48 Unfortunately, this reaction proved unsuccessful and the starting material was 
recovered. Compound 116 was subjected to the same conditions and, again, only 
starting material was recovered. It was unclear as to why this reaction was not 
successful- but it may be due to the unstable nature of the oxazolidine. 
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Reagents and Conditions: a) CSA, DMP, toluene, reflux, 117: 97%. 
Scheme 80. 
 
Compound 103 was subjected to the same conditions and, surprisingly, gave 117 in 
97% yield. This compound was not purified due to its instability on silica gel. The 1H 
NMR spectrum is relatively clean for this compound, however, decomposition occurs 
quickly as IR spectrum analysis show stretches corresponding to the starting material as 
well as the product, and mass spectrometry data analysis shows not only the product 
peak for [M+H]+ at 280.15 but also the starting material peak for [M+H]+ at 240.12. 
Although it is interesting that this reaction worked, the product was not of any use in 
our synthetic approach so we did not continue investigations any further. 
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2.3.3 Synthesis from O-Benzyl-L-Serine 
 
2.3.3.1 Protection of the Amine 
 
As we had predicted the possibility of competing reactions during the cyclization of the 
TIPS protected compound 114, we obtained commercially available O-benzyl-L-serine 
to use as the starting material. Esterification of O-benzyl-L-serine 118 with acetyl 
chloride in methanol gave the O-benzyl-L-serine methyl ester hydrochloride salt 119 in 
quantitative yield without purification. 
 
 
Reagents and Conditions: a) Acetyl chloride, MeOH, reflux, quant. 
Scheme 81. 
 
With 119 in hand, protection of the amine moiety was the next step in the synthesis. As 
described above, the O-benzyl-L-serine derivative was also unstable under reflux, and, 
due to the presence of the benzyl group, the protection method reported by Yoon using 
hydrogenation conditions could not be used. 
 
 
Reagents and Conditions: a) 4-Methoxybenzaldehyde, triethylamine, NaBH3CN, MeOH. 
Scheme 82. 
 
 
 
BnO
COOH
NH2
BnO
CO2Me
NH2 .HCl
a
118 119
BnO
CO2Me
NH2 .HCl
BnO
CO2Me
HN
a
OMe
119
120
	 	 Results	and	Discussion		
	 119	
Treatment of 119 with triethylamine, 4-methoxybenzaldehyde and sodium 
cyanoborohydride in methanol did not afford the desired product. The major product 
isolated from the reaction mixture was p-methoxybenzylalcohol, a by-product formed 
as a result of the reduction of the 4-methoxybenzaldehyde starting material. 
 
 
Reagents and Conditions: a) 4-Methoxybenzyl chloride, potassium carbonate, CH3CN, 45%. 
Scheme 83. 
 
With the protection of the amine group proving much more challenging than expected, 
we decided to investigate a different route. Treatment of 119 with 4-methoxybenzyl 
chloride and potassium carbonate in acetonitrile gave compound 120 in 45% yield. 
Unfortunately, as well as being low yielding, this reaction was not easily reproducible.49 
 
 
Reagents and Conditions: a) 4-Methoxybenzaldehyde, triethylamine, NaBH4, MeOH. 
Scheme 84. 
 
As the PMB protection of 119 was proving difficult, we considered inverting the order 
of the reactions; i.e. attempting the protection before the esterification. Treatment of O-
benzyl-L-serine 118 with 4-methoxybenzaldehyde, triethylamine and sodium 
borohydride in methanol resulted in the formation of a colourless solid. Interestingly, 
this solid was insoluble in all common organic solvents. 
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2.3.3.2 Synthesis of the Dieckmann Cyclization Precursor 
 
 
Reagents and Conditions: a) potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, NMM, 
CH2Cl2, 69%. 
Scheme 85.  
 
With PMB protection proving so difficult we decided to attempt the peptide coupling 
using O-benzyl-L-serine methyl ester hydrochloride as the starting material. Subjecting 
119 to our optimized conditions gave 121 in 69% yield. 
 
In comparison to the Dieckmann cyclization precursor of the leucine derivative 8, 
rotamers were not observed in compound 121; this is probably due to the lack of the 
PMB group, allowing free rotation around the amide C-N bond. 
 
2.3.3.3 The Dieckmann Cyclization 
 
 
Reagents and Conditions: a) TBAF, MeI, THF, 30%. 
Scheme 86. 
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When the O-benzyl-L-serine derivative 121, without the PMB protecting group, was 
subjected to optimized cyclization conditions, the desired compound was not observed 
and compound 122 was isolated in 30% yield. Deprotonation of the acidic malonyl-type 
protons (pKa≈13) occurs as expected and, instead of the desired intramolecular 
cyclization and alkylation reaction, alkylation at this position occurred twice to give the 
quaternary centre due to the excess of methyl iodide present in the reaction. 
 
This result may be due to reduced reactivity, or it is possible that the sizes of the 
functional groups present are preventing cyclization in that the groups are too big and 
cyclization is not favourable. 
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2.4 Synthesis of the Valine Analogue 
 
2.4.1 Proposed Synthetic Route Towards a Novel Analogue of 
Lactacystin 
 
As one of the aims of this project is to design a synthetic route that allows ready access 
to both natural and novel analogues of lactacystin, L-valine methyl ester hydrochloride 
was also used as a starting material. Valine is similar in structure to leucine; it does not 
have the added hydroxyl functionality that played a significant role in the complications 
in the synthesis of the serine analogue. 
 
 
Scheme 87. 
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2.4.2 Synthesis of the Dieckmann Cyclization Precursor 
 
Esterification of commercially available L-valine with acetyl chloride in methanol gave 
L-valine methyl ester hydrochloride 123 in quantitative yield, without purification. As 
described above, L-valine has a similar structure to L-leucine, and it behaves in a 
chemically similar manner to L-leucine, unlike the serine derivatives. 
 
 
Reagents and Conditions: a) Acetyl chloride, MeOH, reflux, quant.; b) 1. 4-Methoxybenzaldehyde, 
acetic acid, toluene, reflux, quant.; 2. NaBH3CN, acetic acid, MeOH, 74%. 
Scheme 88. 
 
Using the optimized conditions described above in our investigations of the leucine 
analogue (section 2.2.2), L-valine methyl ester hydrochloride 123 was treated with 4-
methoxybenzaldehyde and acetic acid then heated under reflux in toluene using a Dean-
Stark apparatus. Full conversion to the imine was achieved, and reduction was 
performed using sodium cyanoborohydride. The desired compound 124 was isolated in 
74% yield. 
 
 
Reagents and Conditions: a) Potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, NMM, 
CH2Cl2, 66%. 
Scheme 89.  
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Treatment of 124 with potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP 
and NMM in dichloromethane under optimized conditions gave compound 125 after 
silica gel column chromatography in 66% yield, a comparable yield to that achieved 
when using the leucine derivative (72%). 
 
As was the case with the leucine derivative, room temperature 1H NMR spectrum 
analysis shows the presence of two rotamers. A variable-temperature (VT) 1H NMR 
experiment was carried out in deuteriated dimethylsulfoxide (d6-DMSO) at 25, 75 and 
100 °C (Figure 15). Analysis of the resulting spectra does not show a significant 
difference between the spectra at 25 °C and 75 °C, but at 100 °C the peaks are clearly 
beginning to coalesce. 
 
 
 
Figure 15. Variable temperature 1H NMR spectra of compound 125 at 1: 25 °C, 2: 75 
°C and 3: 100 °C. 
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2.4.3 The Dieckmann Cyclization 
 
 
Reagents and Conditions: a) TBAF, MeI, THF, (±)-132: 25%, (±)-126: 41%. 
Scheme 90. 
 
Subjecting 125 to optimized one-pot tandem Dieckmann cyclization/methylation 
(section 2.2.3) resulted in the formation of two diastereoisomers. Though we fully 
expected racemization to occur at this point and know (due to this racemization) it is not 
necessary to separate the diastereoisomers for the next step in our synthesis, the 
diastereoisomers were separated using silica gel column chromatography for analytical 
purposes. Compounds (±)-132 and (±)-126 were obtained in 25% and 41% yields, 
respectively. 1H NMR spectrum analysis of the reaction mixture before separation 
shows a 2:1 diastereoisomeric ratio; this reaction thus appears to be more 
diastereoselective than that of the leucine derivative. This increased selectivity is 
probably a result of the iso-propyl moiety at C5 in the product; the steric bulk of the iso-
propyl group is closer to the ring than that of the iso-butyl group, therefore increasing 
steric hindrance on the top face. As expected, specific rotation measurements of each 
diastereoisomer confirmed that racemization had occurred at this point. 
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2.5 Conclusion 
 
One of the aims of our work was to design a synthetic approach that can be applied to 
the synthesis of lactacystin and its analogues. We began our synthesis from a 
commercially available amino acid derivative (either from L-leucine, L-serine or L-
valine); key steps in our approach included a tandem Dieckmann cyclization/alkylation 
to form the lactam ring and install the C7 functionality, and a Mander’s acylation to 
form the C5 quaternary centre. 
 
Our work was mainly focused on the use of the L-leucine derivative (L-leucine methyl 
ester hydrochloride) as the starting material, which would lead to the formation of 
deoxylactacystin. The Dieckmann cyclization precursor was synthesized following 
protection of the amine using 4-methoxybenzaldehyde followed by coupling to 
potassium benzyloxycarbonyl acetate using the carbodiimide reagent, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC·HCl). 
 
The lactam core (common throughout the lactacystin analogues) was formed by a 
tandem Dieckmann cyclization/alkylation reaction. Previous work in the Page group 
described a two-step procedure, wherein cyclization occurs first using TBAF in diethyl 
ether to form the tetrabutylammonium salt, followed by the methylation step in 
tetrahydrofuran to install the C7 functionality. We were able to improve on this and 
complete the step as a one-pot procedure with no notable loss in yield. Disappointingly, 
the reaction did not appear to be diastereoselective and it appeared that racemization 
had also occurred during this step. 
 
Formation of the C5 quaternary centre was achieved using a Mander’s acylation by 
treatment of (±)-9 and/or (±)-34 with methylcyanoformate and LiHMDS. This reaction 
is completely stereoselective and addition occurs at the C5 position to the opposite side 
of the C7 benzyl ester. 
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Reagents and Conditions: a) 1. 4-Methoxybenzaldehyde, acetic acid, toluene, reflux, 100%; 2. 
NaBH3CN, acetic acid, MeOH, 93%; b) Potassium benzyloxycarbonyl acetate 16, EDAC·HCl, DMAP, 
NMM, CH2Cl2, 72%; c) TBAF, MeI, THF, (±)-34: 22%, (±)-9: 39%; d) LiHMDS, DMPU, methyl 
cyanoformate, THF, −78 °C, 86%. 
Scheme 91. 
 
At this point, the synthesis could be completed using two possible routes. Route A 
consists of the reduction of the ketone at the C6 position of (±)-10 to give (±)-51, 
followed by decarboxylation of the benzyl ester moiety at the C7 position. When (±)-51 
was treated under hydrogenolysis conditions, debenzylation occurred resulting in the 
carboxylic acid (±)-57. Many attempts were made to remove the carboxylic acid 
moiety, including a radical-mediated approach involving the synthesis of an acyl 
selenide, the Barton decarboxylation, the Krapcho decarboxylation and an acid-
catalysed decarboxylation; unfortunately, none proved successful.  
 
Route B inverted the order of the reactions; decarboxylation under hydrogenolysis 
conditions followed by the reduction of the ketone moiety at the C6 position. Treatment 
of (±)-10 under hydrogenolysis conditions resulted in debenzylation with concomitant 
decarboxylation to give (±)-81 and (±)-82 as a mixture of inseparable diastereoisomers 
in a 1:1 ratio. All the attempts to reduce the ketone moiety at the C6 position proved 
unsuccessful. A strategy using a thiomethyl derivative reported by Corey in 1998 was 
then employed. Following Corey’s method, we successfully synthesized the desired 
advanced intermediate (±)-11, however, it was isolated alongside diastereoisomer (±)-
101 as an inseparable mixture in a 3:1 ratio. 
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Reagents and Conditions: a) NaBH4, EtOH, −10 °C, 30 min, 52%; b) H2, Pd(OH)2/C, THF, quant.; c) 
H2, Pd(OH)2/C, THF, 30 °C, >90%; d) p-MeC6H4SO2Me, Et3N, CH2Cl2, RT, (±)-97 and (±)-98: 47%; e) 
NaBH4, EtOH, −10 °C, 30 min, (±)-99: 17%, (±)-100: 25%; f) Raney Ni, EtOH, reflux, 4 h. 
Scheme 92. 
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Using L-serine methyl ester hydrochloride as the starting material proved much more 
challenging. The extra hydroxyl functionality present in serine appears to affect the 
chemical behaviour of this compound. It does not have the same properties as the L-
leucine derivative; for example, it is not soluble in the same solvents and so, from the 
start we had to alter our reaction conditions to compensate for this. We used L-serine 
methyl ester hydrochloride and, because the free hydroxyl group was causing problems, 
O-benzyl-L-serine methyl ester hydrochloride as starting materials. We have not yet 
been able to successfully synthesize the lactam core from the L-serine derivatives. 
 
Fortunately, our preliminary work using L-valine methyl ester hydrochloride as the 
starting material to synthesize a novel lactacystin analogue is proving promising. The L-
valine derivative appears, at present, to behave in a similar way to the L-leucine 
derivative. Following the same protection, coupling and cyclization steps, the 
substituted lactam core has been successfully synthesized. 
 
2.6 Recommended Future Work 
 
Work in the immediate future should focus on the stereoselective desulfurization of 
compound (±)-99. As the reaction was carried out under reflux, we would hope that by 
reducing the temperature, the stereoselectivity could be controlled. Once desulfurization 
is successful the synthetic route should be applied to the L-valine derivative to 
synthesize a novel lactacystin analogue. 
 
As the use of serine as the starting material means the hydroxyl functionality found in 
lactacystin is present from the start; in theory this should reduce the overall number of 
steps require in the total synthesis when compared to using the leucine derivative. 
Cyclization of the serine derivative to form the lactam core should be investigated 
further. 
 
The tandem Dieckmann cyclization/alkylation step could be investigated further still by 
changing the alkylating agent. This would allow ready access to a variety of analogues. 
If cyclization using different alkylating agents can be achieved using the L-leucine 
derivative, and successful cyclization of the serine derivative is achieved, this 
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methodology can then be applied to the L-serine derivative to allow ready access to a 
range of analogues. Scheme 93 details how the use of different alkylating agents results 
in the formation of the lactam core where the functionality at C7 corresponds to 
different analogues, for example by using ethyl iodide, the C7 group is now that found 
in salinosporamide B. 
 
 
Scheme 93. 
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3.0 Experimental 
 
3.1 General Experimental 
 
3.1.1 Preparation of Reagents, Solvents and Glassware 
 
Commercially obtained reagents were used as supplied, without further purification, and 
stored in accordance to the supplier’s recommendations, unless otherwise stated.  
 
Solvents used for reactions and column chromatography were purified as required. 
Petroleum ether 40/60 (the fraction which boils between 40 °C and 60 °C) was distilled 
before use. Tetrahydrofuran and diethyl ether were dried over the sodium/benzophenone 
ketyl radical, then distilled. Dichloromethane was dried over calcium chloride and then 
distilled. Toluene was dried over sodium and then distilled. All other solvents were used 
as supplied from the manufacturer. 
 
For reactions performed under anhydrous conditions, glassware was dried in the oven at 
150 °C before being cooled in a desiccator over silica gel. Glassware was sealed with a 
septum cap before being flushed with nitrogen. Solvents used in anhydrous reactions 
were freshly prepared each time and added using a syringe. 
 
3.1.2 Analysis of Compounds: Spectroscopic Techniques 
 
Proton, carbon, fluorine and selenium NMR experiments (including 2D experiments) 
were carried out on a Bruker Advance III 500 MHz NMR spectrometer at 500, 126, 471 
and 95 MHz, respectively. Samples were dissolved in the specified deuteriated solvents. 
All spectra were processed using MestReNova software, and chemical shifts were 
reported in ppm relative to either tetramethylsilane (TMS) or the residual solvent peak. 
Multiplicities are reported as either singlets (s), doublets (d), apparent doublets (app d) 
doublet of doublets (dd), triplets (t), quartets (q) or multiplets (m). Coupling constants 
(J values) are reported in Hertz (Hz). 
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Melting points were carried out on a Büchi B-545 instrument. All melting points were 
observed manually and are quoted as a range. Literature values are reported where 
available. 
 
Mass spectra were obtained from the EPSRC UK National Mass Spectrometry Facility 
(NMSF) at Swansea University (previously known as the National Mass Spectrometry 
Service Centre, NMSSC). 
 
Infra-Red (IR) spectra were recorded using a Perkin-Elmer Spectrum 100 FT-IR 
spectrometer and processed using Spectrum Express Application software, Version: 
1.02.00.0014. 
 
Specific rotation measurements were recorded using a Bellingham and Stanley ADP-
440 polarimeter operating at the sodium (D) line emission of λ = 589 nm at the 
specified temperature. Solutions used were prepared in a volumetric flask using 
spectrophotometric grade solvents. Literature values are quoted where available. 
 
3.1.3 Chromatographic Techniques 
 
Thin layer chromatography (TLC) was carried out on Merck aluminium backed plates 
coated with 0.2 mm Kiesegel 60 GF254. Individual solvent systems are reported in the 
experimental procedures below. TLC plates were visualised under UV irradiation and/or 
stained using phosphomolybdic acid solution or potassium permanganate solution. 
 
Flash column chromatography was carried out using glass columns packed with 
Kieselgel 40-63 μm silica gel. Individual solvent systems are reported in the 
experimental procedures below. 
 
3.1.4 Numbering System 
The numbering system used to assign 1H and 13C chemical shifts is designed by the 
author to simplify characterization. 
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3.2 Individual Experimental Procedures and Characterization 
 
3.2.1 General Procedures 
 
3.2.1.1 General Procedure for the Esterification of an Amino Acid 
 
Acetyl chloride (3 equiv.) was added slowly to methanol (30 mL/g of amino acid) while 
maintaining the temperature below 0 °C.  After 30 min, the amino acid was added as a 
solid at 0 °C and the reaction mixture stirred for another 30 min. The reaction mixture 
was heated under reflux overnight. The solvent was removed under reduced pressure to 
yield the desired product as a solid without further purification. 
 
3.2.1.2 General Procedure for the Peptide Coupling using 
EDAC·HCl 
 
The amine was dissolved in anhydrous dichloromethane (30 mL/g of amine). NMM 
(1.1-2 equiv.), benzyl malonic half ester (1.1-2 equiv.), EDAC·HCl (1.5-2.5 equiv.) and 
DMAP (0.2 equiv.) were added to the reaction mixture. The reaction mixture was 
stirred under an atmosphere of nitrogen for 20 h.  An aqueous solution of HCl (1 M, 1 
mL/g of amine) was added to the reaction mixture and stirring was continued for a 
further 30 min. The organic layer was separated, washed with water (2 x 30 mL/g of 
amine), dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness 
under reduced pressure. The residue was purified using column chromatography on 
silica gel. 
 
3.2.1.3 General Procedure for the One-pot Dieckmann 
Cyclization 
 
The diester was dissolved in THF (50 mL/g of diester) under an atmosphere of nitrogen, 
and TBAF (1 M in THF, 3.5 equiv.) added. The reaction mixture was allowed to stir for 
30 min at room temperature. The solution was cooled to 0 °C, iodomethane (4 equiv.) 
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added and stirred overnight. Water was added, and the solvents were removed under 
reduced pressure. The residue was dissolved in dichloromethane (50 mL/g of diester) 
and the resulting solution was washed with water (2 x 100 mL/g of diester), brine (2 x 
100 mL/g of diester), dried over anhydrous magnesium sulfate, filtered, and evaporated 
to dryness under reduced pressure. The residue was purified using column 
chromatography on silica gel. 
 
3.2.1.4 General Procedure for the Mander’s Acylation Reaction 
 
Procedure A: Hexamethyldisilazane (3 equiv.) was dissolved in anhydrous THF (10 
mL/g of lactam) and the solution was cooled to –78 °C. n-Butyl lithium (2.5 M solution 
in hexanes, 3 equiv.) was added. The solution was allowed to stir for 30 min and DMPU 
(1.5 equiv.) added. The lactam starting material was dissolved in anhydrous THF (10 
mL/mg of lactam), the resulting solution cooled to –78 °C, and DMPU (1.5 equiv.) 
added. The solution of LiHMDS was added dropwise to the solution of the lactam using 
a cannula. The mixture was stirred at –78 °C for 30 min. Methyl cyanoformate (5 
equiv.) was added and the mixture stirred for a further 4 h at –78 °C. Saturated aqueous 
NH4Cl (1 mL/g of lactam) was added at –78 °C. The mixture was allowed to reach 
room temperature and the solvent removed under reduced pressure. The residue was 
dissolved in ethyl acetate and the resulting solution washed with water (2 x 10 mL/mg 
of lactam) and brine (2 x 10 mL/mg of lactam). The organic layer was dried over 
anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure. 
The residue was purified using column chromatography on silica gel. 		
Procedure B: The lactam starting material was dissolved in anhydrous THF (40 mL/g 
of lactam) and the solution cooled to –78 °C. DPMU (3 equiv.) and LiHMDS (1 M in 
THF, 2 equiv.) were added and the mixture stirred at –78 °C for 30 min. Methyl 
cyanoformate (3 equiv.) was added and the mixture stirred for a further 4 h at –78 °C. 
Saturated aqueous NH4Cl (1 mL/g of lactam) was added at –78 °C. The mixture was 
allowed to reach room temperature and the solvent removed under reduced pressure. 
The residue was dissolved in ethyl acetate and the resulting solution washed with water 
(2 x 40 mL/g of lactam) and brine (2 x 40 mL/g of lactam). The organic layer was dried 
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over anhydrous sodium sulfate, filtered and evaporated to dryness under reduced 
pressure. The residue was purified using column chromatography on silica gel. 
 
3.2.1.5 General Procedure for the Ketone Reduction using NaBH4  
 
The ketone was dissolved in ethanol (50 mL/g of ketone). The mixture was cooled to 
−10 °C followed by the addition of NaBH4 (0.5 equiv.). The reaction mixture was 
stirred at −10 °C for 30-120 min after which it was quenched with water (10 mL/g of 
ketone). The solvent was removed under reduced pressure and the resulting residue re-
dissolved in ethyl acetate (50 mL/g of ketone). The mixture was washed with water (2 x 
50 mL/g of ketone) and then brine (2 x 50 mL/g of ketone). The organic layer was dried 
over anhydrous sodium sulfate, filtered and evaporated to dryness under reduced 
pressure. The residue was purified using column chromatography on silica gel (light 
petroleum ether/ethyl acetate). 
 
3.2.1.6 General Procedure for the Treatment of the Benzyl Ester 
Under Hydrogenolysis Conditions 
  
The benzyl ester was dissolved in anhydrous THF (5 mL/g of ester), to this was added 
Pd(OH)2 / C (50% by weight). The reaction mixture was purged with nitrogen and 
treated with a balloon of hydrogen overnight at room temperature. The reaction mixture 
was filtered through celite and the solvent removed under reduced pressure. 
 
3.2.1.7 General Procedure for the Formation of an Acyl Selenide  
 
The carboxylic acid was dissolved in anhydrous dichloromethane (5 mL/g of carboxylic 
acid) under a nitrogen atmosphere and diphenyldiselenide (1.5 equiv.) added. The 
mixture was cooled to 0 °C and tributylphosphine (2 equiv.) added. The solution was 
warmed to room temperature and stirred overnight. The solution was diluted with 
dichloromethane (10 mL/g of carboxylic acid) and water (10 mL/g of carboxylic acid). 
The aqueous layer was extracted again with dichloromethane (10 mL/g of carboxylic 
acid). The organic fractions were combined, washed with brine (5 mL/g of carboxylic 
	 	 Experimental		
	 139	
acid), dried over anhydrous magnesium sulfate and evaporated to dryness under reduced 
pressure. The residue was purified using column chromatography on silica gel (light 
petroleum ether/ethyl acetate). 
 
3.2.1.8 General Procedure for the Silyl Protection of the Hydroxyl 
Moiety  
 
The silyl protection reagent (1.2 equiv.) and imidazole (2.5 equiv.) were added to a 
solution of the reduced Mander’s reaction product in DMF (5 mL/g of reduced 
Mander’s reaction product). The reaction mixture was stirred at 35 °C under an 
atmosphere of nitrogen overnight. The reaction was quenched with water (1 mL/g of 
reduced Mander’s reaction product) and the solvent removed under reduced pressure. 
The resulting product was re-dissolved in diethyl ether (5 mL/g of reduced Mander’s 
reaction product) and washed with water (2 x 10 mL/g of reduced Mander’s reaction 
product) and brine (2 x 10 mL/g of reduced Mander’s reaction product). The organic 
layer was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness 
with no further purification. 
 
3.2.1.9 General Procedure for the Protection of the Hydroxyl 
Moiety at C6 using Trifluoroacetic Anhydride 
 
The hydroxyl compound was dissolved in dry diethyl ether (10 mL/g of hydroxyl). The 
mixture was cooled to ca. 0 °C. Pyridine (2.5 equiv.) and trifluoroacetic anhydride (2.5 
equiv.) were added to the reaction mixture. The reaction was monitored using TLC 
(light petroleum ether/ethyl acetate). On completion, pentane (10 mL/g of hydroxyl) 
was added and the mixture filtered through celite to remove the pyridinium 
trifluoroacetate by-product. The solvent was removed under reduced pressure and the 
resulting residue re-dissolved in dichloromethane (10 mL/g of hydroxyl), washed with 
water (2 x 10 mL/g of hydroxyl) and brine (2 x 10 mL/g of hydroxyl). The organic layer 
was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under 
reduced pressure.  
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3.2.2 Individual Experimental Procedures 
 
3.2.2.1 Synthesis from L-Leucine 
 
R2-{[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-amino}-4-methyl-pentanoic acid 
methyl ester 13 
 
 
 
L-Leucine methyl ester hydrochloride (10.01 g, 0.06 mol) and 4-methoxybenzaldehyde 
(7.30 mL, 0.06 mmol, 1.1 equiv.) were dissolved in toluene (100 mL). Acetic acid (2 
mL) was added and the reaction mixture heated under reflux using a Dean-Stark 
apparatus overnight. The solvent was evaporated to dryness under reduced pressure. 
The resulting product was obtained as a brown oil (15.82 g, quant.).  
 
νmax (thin film)/cm−1 2956 and 1739. 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H, H8), 
7.73 (app d, 2H, J = 8.9 Hz, H11 and H13), 6.93 (app d, 2H, J = 8.9 Hz, H10 and H14), 
4.05 (dd, 1H, J = 8.8, 5.6 Hz, H5), 3.85 (s, 3H, H15), 3.74 (s, 3H, H7), 1.87–1.79 (m, 
2H, H4), 1.61–1.54 (m, 1H, H3), 0.94 (d, 3H, J = 6.6 Hz, H1 or H2), 0.89 (d, 3H, J = 
6.6 Hz, H1 or H2). 
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2-(4’-Methoxy-benzylamino)-4-methyl-pentanoic acid methyl ester 71 
 
 
 
Direct synthesis of compound 7: L-Leucine methyl ester hydrochloride (0.99 g 5.45 
mmol) was dissolved in methanol (50 mL). Triethylamine (0.76 mL, 5.45 mmol) and 4-
methoxybenzaldehyde (0.75 mL, 6.81 mmol, 1.25 equiv.) were added and the reaction 
mixture was stirred at room temperature for 90 min. The reaction mixture was cooled to 
0 °C and sodium borohydride (0.38 g, 13.62 mmol, 2 equiv.) added. Stirring was 
continued for a further 30 min. The solvent was removed under reduced pressure and 
the resulting residue re-dissolved in ethyl acetate (75 mL). The organic layer was 
washed with water (2 x 30 mL), brine (2 x 30 mL) and saturated aqueous Na2CO3 (2 x 
30 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, and 
evaporated to dryness under reduced pressure. The title compound was obtained as a 
yellow/brown oil (0.77 g, 53%).  
 
Synthesis of compound 7 using the Dean-Stark protocol 
 
Procedure A: Compound 13 (15.82 g, 0.06 mol) was dissolved in ethanol (100 mL) 
and sodium borohydride (1.61 g, 0.04 mol, 0.7 equiv.) added slowly in small portions. 
The reaction was monitored by TLC then quenched with water (30 mL). The solvent 
was removed under reduced pressure. The residue was dissolved in dichloromethane 
(50 mL) and the resulting solution was washed with water (2 x 50 mL), brine (2 x 50 
mL) and saturated aqueous Na2CO3 (2 x 50 mL). The organic layer was dried over 
anhydrous magnesium sulfate, filtered, and evaporated to dryness under reduced 
pressure. The title compound was obtained as a yellow/brown oil (8.42 g, 58%). 
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Procedure B: Compound 13 (22.32 g, 0.85 mol) and acetic acid (4.5 mL) were 
dissolved in methanol (200 mL). The reaction mixture was cooled to 0 °C and sodium 
cyanoborohydride (10.66 g, 0.17 mol, 2 equiv.) added slowly in small portions. The 
reaction was stirred for 30 min at 0 °C then allowed to reach room temperature and 
stirred for a further 5 h. Water (20 mL) was added to quench the reaction mixture and 
the solvents were removed under reduced pressure. The residue was dissolved in 
dichloromethane (100 mL), washed with water (2 x 100 mL), brine (2 x 100 mL) and a 
saturated solution of Na2CO3 (2 x 100 mL). The organic layer was dried over anhydrous 
magnesium sulfate, filtered, and evaporated to dryness under reduced pressure. The title 
compound was obtained as a yellow/brown oil (20.89 g, 93%).  
 
Found (NSI): [M+H]+ 266.1755; [C15H23NO3+H]+ requires 266.1751. νmax (thin 
film)/cm−1 2955 and 1733. [α]D = +7 (c 1.5, CDCl3, 25 °C, lit −31.17, c 1.5, CDCl3, 27 
°C).1 1H NMR (500 MHz, CDCl3) δ 7.23 (app d, 2H, J = 8.6 Hz, H11 and H13), 6.84 
(app d, 2H, J = 8.6 Hz, H10 and H14), 3.77 (d, 3H, J = 0.8 Hz, H15), 3.73 (d, 1H, J = 
12.7 Hz, H8), 3.70 (s, 3H, H7), 3.54 (d, 1H, J = 12.7 Hz, H8), 3.29 (dd, 1H, J = 7.7, 6.8 
Hz, H5), 1.82 – 1.72 (m, 2H, H3 and H16), 1.46 (ddd, 2H, J = 7.4, 6.7, 2.1 Hz, H4), 
0.91 (d, 3H, J = 6.7 Hz, H1 or H2), 0.84 (d, 3H, J = 6.7 Hz, H1 or H2). 13C NMR (126 
MHz, CDCl3) δ 176.5 (C6), 158.7 (C12), 132.0 (C9), 129.4 (C11 and C13), 113.7 (C10 
and C14), 59.1 (C5), 55.2 (C15), 51.6 (C8), 51.5 (C7), 42.8 (C4), 24.9 (C3), 22.8 (C1 or 
C2), 22.2 (C1 or C2).  
 
Potassium benzyloxycarbonyl acetate 162 
 
 
 
Malonic acid (50.10 g, 0.48 mol), benzyl alcohol (105 mL, 1.01 mol, 2.1 equiv.) and p-
TsOH (0.92 g, 4.81 mmol, 0.01 equiv.) were dissolved in toluene (500 mL) and heated 
under reflux using a Dean-Stark apparatus overnight. The solvents were removed under 
reduced pressure and the residue was dissolved in a solution of KOH in BnOH (1 M, 
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26.00 g in 480 mL). A yellow solid precipitated which was then filtered and washed 
with diethyl ether (300 mL). The solid was dried in the vacuum oven overnight yielding 
the title compound as a colourless solid (80.10 g, 72%).  
 
νmax (solid) cm−1 1722 and 1599. mp 199-202 °C, lit mp 201 °C.2 1H NMR (500 MHz, 
D2O) δ 7.40 – 1.35 (m, 5H, H6-10), 5.15 (s, 2H, H4), 3.29 (s, 2H, H2). 13C NMR (126 
MHz, D2O) δ 173.9 (C1 or C3), 171.1 (C1 or C3), 135.6 (C5), 128.6 (C6-10), 67.2 
(C4), 44.6 (C2). 
	
2-{(4-Methoxy-benzyl)-[2-(benzyloxycarbonyl)-acetyl]-amino}-4-methyl-pentanoic 
acid methyl ester 8 
 
 
 
Coupling using EDAC·HCl: Compound 7 (9.84 g, 0.37 mol) was subjected to the 
general procedure for peptide coupling using EDAC·HCl 17.73 g, 0.93 mol, 2.5 equiv.), 
NMM (8.2 mL, 0.75 mol, 2 equiv.), benzyl malonic half ester (17.19 g, 0.75 mol, 2 
equiv.) and DMAP (0.90 g, 0.07 mol, 0.2 equiv.). The residue was purified using 
column chromatography on silica gel (30% ethyl acetate in light petroleum ether).  
Compound 8 was isolated as a yellow oil (11.73 g, 72%). 
 
Coupling using T3P®: Compound 7 (0.22 g, 0.80 mmol) was dissolved in THF (5 mL) 
and benzyl malonic half ester (0.23 g, 0.10 mmol, 1.2 equiv.) was added. The mixture 
was cooled to 0 °C and DIPEA (0.26 mL, 1.49 mmol, 1.8 equiv.), followed by T3P® 
(50% solution in THF, 0.79 g, 1.29 mmol, 1.5 equiv.) were added. The reaction was 
allowed to reach room temperature and then stirred for 20 h. Water (10 mL) was then 
added to the reaction mixture and extracted with ethyl acetate (2 x 10 mL). The organic 
layers were combined, washed with water (2 x 20 mL) and brine (2 x 20 mL), dried 
over anhydrous magnesium sulfate, filtered, and evaporated to dryness under reduced 
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pressure. The residue was purified using column chromatography on silica gel (30% 
ethyl acetate in light petroleum ether) to yield the title compound as a yellow oil (0.23 
g, 62%). 
 
Coupling from the acid chloride of the malonic half ester: Potassium 
benzyloxycarbonyl acetate (0.72 g, 3.08 mmol) was suspended in toluene (5 mL) and 
oxalyl chloride (0.83 mL, 9.87 mmol, 3.2 equiv.) added. The reaction mixture was 
stirred at 34 °C for 24 h. The solvent and excess oxalyl chloride were removed under 
reduced pressure to give the corresponding acyl chloride which was used without 
purification. Compound 7 (1.01 g, 3.70 mmol, 1.2 equiv.) was dissolved in anhydrous 
dichloromethane (20 mL) and the solution cooled to 0 °C. The acyl chloride was 
dissolved in anhydrous dichloromethane (10 mL) and added to the amine solution. 
While maintaining the temperature at 0 °C, pyridine (0.01 mL, 0.03 mmol, 0.01 equiv.) 
and DMAP (0.02 g, 0.15 mmol, 0.05 equiv.) were added. After addition the reaction 
mixture was allowed to reach room temperature and stirred for 4 h. The reaction 
mixture was washed with an aqueous solution of HCl (5%, 20 mL), dried over 
anhydrous magnesium sulfate, filtered, and evaporated to dryness under reduced 
pressure. The residue was purified using column chromatography on silica gel (30% 
ethyl acetate in light petroleum ether) to yield the title compound as a yellow oil (0. 97 
g, 58%).  
 
Found (NSI): [M+H]+ 442.2226; [C25H31NO6+H]+ requires 442.2224. νmax (thin 
film)/cm−1 2955, 1740 and 1655. [α]D = +12 (c 1, CHCl3, 25 °C). 
 
Major Rotamer: 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.33 (m, 5H, H21-25), 7.15 
(app d, 2H, J = 8.7 Hz, H11 and H13), 6.85 (app d, 2H, J = 8.7 Hz, H10 and H14), 5.16 
(d, 2H, J = 2.4 Hz, H17), 4.82 (dd, 1H, J = 7.4, 6.3 Hz, H5), 4.55 (d, 1H, J = 17.1 Hz, 
H8), 4.42 (d, 1H, J = 17.1 Hz, H8), 3.79 (s, 3H, H15), 3.57 (s, 3H, H7), 3.48 (d, 2H, J = 
3.7 Hz, H19), 1.89 – 1.81 (m, 1H, H4), 1.58 – 1.53 (m, 1H, H4 and H3) 0.88 (d, 3H, J = 
6.3 Hz, H1 or H2), 0.80 (d, 3H, J = 6.3 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 
171.7, 167.2, 159.2, 135.4, 128.6 (Ar), 128.4 (Ar), 128.4 (Ar), 128.1, 127.96 (C11 and 
C13), 114.2 (C10 and C14), 67.2 (C17), 56.1 (C5), 55.3 (C15), 52.0 (C7), 50.0 (C8), 
41.7 (C19), 38.3 (C4), 25.1 (C3), 22.6 (C1 or C2), 22.3(C1 or C2). 
	 	 Experimental		
	 145	
The Dieckmann Cyclization 
 
 
 
Two-step synthesis: Diester 8 (8.86 g, 0.02 mol) was dissolved in diethyl ether (50 mL) 
under an atmosphere of nitrogen. TBAF (1 M solution in THF, 50 mL, 0.05 mol, 2.5 
equiv.) was added and the reaction mixture was stirred overnight. The solvents were 
removed under reduced pressure and the resulting residue was dissolved in THF (50 
mL) under an atmosphere of nitrogen and the solution was cooled to 0 °C. Iodomethane 
(5.00 mL, 0.08 mol, 4 equiv.) was added and the reaction was stirred overnight. The 
solvent was removed under reduced pressure and the resulting residue was dissolved in 
dichloromethane (50 mL). The solution was washed with water (2 x 50 mL), dried over 
anhydrous magnesium sulfate, filtered, and evaporated to dryness under reduced 
pressure. The resulting residue was purified using column chromatography on silica gel 
(20% ethyl acetate in light petroleum ether). The first eluting diastereoisomer (±)-34 
was obtained as a pale yellow oil (2.59 g, 30%), the second eluting diastereoisomer (±)-
9 was obtained as a darker yellow oil (2.47 g, 29%). 
 
One-pot synthesis: Diester 8 (0.21 g, 0.5 mmol) was subjected to the general procedure 
for the one-pot Dieckmann cyclization using TBAF (1 M in THF, 1.60 mL, 1.6 mmol, 
3.5 equiv.) and iodomethane (0.12 mL, 1.8 mmol, 4 equiv.). The residue was purified 
using column chromatography on silica gel (20% ethyl acetate in light petroleum ether 
as the eluent). The first eluting diastereoisomer (±)-34 was obtained as a pale yellow oil 
(0.044 g, 22%), the second eluting diastereoisomer (±)-9 was obtained as a dark yellow 
oil (0.08 g, 39%). 
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(±)-(3S,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-pyrrolidin-2,4-
dione-3-carboxylic acid benzyl ester (±)-34 
Found (NSI): [M+Na]+ 424.2110; [C27H31NO7+Na]+ requires 424.2118. νmax (thin 
film)/cm−1 2958, 1778, 1747 and 1697. 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, 3H, J = 
5.0, 1.9 Hz, Ar), 7.24 – 7.21 (m, 2H, Ar), 7.02 (app d, 2H, J = 8.6 Hz, H12 and H14), 
6.59 (app d, 2H, J = 8.6 Hz, H11 and H15), 5.42 (d, 1H, J = 15.0 Hz, H9), 5.19 (d, 1H, 
J = 12.3 Hz, H18), 5.09 (d, 1H, J = 12.3 Hz, H18), 3.85 (dd, 1H, J = 7.8, 3.9 Hz, H5), 
3.80 (d, 1H, J = 15.0 Hz, H9), 3.73 (s, 3H, H16), 1.82 – 1.73 (m, 1H, H3), 1.67 – 1.61 
(m, 1H, H4), 1.58 (s, 3H, H25), 1.56 – 1.48 (m, 1H, H4), 0.87 (d, 3H, J = 6.6 Hz, H1 or 
H2), 0.76 (d, 3H, J = 6.6 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 205.9 (C6), 
169.6 (C8), 165.6 (C17), 159.2 (C13), 134.8 (C10 and C19), 129.4 (C12 or C14), 128.7 
(Ar), 128.5 (Ar), 128.2 (Ar), 126.2 (C7), 114.1 (C11 or C15), 68.1 (C18), 62.4 (C5), 
58.6, 55.2 (C16), 43.2 (C9), 37.9 (C4), 24.6 (C3), 23.2 (C1 or C2), 22.4 (C1 or C2), 
16.1 (C25).  
 
(±)-(3R,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-pyrrolidin-2,4-
dione-3-carboxylic acid benzyl ester (±)-9 
Found (NSI): [M+Na]+ 424.2108; [C27H31NO7+Na]+ requires 424.2118. νmax (thin 
film)/cm−1 2927, 1775, 1746 and 1696. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.26 (m, 
5H, H20-24), 7.13 (app d, 2H, J = 8.6 Hz, H12 and H14), 6.83 (app d, 2H, J = 8.6 Hz, 
H11 and H15), 5.26 (d, 1H, J = 12.1 Hz, H18), 5.19 (d, 1H, J = 14.9 Hz, H9), 5.08 (d, 
1H, J = 12.1 Hz, H18), 4.01 (d, 1H, J = 14.9 Hz, H9), 3.79 (s, 3H, H16), 3.67 (t, 1H, J = 
6.8 Hz, H5), 1.77 – 1.72 (m, 1H, H3), 1.54 (s, 3H, H25), 1.50 (dd, 2H, J = 7.4, 6.5 Hz, 
H4), 0.73 (d, 3H, J = 6.5 Hz, H1 or H2), 0.70 (d, 3H, J = 6.5 Hz, H1 or H2). 13C NMR 
(126 MHz, CDCl3) δ 205.6 (C6), 169.3 (C8), 165.6 (C17), 159.4 (C13), 134.7 (C10 and 
C19), 129.4 (C12 and C14), 128.7, 128.6, 128.4, 127.1, 114.3 (C11 and C15), 68.2 
(C18), 62.4 (C5), 58.6, 55.30 (C16), 43.5 (C9), 38.9 (C4), 24.4 (C3), 23.0 (C1 or C2), 
21.9 (C1 or C2), 16.6 (C25). 
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(±)-(3R,5R)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-pyrrolidin-2,4-
dione-3,5-dicarboxylic acid-3-benzyl ester-5-methyl ester (±)-10 
 
 
 
Synthesized according to the general procedure for the Mander’s acylation reaction 
(Procedure A) from the first eluting diastereoisomer (±)-34. Compound (±)-34 (0.16 g, 
0.38 mmol), hexamethyldisilazane (0.24 mL, 1.13 mmol, 3 equiv.), n-BuLi (2.5 M in 
THF, 0.46 mL, 1.13 mmol, 3 equiv.), DMPU (0.07 mL, 0.57 mmol, 1.5 equiv.) and 
methyl cyanoformate (0.15 mL, 1.88 mmol, 5 eqiuv.). Compound (±)-10 was isolated as 
an off-white solid (0. 13 g, 73%). 
 
Synthesized according to the general procedure for the Mander’s acylation reaction 
(Procedure A) from the second eluting diastereoisomer (±)-9. Compound (±)-9 (0.22 g, 
0.52 mmol), hexamethyldisilazane (0.32 mL, 1.56 mmol, 3 equiv.), n-BuLi (2.5 M in 
THF, 0.62 mL, 1.56 mmol, 3 equiv.), DMPU (0.06 mL, 0.78 mmol, 1.5 equiv.) and 
methyl cyanoformate (0.20 mL, 2.60 mmol, 5 equiv.). Compound (±)-10 was isolated as 
an off-white solid (0.19 g, 79%). 
 
Synthesized according to the general procedure for the Mander’s acylation reaction 
(Procedure A) from the mixture of diastereoisomers (±)-34 and (±)-9. A mixture of 
compounds (±)-34 and (±)-9 (0.34 g, 0.80 mmol, 3 equiv.), hexamethyldisilazane (0.50 
mL, 2.41 mmol, 3 equiv.), n-BuLi (2.5 M in THF, 0.96 mL, 2.41 mmol, 3 equiv.), 
DMPU (0.15 mL, 1.20 mmol, 1.5 equiv.) and methyl cyanoformate (0.32 mL, 4.01 
mmol, 5 equiv.). Compound (±)-10 was isolated as an off-white solid (0.34 g, 78%). 
 
Synthesized according to the general procedure for the Mander’s acylation reaction 
(Procedure B) from a mixture of diastereoisomers (±)-34 and (±)-9. A mixture of 
N
O
O
PMB
OBn
O
76
5 8
9
4
3
1
25
17
2
10
15
14
13
12
11
18
19
24
23
22
21
20
16
N
O
O
O
O
OMe
O
MeO 26
27
(±)-10
	 	 Experimental		
	 148	
compounds (±)-34 and (±)-9 (0.34 g, 0.8 mmol), DPMU (1.10 mL, 9.19 mmol, 3 
equiv.), LiHMDS (1 M in THF, 6.1 mL, 6.13 mmol, 2 equiv.) and methyl cyanoformate 
(0.78 mL, 9.19 mmol, 3 equiv.). Compound (±)-10 was isolated as an off-white solid 
(1.26 g, 86%). 
 
Found (NSI): [M+Na]+ 504.1979; [C27H31NO7+Na]+ requires 504.1993. νmax (thin 
film)/cm−1 2958, 1782, 1751 and 1699. mp 79-82 °C. 1H NMR (400 MHz, CDCl3) δ 
7.39 – 7.28 (m, 5H, H20-24), 7.19 (app d, 2H, J = 8.7 Hz, H12 and H14), 6.77 (app d, 
2H, J = 8.7 Hz, H11 and H15), 5.20 (d, 1H, J = 12.1 Hz, H18), 5.14 (d, 1H, J = 12.1 Hz, 
H18), 4.89 (d, 1H, J = 15.0 Hz, H9), 4.15 (d, 1H, J = 15.0 Hz, H9), 3.77 (s, 3H, H16), 
3.23 (s, 3H, H27), 2.15 (dd, 1H, J = 15.2, 5.4 Hz, H4), 1.86 (dd, 1H, J = 15.2, 6.3 Hz, 
H4), 1.72 (s, 3H, H25), 1.47 – 1.41 (m, 1H, H3), 0.65 (d, 3H, J = 6.6 Hz, H1 or H2), 
0.52 (d, 3H, J = 6.6 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 201.8 (C6), 170.8 
(C8), 167.6 (C17 or C26), 165.2 (C17 or C26), 159.23 (C13), 134.5 (C10 and C19), 
130.3 (C12 and C14), 128.7 (Ar), 128.6 (Ar), 128.6 (Ar), 127.6 (C5 or C7), 113.8 (C11 
and C15), 76.1 (C5 or C7), 68.5 (C18), 58.4, 55.3 (C16), 52.9 (C27), 43.9 (C9), 38.7 
(C4), 24.2 (C1 or C2), 23.4 (C1 or C2), 23.1 (C3), 18.9 (C25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 Experimental		
	 149	
Reduction of the Mander’s Acylation Reaction Product (±)-10 
 
 
 
Procedure A: Compound (±)-10 (0.15 g, 0.32 mmol) was subjected to the general 
procedure for ketone reduction using NaBH4 (0.01 g, 0.22 mmol, 0.5 equiv.). The 
reaction was stirred at −10 °C for 2 h. The residue was purified using column 
chromatography on silica gel (light petroleum ether/ethyl acetate, 2:1). Compound (±)-
51 was isolated as a white foam (0.07 g, 42%). Compound (±)-52 or (±)-53 (0.04 g, 
29%). Compound (±)-52 or (±)-53 (0.01 g, 10%). 
 
Procedure B: Compound (±)-10 (0.21 g, 0.44 mmol, 1 equiv.) was subjected to the 
general procedure for ketone reduction using NaBH4 (0.01 g, 0.22 mmol, 0.5 equiv.). 
The reaction was stirred at −10 °C for 30 min. The residue was purified using column 
chromatography on silica gel (light petroleum ether/ethyl acetate, 2:1). Compound (±)-
51 was isolated as a white foam (0.11 g, 52%). Starting material (0.07 g, 31%). 
 
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-hydroxy-5-(2’-methylpropyl)-
pyrrolidin-2-one-3,5-dicarboxylic acid-3-benzyl ester-5-methyl ester (±)-51 
Found (NSI): [M+Na]+ 506.2134; [C27H33NO7+Na]+ requires 506.2149. νmax (thin 
film)/cm−1 3373, 1735 and 1676. 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.33 (m, 5H, 
H20-24), 7.11 (app d, 2H, J = 8.7 Hz, H12 and H14), 6.68 (app d, 2H, J = 8.7 Hz, H11 
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and H15), 5.27 (d, 1H, J = 12.4 Hz, H18), 5.24 (d, 1H, J = 12.4 Hz, H18), 4.94 (d, 1H, J 
= 16.1 Hz, H9), 4.69 (d, 1H, J = 8.4 Hz, H6), 4.39 (d, 1H, J = 16.1 Hz, H9), 3.75 (s, 3H, 
H16), 3.70 (s, 3H, H27), 3.14 (d, 1H J = 8.4 Hz, H28), 1.71 – 1.67 (m, 2H, H4), 1.67 – 
1.62 (m, 1H, H3), 1.48 (s, 3H, H25), 0.83 (d, 3H, J = 6.2 Hz, H1 or H2), 0.70 (d, 3H, J 
= 6.2 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 172.8, 172.18, 170.8, 158.5, 135.1, 
130.3, 128.7 (Ar), 128.4 (Ar), 128.3 (Ar), 127.9 (C12 and C14), 113.8 (C11 and C15), 
77.5 (C6), 72.1, 67.7 (C18), 56.2, 55.3 (C16), 52.5 (C27), 45.1 (C9), 40.3 (C4), 24.1 
(C1 or C2), 24.1 (C3), 23.4 (C1 or C2), 19.2 (C25). 
 
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-hydroxymethyl-4-hydroxy-5-(2’-
methylpropyl)-pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-52 
 
(±)-(3R,4S,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-hydroxymethyl-4-hydroxy-5-(2’-
methylpropyl)-pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-53 
 
Compound (±)-52 or (±)-53: Found (NSI): [M+H]+ 380.2065; [C20H29NO6+H]+ requires 
380.2068. νmax (thin film)/cm−1 3356, 2961, 1735 and 1671. 1H NMR (500 MHz, CDCl3) 
δ 7.15 (app d, 2H, J = 8.6 Hz, H12 and H 14), 6.83 (app d, 2H J = 8.6 Hz, H11 and 
H15), 4.99 (d, 1H, J = 16.2 Hz, H9), 4.70 (d, 1H, J = 7.3 Hz, H6), 4.40 (d, 1H, J = 16.2 
Hz, H9), 4.27 (s, 1H, H21), 3.96 – 3.88 (m, 2H, H17), 3.78 (s, 3H, H16), 3.73 (s, 3H, 
H20), 2.95 (s, 1H, H18), 1.77 (dd, 1H, J = 12.8, 5.7 Hz, H4), 1.74 – 1.69 (m, 1H, H3), 
1.66 (dd, 1H, J = 12.8, 4.9 Hz, H4), 0.99 (s, 3H, H22), 0.91 (d, 3H, J = 6.3 Hz, H1 or 
H2), 0.74 (d, 3H, J = 6.3 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 176.69 (C8), 
173.58 (C19), 158.51 (C13), 130.64 (C10), 127.85 (C12 and C14), 113.91 (C11 and 
C15), 79.03 (C6), 72.87 (C5 or C7), 65.99 (C17), 55.26 (C16), 52.28 (C20), 49.26 (C5 
or C7), 44.96 (C9), 40.38 (C4), 24.14 (C1 or C2), 24.12 (C3), 23.52 (C1 or C2), 18.17 
(C22). 
 
Compound (±)-52 or (±)-53: Found (NSI): [M+H]+ 380.2065; [C20H29NO6+H]+ requires 
380.2068. νmax (thin film)/cm−1 3393, 2955, 1738 and 1669. 1H NMR (500 MHz, CDCl3) 
δ 7.11 (app d, 2H, J = 8.7 Hz, H12 and H14), 6.82 (app d, 2H, J = 8.7 Hz, H11 and 
H15), 4.59 (d, 1H, J = 15.6 Hz, H9), 4.45 (d, 1H J = 15.6 Hz, H9), 4.43 (d, 1H J = 10.8 
Hz, H6), 3.82 (dd, 1H J = 10.8, 5.3 Hz, H17), 3.78 (s, 3H, H16), 3.56 (dd, 1H, J = 10.8, 
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5.4 Hz, H17), 3.44 (s, 3H, H20), 2.10 (dd, 1H, J = 14.2, 7.3 Hz, H4), 1.98 – 1.92 (m, 
1H, H3), 1.57 (dd, 1H, J = 14.2, 4.8 Hz, H4), 1.14 (s, 3H, H22), 0.87 (d, 3H J = 2.2 Hz, 
H1 or H2), 0.86 (d, 3H, J = 2.2 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 177.56 
(C8 or C19), 158.73 (C8 or C19), 128.60 (C12 and C14), 113.86 (C11 and C15), 74.86 
(C6), 68.14 (C5 or C7), 66.51 (C17), 55.30 (C16), 52.20 (C20), 48.57 (C5 or C7), 44.16 
(C4), 43.67 (C9), 24.46 (C1 or C2), 23.57 (C1 or C2), 23.49 (C3), 13.51 (C22).  
 
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-hydroxy-5-(2’-methylpropyl)-
pyrrolidin-2-one-3,5-dicarboxylic acid-5-methyl ester (±)-57 
 
 
 
Compound (±)-51 (1.29 g, 2.7 mmol) was subjected to the general procedure for the 
treatment of the benzyl ester under hydrogenolysis conditions using Pd(OH)2 / C (0.65 
g). The product (±)-57 was obtained as a colourless solid (0.89 g, 86%). No further 
purification was carried out. 
 
Found (NSI): [M-H]- 392.1704; [C20H27NO7-H]- requires 392.1715. νmax (thin film)/cm−1 
3343, 1741 and 1673. mp 108-111 °C. 1H NMR (500 MHz, CDCl3) δ 7.14 (app d, 2H, J 
= 8.6 Hz, H12 and H14), 6.85 (app d, 2H, J = 8.6 Hz, H11 and H15), 4.98 (d, 1H, J = 
16.2 Hz, H9), 4.91 (s, 1H, H6), 4.54 (d, 1H, J = 16.2 Hz, H9), 3.79 (s, 3H, H16), 3.77 
(s, 3H, H20), 1.89 – 1.84 (m, 1H, H4), 1.70 – 1.64 (m, 2H, H3 and H4), 1.44 (s, 3H, 
H18), 0.90 (d, 3H, J = 6.3 Hz, H1 or H2), 0.75 (d, 3H, J = 6.3 Hz, H1 or H2). 13C NMR 
(126 MHz, CDCl3) δ 172.2, 158.8, 127.9 (C12 and C14), 114.1 (C11 and C15), 77.2 
(C5 or C7), 74.4 (C6), 72.3 (C5 or C7), 55.3 (C16), 52.7 (C20), 45.4 (C9), 39.5 (C4), 
24.2 (C3), 24.0 (C1 or C2), 23.3 (C1 or C2), 20.9 (C18). 
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(±)-(3R,4S,5R)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-3-
azabicyclo[3.2.0] heptane-2,7-dione-5-carboxylic acid methyl ester (±)-66 
 
 
 
Compound (±)-57 (0.13 g, 0.3 mmol) was subjected to the general procedure for the 
formation of an acyl selenide using diphenyldiselenide (0.16 g, 0.5 mmol, 1.5 equiv.) 
and tributylphosphine (0.16 mL, 0.7 mmol, 2 equiv.). Compound (±)-66 was isolated as 
an off-white solid (0.05 g, 43%).  
 
Found (NSI): [M+H]+ 376.1756; [C20H25NO6+H]+ requires 376.1755. νmax (thin 
film)/cm−1 1842, 1731 and 1702. mp 104-109 °C 1H NMR (500 MHz, CDCl3) δ 7.12 
(app d, 2H, J = 8.7 Hz, H12 and H13), 6.83 (app d, 2H, J = 8.7 Hz, H11 and H15), 5.15 
(s, 1H, H6), 4.51 (d, 2H, J = 1.8 Hz, H9), 3.78 (s, 3H, H16), 3.52 (s, 3H, H19), 2.11 (dd, 
1H, J = 13.4, 7.7 Hz, H4), 1.77 – 1.71 (m, 1H, H3), 1.67 (s, 3H, H17), 1.62 (dd, 1H, J = 
13.4, 5.5 Hz, H4), 0.93 (d, 3H, J = 6.6 Hz, H1 or H2), 0.86 (d, 3H, J = 6.6 Hz, H1 or 
H2). 13C NMR (126 MHz, CDCl3) δ 169.7, 168.4, 165.8, 159.0, 128.8, 128.8 (C12 and 
C14), 114.0 (C11 and C15), 76.0 (C6), 68.6 (C5 or C7), 64.9 (C5 or C7), 55.3 (C16), 
52.7 (C19), 43.9 (H9), 37.3 (C4), 24.6 (C3), 23.8 (C1 or C2), 22.8 (C1 or C2), 11.7 
(C17). 
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(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-hydroxy-5-(2’-methylpropyl)-
pyrrolidin-2-one-3-phenylseleno ester-5-carboxylic acid methyl ester (±)-65 
 
 
 
Compound (±)-72 (0.36 g, 0.7 mmol) was subjected to the general procedure for the 
formation of an acyl selenide using diphenyldiselenide (0.35 g, 1.0 mmol, 1.5 equiv.) 
and tributylphosphine (0.36 mL, 0.7 mmol, 2 equiv.). The desired compound (±)-65 was 
isolated as a yellow oil (0.12 g, 31%). Compound (±)-66 was also isolated (0.03 g, 
10%).  
 
νmax (thin film)/cm−1 3423, 1736 and 1690. 1H NMR (500 MHz, CDCl3) δ 7.55 – 7.51 
(m, 2H, H23 and H27), 7.44 – 7.37 (m, 3H, H24-26), 7.22 (app d, 2H, J = 8.6 Hz, H12 
and H14), 6.86 (app d, 2H, J = 8.6 Hz, H11 and H15), 4.98 (d, 1H, J = 16.1 Hz, H9), 
4.84 (d, 1H, J = 5.2 Hz, H6), 4.49 (d, 1H, J = 16.1 Hz, H9), 3.79 (s, 3H, H16), 3.73 (s, 
3H, H20), 2.94 (d, 1H, J = 5.2 Hz, H21), 1.85 – 1.77 (m, 1H, H4), 1.72 – 1.64 (m, 2H, 
H4 and H3), 1.51 (s, 3H, H18), 0.87 (d, 3H, J = 6.4 Hz, H1 or H2), 0.75 (d, 3H, J = 6.4 
Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 204.9, 172.6, 172.5, 158.6, 136.2, 130.2, 
129.3 (Ar), 129.1 (Ar), 128.1 (C12 and C14), 126.6 (Ar), 114.0 (C11 and C12), 77.0 
(C6), 71.5 (C5 or C7), 64.3 (C5 or C7), 55.3 (C16), 52.5 (C20), 45.0 (C9), 40.3 (C4), 
24.1 (C3), 24.1 (C1 or C2), 23.5 (C1 or C2), 21.4 (C18). 77Se NMR (95 MHz, CDCl3) δ 
700.24. 
 
 
 
 
 
N O
PMB
MeO2C
O
Me
O
8
6
5
7
2
4
3
1
18
17
10
9
15
14
13
12
11
19
20
16
N
HO
O
Se
O
MeO
O
OMe
21
22
N
O
PMB
O
MeO2C
Me
CO2H
F3C
O
(±)-72 (±)-65 (±)-66
23 24
25
26
27
	 	 Experimental		
	 154	
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-(tri-methylsilanyloxy)-5-(2’-
methylpropyl)-pyrrolidin-2-one-3,5-dicarboxylic acid-3-benzyl ester-5-methyl ester 
(±)-67 
 
 
 
Compound (±)-51 (0.41 g, 0.8 mmol) was subjected to the general procedure for the 
silyl protection of the hydroxyl moiety using trimethylsilyl chloride (0.13 mL, 1.0 
mmol, 1.2 equiv.) and imidazole (0.15 g, 2.1 mmol, 2.5 equiv.). No further purification 
was carried out. The product (±)-67 was obtained as a yellow oil (0.48 g, quant.). 
 
Found (NSI): [M+H]+ 556.2728; [C30H41NO7Si+H]+ requires 556.2725. νmax (thin 
film)/cm−1 2957, 1740 and 1697. 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.43 (m, 5H, 
H20-24), 7.19 (app d, 2H, J = 8.7 Hz, H11 and H15), 6.75 (app d, 2H, J = 8.7 Hz, H12 
and H14), 5.35 (d, 1H, J = 12.2 Hz, H18), 5.18 (d, 1H, J = 12.2 Hz, H18), 4.74 (d, 1H, J 
= 16.0 Hz, H9), 4.65 (d, 1H, J = 16.0 Hz, H9), 4.50 (s, 1H, H6), 3.83 (s, 3H, H16), 3.57 
(s, 3H, H27), 1.97 (dd, 1H, J = 15.1, 8.4 Hz, H4), 1.90 (dd, 1H, J = 15.1, 3.8 Hz, H4), 
1.84 – 1.78 (m, 1H, H3), 1.65 (s, 3H, H25), 0.81 (d, 3H, J = 6.6 Hz, H1 or H2), 0.70 (d, 
3H, J = 6.6 Hz, H1 or H2), 0.22 (s, 9H, H28). 13C NMR (126 MHz, CDCl3) δ 173.3, 
172.8, 169.4, 158.4, 135.4, 129.6, 128.7 (Ar), 128.6 (Ar), 128.3 (Ar), 128.2 (C12 and 
C15), 113.6 (C11 and C15), 81.1 (C6), 71.5 (C5 or C7), 67.4 (C18), 56.6 (C5 or C7), 
55.3 (C16), 52.1 (C27), 46.2 (C9), 40.1 (C4), 24.8 (C1 or C2), 23.63 (C3), 23. (C1 or 
C2), 21.2 (C25), 0.1 (C28). 
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(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-(tri-ethylsilanyloxy)-5-(2’-
methylpropyl)-pyrrolidin-2-one-3,5-dicarboxylic acid-3-benzyl ester-5-methyl ester 
(±)-68 
 
 
 
Compound (±)-51 (0.11 g, 0.2 mmol) was subjected to the general procedure for the 
silyl protection of the hydroxyl moiety using triethylsilyl chloride (0.05 ml, 0.3 mmol, 
1.2 equiv.) and imidazole (0.04 g, 0.6 mmol, 2.5 equiv.). No further purification was 
carried out. The product (±)-68 was obtained as a yellow oil (0.13 g, quant.).  
 
Found (NSI): [M+H]+ 598.3178; [C33H47NO7Si+H]+ requires 598.3195. νmax (thin 
film)/cm−1 2957, 1741 and 1697. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.33 (m, 5H, 
H20-24), 7.08 (app d, 2H, J = 8.6 Hz, H 12 and H14), 6.64 (app d, 2H, J = 8.6 Hz, H11 
and H15), 5.21 (d, 1H, J = 12.2 Hz, H18), 5.12 (d, 1H J = 12.2 Hz, H18), 4.61 (d, 1H J 
= 16.0 Hz, H9), 4.52 (d, 1H, J = 16.0 Hz, H9), 4.38 (s, 1H, H6), 3.73 (s, 3H, H16), 3.46 
(s, 3H, H27), 1.88 (d, 2H, J = 7.3 Hz, H4), 1.78 – 1.70 (m, 1H, H2), 1.56 (s, 3H, H25), 
0.96 (t, 9H, J = 7.9 Hz, H29), 0.69 (d, 3H, J = 6.6 Hz, H1 or H2), 0.63 (q, 6H, J = 8.1 
Hz, H28), 0.59 (d, 3H, J = 6.6 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 173.5, 
172.8, 169.3, 158.4, 135.23, 129.5, 128.7 (Ar), 128.5 (Ar), 128.3 (Ar), 128.2 (C12 and 
C14), 113.6 (C11 and C15), 81.4 (C6), 71.7 (C5 or C7), 67.5 (C18), 56.7 (C5 or C7), 
55.2 (C16), 52.1 (C27), 46.5 (C9), 39.8 (C4), 25.0 (C1 or C2), 23.7 (C3), 22.7 (C1 or 
C2), 21.5 (C25), 6.7 (C29), 4.8 (C28). 
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Protection of the Hydroxyl Moiety at C6 Using Trifluoroacetic Anhydride 
 
 
 
Procedure A: Compound (±)-51 (0.35 g, 0.7 mmol) was subjected to the general 
procedure for the protection of the hydroxyl moiety at C6 using trifluoroacetic 
anhydride (0.25 mL, 1.8 mmol, 2.5 equiv.) and pyridine (0.15 mL, 1.8 mmol, 2.5 
equiv.). Purification using column chromatography on silica gel (light petroleum 
ether/ethyl acetate 1:1) gave compounds (±)-70 (0.22 g, 52%) and (±)-71 (0.08 g, 21%). 
 
Procedure B: Compound (±)-51 (1.21 g, 2.5 mmol) was subjected to the general 
procedure for the protection of the hydroxyl moiety at C6 using trifluoroacetic 
anhydride (0.87 mL, 6.2 mmol, 2.5 equiv.) and pyridine (0.50 mL, 6.2 mmol, 2.5 
equiv.). No further purification was carried out. Compound (±)-70 was isolated as a 
colourless oil (1.45 g, quant.). 
 
(±)-(3R,4R,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-4-
(trifluoroacetoxy)-pyrrolidin-2-one-3,5-dicarboxylic acid-3-benzyl ester-5-methyl 
ester (±)-70 
νmax (thin film)/cm−1 1796, 1742 and 1708. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.33 
(m, 5H, H20-24), 7.09 (app d, 2H, J = 8.7 Hz, H12 and H14), 6.68 (app d, 2H, J = 8.7 
Hz, H11 and H15), 6.05 (s, 1H, H6), 5.15 (s, 2H, H18), 4.85 (d, 1H, J = 16.1 Hz, H9), 
4.57 (d, 1H, J = 16.1 Hz, H9), 3.75 (s, 3H, H16), 3.65 (s, 3H, H27), 1.72 (qd, 2H, J = 
14.7, 6.0 Hz, H4), 1.62 (s, 3H, H25), 1.55 – 1.47 (m, 1H, H3), 0.70 (d, J = 6.6 Hz, 3H, 
H1 or H2), 0.67 (d, J = 6.6 Hz, 3H, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 171.0, 
171.0, 168.0, 158.7, 134.6, 129.3, 128.7 (Ar), 128.5 (Ar), 128.5 (Ar), 128.0 (C12 and 
C14), 113.9 (C11 and C15), 79.8 (C6), 70.0, 68.2 (C18), 55.5, 55.2 (C16), 53.0 (C27), 
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45.0 (C9), 39.9 (C4), 23.7 (C1 or C2), 23.6 (C3), 23.4 (C1 or C2), 19.9 (C25). 19F NMR 
(471 MHz, CDCl3) δ -74.45. 
 
(±)-(3R,4R,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-4-
(trifluoroacetoxy)-pyrrolidin-2-one-3-carboxylic acid benzyl ester (±)-71 
νmax (thin film)/cm−1 1794, 1746 and 1705. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.33 
(m, 4H, H20, H21, H23 and H24), 7.24 (dd, 1H, J = 4.0, 2.1 Hz, H22), 7.08 (app d, 2H, 
J = 8.5 Hz, H12 and H14), 6.62 (app d, 2H, J = 8.5 Hz, H11 and H15), 5.26 (d, 1H, J = 
12.2 Hz, H18), 5.18 (d, 1H, J = 15.1 Hz, H9), 5.12 (d, 1H, J = 6.5 Hz, H6), 5.03 (d, 1H, 
J = 12.2 Hz, H18), 3.79 (d, 1H, J = 15.1 Hz, H9), 3.75 (s, 3H, H16), 3.63 (ddd, 1H, J = 
10.4, 6.5, 3.7 Hz, H5), 1.74 – 1.67 (m, 1H, H4), 1.65 (s, 3H, H25), 1.42 – 1.37 (m, 1H, 
H3) 1.30 – 1.28 (m, 1H, H4), 0.88 (d, 3H, J = 6.5 Hz, H1 or H2), 0.65 (d, 3H, J = 6.5 
Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 169.9, 167.6, 159.1, 129.4 (C12 and 
C14), 128.7 (Ar), 128.5 (Ar), 128.4 (Ar), 126.4, 114.0 (C11 and C15), 100.0, 83.3 (C6), 
77.2, 67.9 (C18), 56.1, 56.0 (C5), 55.2 (C16), 43.5 (C9), 41.2 (C4), 29.7, 24.3 (C1 or 
C2), 24.1 (C3), 20.8 (C1 or C2), 19.5 (C25). 19F NMR (471 MHz, CDCl3) δ -75.07. 
 
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-(trifluoroacetoxy)-5-(2’-
methylpropyl)-pyrrolidin-2-one-3,5-dicarboxylic acid-5-methyl ester (±)-72 
 
 
 
Compound (±)-70 (1.30 g, 2.6 mmol) was subjected to the general procedure for the 
treatment of the benzyl ester under hydrogenolysis conditions using Pd(OH)2 / C (0.65 
g). Purification using column chromatography on silica gel (light petroleum ether/ethyl 
acetate 2:1, then 10% methanol in dichloromethane) gave the desired product (±)-72 as 
a colourless oil (0.22 g, 20%) and compound (±)-57 (0.14 g, 16%). 
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Compound (±)-57 (0.30 g, 0.80 mmol) was subjected to the general procedure for the 
protection of the hydroxyl moiety at C6 using trifluoroacetic anhydride (0.26 mL, 1.90 
mmol, 2.5 equiv.) and pyridine (0.15 mL, 1.90 mmol, 2.5 equiv.). No further 
purification was carried out. The desired compound (±)-72 was isolated as a yellow oil 
(0.30 g, 81%). 
 
νmax (thin film)/cm−1 1799, 1742, 1707 and 1676. 1H NMR (500 MHz, CDCl3) δ 7.11 
(app d, 2H, J = 8.7 Hz, H12 and H14), 6.87 (app d, 2H, J = 8.7 Hz, H11 and H15), 6.35 
(s, 1H, H6), 5.08 (d, 1H, J = 16.2 Hz, H9), 4.57 (d, 1H, J = 16.2 Hz, H9), 3.82 (s, 3H, 
H16), 3.80 (s, 3H, H21), 1.74 (dd, 1H, J = 14.0, 6.6 Hz, H4), 1.56 (s, 3H, H19), 1.55 – 
1.53 (m, 1H, H3), 1.50 (dd, 1H, J = 14.0, 4.2 Hz, H4), 0.72 (d, 3H, J = 6.4 Hz, H1 or 
H2), 0.68 (d, 3H, J = 6.4 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 175.1, 170.7, 
168.6, 159.1, 128.4, 127.7 (C12 and C14), 114.2 (C11 and C15), 77.9 (C6), 70.9, 55.3 
(C16), 53.8, 53.3 (C21), 45.5 (C9), 40.3 (C4), 23.9 (C1 or C2), 23.3 (C1 or C2), 23.2 
(C3), 21.1 (C19). 19F NMR (471 MHz, CDCl3) δ -74.76. 
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The Barton Decarboxylation 
 
 
Procedure A: Compound (±)-57 (0.10 g, 0.24 mmol) was dissolved in chloroform (5 
mL) with oxalyl chloride (0.03 mL, 0.32 mmol, 1.2 equiv.) and 1 drop of DMF. The 
reaction was stirred for 2 h. In a separate flask, 2-mercaptopyridine N-oxide sodium salt 
(0.06 g, 0.39 mmol, 1.5 equiv.) was dissolved in chloroform (5 mL). The acid chloride 
solution was added to the 2-mercaptopyridine N-oxide sodium salt solution dropwise 
using a cannula whilst irradiating with a UV lamp. The reaction was left under UV 
irradiation for 3 h after which the solvent was removed and the residue was re-dissolved 
in diethyl ether. The organic phase was washed with a solution of HCl (1 M, 3 x 20 
mL), brine (3 x 20 mL), dried over anhydrous magnesium sulfate and evaporated to 
dryness under reduced pressure.  
 
Procedure B: The carboxylic acid starting material was dissolved in anhydrous 
dichloromethane (50 mL/g of carboxylic acid). NMM (2 equiv.), 2-mercaptopyridine N-
oxide sodium salt (2 equiv.), EDAC·HCl (2.5 equiv.) and DMAP (0.2 equiv.) were 
added to the reaction mixture. The reaction mixture was stirred under an atmosphere of 
nitrogen for 20 h.  An aqueous solution of HCl (1 M, 3 mL) was added to the reaction 
mixture and stirring was continued for a further 30 min. The organic layer was 
separated, washed with water (3 x 20 mL), dried over anhydrous magnesium sulfate, 
filtered, and evaporated to dryness under reduced pressure.  
 
Compound (±)-57 (0.10 g, 0.24 mmol) was subjected to the conditions described above 
in procedure B using NMM (0.05 mL, 0.49 mmol, 2 equiv.), 2-mercaptopyridine N-
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oxide sodium salt (0.07 g, 0.49 mmol, 2 equiv.), EDAC·HCl (0.12 g, 0.62 mmol, 2.5 
equiv.) and DMAP (0.01 g, 0.05 mmol, 0.2 equiv.). Compound (±)-66 was isolated. 
 
Compound (±)-72 (0.12 g, 0.25 mmol) was subjected to the conditions described above 
in procedure B using NMM (0.06 mL, 0.50 mmol, 2 equiv.), 2-mercaptopyridine N-
oxide sodium salt (0.08 g, 0.50 mmol, 2 equiv.), EDAC·HCl (0.12 g, 0.62 mmol, 2.5 
equiv.) and DMAP (0.01 g, 0.05 mmol, 0.2 equiv.). Compound (±)-66 was isolated. 
 
The Krapcho Decarboxylation 
 
 
 
Compound (±)-51 (0.18 g, 0.4 mmol) was dissolved in wet DMF (5 mL) and LiCl (0.05 
g, 1.1 mmol, 3 equiv.) added to the mixture. The reaction was heated at 135 °C for 4 h. 
The solution was cooled to room temperature. An aqueous solution of NH4OH (5%) 
was added to the reaction mixture. The aqueous phase was extracted with diethyl ether 
(3 x 10 mL). The organic layers were combined, washed with brine (2 x 10 mL), dried 
over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The crude 
product was purified by silica gel column chromatography using 20% ethyl acetate in 
light petroleum ether to give the first eluting compound (±)-78 as an oil (0.05 g, 49%) 
and the second eluting compound (±)-79 as an oil (0.04 g, 38%). 
 
(±)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-3,4-dehydropyrrolidin-2-
one (±)-78 
νmax (thin film)/cm−1 1713 and 1671. 1H NMR (500 MHz, CDCl3) δ 7.15 (app d, 2H, J = 
8.6 Hz, H12 and H14), 6.82 (app d, 2H, J = 8.6 Hz, H11 and H15), 4.57 (d, 2H, J = 2.0 
Hz, H9), 4.51 (dt, 1H, J = 9.5, 2.2 Hz, H5), 3.78 (s, 3H, H16), 2.91 (ddd, 1H, J = 16.1, 
9.7, 2.0 Hz, H4), 2.72 – 2.61 (m, 1H, H6), 2.39 – 2.31 (m, 1H, H3), 2.22 (ddd, 1H, J = 
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16.1, 6.3, 2.4 Hz, H4), 1.29 (d, 3H, J = 7.2 Hz, H17), 0.92 (d, 3H, J = 4.9 Hz, H1 or 
H2), 0.91 (d, 3H, J = 4.9 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 178.3, 158.7, 
135.8, 128.70, 128.5 (C12 and C14), 113.8 (C11 and C15), 109.7 (C5), 55.2 (C16), 43.1 
(C9), 35.1 (C6), 30.3 (C4), 26.8 (C3), 23.6 (C1 or C2), 23.5 (C1 or C2), 17.3 (C17). 
 
(±)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-4,5-dehydropyrrolidin-2-
one (±)-79 
νmax (thin film)/cm−1 1675. 1H NMR (500 MHz, CDCl3) δ 7.15 (app d, 2H, J = 8.6 Hz, 
H12 and H14), 6.83 (app d, 2H, J = 8.6 Hz, H11 and H15), 6.70 – 6.66 (m, 1H, H7), 
5.09 (d, 1H, J = 15.0 Hz, H9), 4.01 (d, 1H, J = 15.0 Hz, H9), 3.78 (s, 4H, H16 and H6), 
1.92 (t, 3H, J = 1.7 Hz, H17), 1.68 – 1.60 (m, 1H, H3), 1.65 (d, 1H, J = 9.7 Hz, H4), 
1.25 (d, 1H, J = 9.7 Hz, H4), 0.89 (d, 3H, J = 6.1 Hz, H1 or H2), 0.85 (d, 3H, J = 6.1 
Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 171.7, 158.9, 140.6 (C7), 134.5, 129.9, 
129.3 (C12 and C14), 114.0 (C11 and C15), 58.1 (C6 or C16), 55.3 (C7 or C16), 43.3 
(C9), 39.8 (C4), 25.1 (C3), 23.9 (C1 or C2), 22.3 (C1 or C2), 11.3 (C17). 
 
(±)-(3R,5R)-N-(4’-Methoxybenzyl)-3-methyl-5-(2’-methylpropyl)-pyrrolidin-2-one-
5-carboxylic acid methyl ester (±)-81 and (±)-(3S,5R)-N-(4’-Methoxybenzyl)-3-
methyl-5-(2’-methylpropyl)-pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-82 
 
 
 
Compound (±)-10 (0.33 g, 0.70 mmol) was subjected to the general procedure for the 
treatment of the benzyl ester under hydrogenolysis conditions using Pd(OH)2 / C (0.17 
g). The product was obtained as an inseparable mixture of diastereoisomers (±)-81 and 
(±)-82 in a 1:1 ratio as a colourless oil (0.26 g, quant.). No further purification was 
carried out.  
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Found (NSI): [M+H]+ 348.1806; [C19H25NO5+H]+ requires 348.1085. νmax (thin 
film)/cm−1 2955, 1743 and 1638. 1H NMR (500 MHz, CDCl3) δ 7.25 (app d, 4H, J = 8.7 
Hz, H12 and H14), 6.82 (app d, 4H, J = 8.7 Hz, H11 and H15), 5.22 (d, 1H, J = 14.8 
Hz, H9), 4.97 (d, 1H, J = 14.8 Hz, H9), 4.02 (d, 1H, J = 14.8 Hz, H9), 3.84 (d, 1H, J = 
14.8 Hz, H9), 3.78 (s, 6H, H16), 3.20 – 3.18 (m, 1H, H7), 3.17 (s, 3H, H19), 3.14 (s, 
3H, H19), 2.89 (q, 1H, J = 7.4 Hz, H7), 2.17 – 2.08 (m, 4H, H4), 1.45 (d, 3H, J = 7.6 
Hz, H17), 1.45 – 1.37 (m, 2H, H3) 1.37 (d, 3H, J = 7.6 Hz, H17), 0.92 (d, 3H, J = 6.8 
Hz, H1 or H2), 0.86 (d, 3H, J = 6.8 Hz, H1 or H2), 0.78 (d, 3H, J = 6.6 Hz, H1 or H2), 
0.76 (d, 3H, J = 6.6 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 207.4, 206.0, 173.6, 
173.2, 167.9, 159.3, 130.8 (C12 and C14), 130.8 (C12 and C14), 127.7, 113.8 (C11 and 
C15), 113.7 (C11 and C15), 75.7, 75.2, 55.3 (C16), 52.8 (C19), 44.5 (C7), 44.2 (C7), 
43.7 (C9), 38.1 (C4), 36.9 (C4), 25.61, 23.9 (C1, C2 or C3), 23.8 (C1, C2 or C3), 23.7 
(C1, C2 or C3), 23.6 (C1, C2 or C3), 23.6 (C1, C2 or C3), 23.5 (C1, C2 or C3), 12.5 
(C17), 10.0 (C17). 
 
The Noyori Asymmetric Hydrogenation Reaction 
 
 
 
Procedure A: The mixture of compounds (±)-81 and (±)-82 (0.15 g, 0.43 mmol) and 
potassium carbonate (0.01 g, 0.25 equiv.) were dissolved in a mixture of 2-propanol and 
THF (5:1, 3 mL). The reaction was flushed with argon for 5 min after which the 
catalyst, RuCl2[(R)−DM−BINAP][(R)−DAIPEN] (0.03 g, 5 mol%), was added and 
flushed with argon for a further 5 min. The argon was replaced with a balloon of 
hydrogen and the reaction mixture left to stir for 6 d. The solvent was removed under 
reduced pressure and the resulting residue re-dissolved in toluene (5 mL) and washed 
with water (2 x 5 mL). The organic layer was dried over anhydrous magnesium sulfate, 
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filtered, and evaporated to dryness under reduced pressure. The residue was purified 
using column chromatography on silica gel (light petroleum ether/ethyl acetate, 3:1). 
Two products were isolated from the reaction mixture, the first with the possible 
structure (±)-87 or (±)-88, the second is unknown. 
 
Procedure B: The mixture of compounds (±)-81 and (±)-82 (0.12 g, 0.38 mmol) and 
potassium carbonate (0.01 g, 0.25 equiv.) were dissolved in a mixture of 2-propanol and 
THF (5:1, 3 mL). The reaction was degassed via nitrogen/vacuum for 5 min after which 
the catalyst, RuCl2[(R)−DM−BINAP][(R)−DAIPEN] (0.02 g, 5 mol%), was added. The 
reaction was hydrogenated at 40 psi for 3 d. The solvent was removed under reduced 
pressure and the resulting residue re-dissolved in toluene (5 mL) and washed with water 
(2 x 5 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, 
and evaporated to dryness under reduced pressure. The residue was purified using 
column chromatography on silica gel (light petroleum ether/ethyl acetate, 3:1). Two 
products were isolated from the reaction mixture, the first with the possible structure 
(±)-87 or (±)-88, the second is unknown. 
 
(±)-(5R)-3,4-Dehydro-N-(4’-methoxybenzyl)-3-methyl-4-(isopropoxy carbonate)-5-
(2’-methylpropyl)-pyrrolidin-2-one-3,4-oxide (±)-87 or (±)-(5R)-3,4-Dehydro-N-(4’-
methoxybenzyl)-3-methyl-4-isopropoxy-5-(2’-methylpropyl)-pyrrolidin-2-one-3,4-
carbonate (±)-88 
Found (NSI): [M+H]+ 392.2063; [C21H29NO6+H]+ requires 392.2068. νmax (thin 
film)/cm−1 1758 and 1669. 1H NMR (500 MHz, CDCl3) δ 7.16 (app d, 2H, J = 8.6 Hz, 
H12 and H14), 6.86 (app d, 2H, J = 8.6 Hz, H11 and H15), 5.48 (d, 1H, J = 14.8 Hz, 
H9), 5.06 (p, 1H, J = 6.3 Hz, H21), 4.03 (dd, 1H, J = 8.5, 3.1 Hz, H5), 3.80 (s, 3H, 
H16), 3.74 (d, 1H, J = 14.8 Hz, H9), 1.93 – 1.88 (m, 1H, H4), 1.88 (s, 3H, H17), 1.87 – 
1.82 (m, 1H, H4), 1.82 – 1.76 (m, 1H, H3), 1.25 (d, 3H, J = 1.0 Hz, H19 or H20), 1.24 
(d, 3H, J = 1.0 Hz, H19 or H20), 0.97 (d, 3H, J = 6.1 Hz, H1 or H2), 0.92 (d, 3H, J = 
6.1 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 166.2, 165.6, 163.8, 159.6, 129.5 
(C12 and C14), 126.6, 114.4 (C11 and C15), 83.6, 71.3 (C21), 55.4 (C16), 55.0 (C5), 
45.9 (C9), 41.0 (C4), 24.5 (C3), 23.4 (C1 or C2), 21.7 (C7), 21.6 (C1 or C2), 21.5 (C19 
and C20). 
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Preparation of S-Methyl-p-toluenethiosulfonate 96 
 
 
 
Sodium p-toluenesulfinate (3.23 g, 18.13 mmol, 3.2 equiv.) was dissolved in 
dichloromethane (50 mL) and dimethyl disulfide (0.50 mL, 5.66 mmol) added to the 
solution. Iodine (2.81 g, 11.33 mmol, 2 equiv.) was added to the mixture with vigorous 
stirring. The reaction mixture was stirred and monitored by TLC until the dimethyl 
disulfide was consumed. The mixture was diluted with dichloromethane (30 mL) 
followed by the addition of aqueous Na2S2O3 (1 M) with stirring until the iodine colour 
disappeared. The organic layer was washed with water (2 x 50 mL), dried over 
anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure. 
The product precipitated as an off-white solid (1.15 g, quant.). 
 
νmax (thin film)/cm−1 2926 and 1594. 1H NMR (500 MHz, CDCl3) δ 7.80 (d, 2H, J = 8.3 
Hz), 7.36 (d, 2H, J = 8.3 Hz), 2.50 (s, 3H), 2.46 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
144.9, 140.9, 129.9, 127.2, 21.7, 18.1. 
 
Synthesis of the Thiomethyl Derivative from (±)-81 and (±)-82 
 
 
 
Triethylamine (0.2 mL, 1 mmol, 1.2 equiv.) and S-methyl-p-toluenethiosulfonate (0.18 
g, 0.8 mmol) were added to a solution of the mixture of (±)-81 and (±)-82 (0.30 g, 0.86 
mmol) in dichloromethane (5 mL) at room temperature under a nitrogen atmosphere. 
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The mixture was stirred overnight at room temperature. The solvent was removed under 
reduced pressure and the residue purified using column chromatography on silica gel 
(10% ethyl acetate in light petroleum ether) to yield compounds (±)-97 and (±)-98 as an 
inseparable mixture (0.16 g, 47%). 
 
Compounds (±)-97 and (±)-98: Found (NSI): [M+H]+ 394.1682; [C20H27NO5S+H]+ 
requires 394.1683. νmax (thin film)/cm−1 2960, 1769, 1745 and 1698. 
 
(±)-(3R,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-methylsulfanyl-5-(2’-methylpropyl)-
pyrrolidin-2,4-dione-5-carboxylic acid methyl ester (±)-97 
1H NMR (500 MHz, CDCl3) δ 7.27 (app d, 2H, J = 8.7 Hz, H12 and H14), 6.83 (app d, 
2H, J = 8.7 Hz, H11 and H15), 4.80 (d, 1H, J = 15.2 Hz, H9), 4.43 (d, 1H, J = 15.2 Hz, 
H9), 3.78 (s, 3H, H16), 3.45 (s, 3H, H19), 2.25 (dd, 1H, J = 15.2, 6.8 Hz, H4), 2.15 (s, 
3H, H20), 1.96 (dd, 1H, J = 15.2, 5.7 Hz, H4), 1.58 (s, 3H, H17), 1.38 – 1.29 (m, 1H, 
H3), 0.75 (d, 3H, J = 4.5 Hz, H1 or H2), 0.74 (d, 3H, J = 4.5 Hz, H1 or H2). 13C NMR 
(126 MHz, CDCl3) δ 200.2, 171.7, 167.9, 159.0, 129.8 (C12 and C14), 128.5, 113.8 
(C11 and C15), 75.4, 55.3 (C16), 52.9 (C19), 49.3, 44.9 (C9), 40.0 (C4), 23.9 (C3), 23.5 
(C1 and C2), 16.9 (C17), 12.3 (C20). 
 
(±)-(3S,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-methylsulfanyl-5-(2’-methylpropyl)-
pyrrolidin-2,4-dione-5-carboxylic acid methyl ester (±)-98 
1H NMR (500 MHz, CDCl3) δ 7.24 (app d, 2H, J = 8.6 Hz, H12 and H14), 6.82 (app d, 
2H, J = 8.6 Hz, H11 and H15), 4.96 (d, 1H, J = 14.9 Hz, H9), 4.03 (d, 1H, J = 14.9 Hz, 
H9), 3.77 (s, 3H, H16), 3.16 (s, 3H, H19), 2.28 (s, 3H, H20), 2.24 (dd, 1H, J = 15.3, 5.4 
Hz, H4), 1.98 (dd, 1H, J = 15.3, 6.2 Hz, H4), 1.74 (dtd, 1H, J = 13.1, 6.6, 1.2 Hz, H3), 
1.67 (s, 3H, H17), 0.93 (d, 3H, J = 6.6 Hz, H1 or H2), 0.87 (d, 3H, J = 6.6 Hz, H1 or 
H2). 13C NMR (126 MHz, CDCl3) δ 202.6, 172.4, 168.0, 159.3, 130.7 (C12 and C14), 
127.5, 113.8 (C11 and C15), 75.2, 55.3 (C16), 52.8 (C19), 48.2, 43.7 (C9), 38.3 (C4), 
24.6 (C1 or C2), 23.9 (C1 or C2), 23.7 (C3), 18.5 (C17), 11.6 (C20). 
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Reduction of the Thiomethyl Derivative (±)-97 and (±)-98 
 
 
 
The inseparable mixture of compounds (±)-97 and (±)-98 (0.088 g, 0.22 mmol) was 
subjected to the general procedure for ketone reduction using NaBH4 (0.004 g, 0.11 
mmol, 0.5 equiv.). The mixture was stirred at –10 °C for 30 minutes. After quenching 
and subsequent washing the resulting residue was purified using column 
chromatography on silica gel (light petroleum ether/ethyl acetate, 3:1). The first eluting 
diastereoisomer (±)-99 was obtained as a yellow oil (0.015 g, 17%), the second eluting 
diastereoisomer (±)-100 was obtained as a dark yellow oil (0.023 g, 25%). The starting 
material, an inseparable mixture of compounds (±)-97 and (±)-98, was recovered (0.020 
g, 23%). 
 
(±)-(3S,4S,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-methylsulfanyl-4-hydroxy-5-(2’-
methylpropyl)-pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-99 
Found (NSI): [M+H]+ 396.1830; [C20H29NO5S+H]+ requires 396.1839. νmax (thin 
film)/cm−1 3432, 2957, 2927, 1741 and 1698. 1H NMR (500 MHz, CDCl3) δ 7.15 (app 
d, 2H, J = 8.7 Hz, H12 and H14), 6.82 (app d, 2H, J = 8.7 Hz, H11 and H15), 4.84 (d, 
1H, J = 15.9 Hz, H9), 4.47 (d, 1H, J = 10.0 Hz, H21), 4.36 (d, 1H, J = 15.9 Hz, H9), 
4.03 (d, 1H, J = 10.0 Hz, H6), 3.78 (s, 3H, H16), 3.66 (s, 3H, H19), 2.14 (s, 3H, H20), 
1.85 (dd, 1H, J = 14.5, 6.0 Hz, H4), 1.77 – 1.72 (m, 1H, H3), 1.65 (dd, 1H, J = 14.5, 4.5 
Hz, H4), 1.63 (s, 3H, H17), 0.82 (d, 3H, J = 6.6 Hz, H1 or H2), 0.71 (d, 3H, J = 6.6 Hz, 
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H1 or H2). 13C NMR (126 MHz, CDCl3) δ 174.6, 173.1, 158.7, 130.2, 128.7 (C12 and 
C14), 113.8 (C11 and C15), 81.3 (C6), 67.4, 55.3 (C16), 52.7 (C19), 51.5, 44.8 (C9), 
44.0 (C4), 24.4 (C1 or C2), 23.9 (C1 or C2), 23.5 (C3), 21.8 (C17), 11.5 (C20). 
 
(±)-(3R,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-3-methylsulfanyl-4-hydroxy-5-(2’-
methylpropyl)-pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-100 
Found (NSI): [M+H]+ 396.1832; [C20H29NO5S+H]+ requires 396.1839. νmax (thin 
film)/cm−1 3484, 2957, 2928, 1738 and 1682. 1H NMR (500 MHz, CDCl3) δ 7.15 (app 
d, 2H, J = 8.7 Hz, H12 and H14), 6.82 (app d, 2H, J = 8.7 Hz, H11 and H15), 4.89 (d, 
1H, J = 16.0 Hz, H9), 4.47 (d, 1H, J = 3.3 Hz, H6), 4.43 (d, 1H, J = 16.0 Hz, H9), 3.78 
(s, 3H, H16), 3.70 (s, 3H, H19), 3.20 (d, 1H, J = 3.3 Hz, H21), 2.15 (s, 3H, H20), 1.88 
(dd, 1H, J = 13.7, 6.3 Hz, H4), 1.80 (dd, 1H, J = 13.7, 5.3 Hz, H4), 1.76 – 1.71 (m, 1H, 
H3), 1.50 (s, 3H, H17), 0.91 (d, 3H, J = 6.6 Hz, H1 or H2), 0.77 (d, 3H, J = 6.6 Hz, H1 
or H2). 13C NMR (126 MHz, CDCl3) δ 173.2, 173.1, 158.5, 130.5, 128.2 (C12 and 
C14), 113.8 (C11 and C15), 75.9 (C6), 71.6, 57.5, 55.3 (C16), 52.4 (C19), 45.2 (C9), 
40.7 (C4), 24.2 (C3) 24.2 (C1 or C2), 23.5 (C1 or C2), 21.9 (C17), 12.6 (C20). 
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(±)-(3S,4R,5R)-N-(4’-Methoxybenzyl)-3-methyl-4-hydroxy-5-(2’-methylpropyl)-
pyrrolidin-2-one-5-carboxylic acid methyl ester (±)-11 and (±)-(3R,4R,5R)-N-(4’-
Methoxybenzyl)-3-methyl-4-hydroxy-5-(2’-methylpropyl)-pyrrolidin-2-one-5-
carboxylic acid methyl ester (±)-101 
 
 
 
Raney nickel was washed using ethanol and dried under an atmosphere of nitrogen 
before being added to a solution of (±)-99 (0.02 g, 0.05 mmol) in ethanol. The reaction 
mixture was heated under reflux for 4 h. After removal of the Raney nickel by filtration 
the solvent was removed under reduced pressure. The resulting residue was purified 
using column chromatography on silica gel (light petroleum ether/ethyl acetate, 3:1). 
Compounds (±)-11 and (±)-101 were isolated as an inseparable mixture of 
diastereoisomers in a 3:1 ratio. 
 
Found (NSI): [M+H]+ 350.1963; [C19H27NO5+H]+ requires 350.1962.  
 
Major diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 7.11 (app d, 2H, J = 8.7 Hz, 
H12 and H14), 6.75 (app d, 2H, J = 8.7 Hz, H11 and H15), 4.75 (d, 1H, J = 15.9 Hz, 
H9), 4.65 (dd, 1H, J = 10.8, 5.2 Hz, H6), 4.25 (d, 1H, J = 15.9 Hz, H9), 3.71 (s, 3H, 
H16), 3.58 (s, 3H, H19), 2.71 (qd, 1H, J = 7.3, 4.9 Hz, H7), 1.75 (dd, 1H, J = 13.3, 6.4 
Hz, H4), 1.67 – 1.60 (m, 1H, H3), 1.56 (dd, 1H, J = 13.3, 5.7 Hz, H4), 1.18 (d, 3H, J = 
7.2 Hz, H17), 0.85 (d, 3H, J = 6.6 Hz, H1 or H2), 0.73 (d, 3H, J = 6.6 Hz, H1 or H2). 
13C NMR (126 MHz, CDCl3) δ 175.9, 172.0, 158.5, 131.1, 128.3 (C12 and C14), 113.8 
(C11 and C15), 72.3 (C6), 72.0, 55.3 (C16), 52.1 (C19), 43.8 (C9), 41.1 (C7), 39.2 
(C4), 24.1 (C1 or C2), 24.0 (C3), 23.4 (C1 or C2), 8.6 (C17). 
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3.2.2.2 Synthesis from L-Serine 
 
L-Serine methyl ester hydrochloride 1023 
 
 
 
L-Serine (10.06 g, 0.10 mol) was subjected to the general procedure for the 
esterification of an amino acid using acetyl chloride (20 mL, 0.29 mol, 3 equiv.). The 
product L-serine methyl ester hydrochloride 102 was obtained as off-white solid (14.90 
g, quant.). No further purification was carried out. 
 
Found (APCI): [M+H]+ 120.0653; [C4H9NO3+H]+ requires 120.0655. mp 159-164 °C, lit 
155-163 °C.3 [α]D = +4 (c 2, MeOH, 25 °C, lit +5, c 2, MeOH, 20 °C).3 1H NMR (500 
MHz, D2O) δ 4.13 (t, 1H, J = 3.5 Hz, H3), 3.96 (dd, 1H, J = 12.9, 4.3 Hz, H2), 3.85 (dd, 
1H, J = 12.9, 3.7 Hz, H2), 3.71 (s, 3H, H5). 13C NMR (126 MHz, D2O) δ 168.9 (C4), 
59.2 (C2), 54.7 (C3), 53.7 (C5). 
 
2-(4’-Methoxy-benzylamino)-3-hydroxy-propanoic acid methyl ester 1034 
 
 
 
L-Serine methyl ester hydrochloride (0.36 g, 2 mmol) was dissolved in methanol (10 
mL) and triethylamine (0.48 mL, 3.4 mmol, 1.5 equiv.) added. The reaction mixture 
was stirred for 1 h. 4-Methoxybenzaldehyde (0.31 mL, 2.5 mmol, 1.1 equiv.) was added 
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and the reaction mixture stirred for a further hour. The reaction mixture was purged 
with nitrogen and Pd/C (10% by weight, 0.04 g) added, the mixture was again purged 
with nitrogen and then treated with hydrogen under balloon pressure overnight at room 
temperature. The reaction mixture was filtered through celite and the solvents removed 
under reduced pressure. The residue was purified using column chromatography on 
silica gel (light petroleum ether/ethyl acetate 1:1) to yield the title compound as a pale 
yellow oil (0.35 g, 64%).  
 
Found (NSI): [M+H]+ 240.1228; [C12H17NO4+H]+ requires 240.1230. νmax (thin 
film)/cm−1 3321, 2953, and 1736. 1H NMR (500 MHz, CDCl3) δ 7.24 (app d, 2H, J = 
8.7 Hz, H9 and H11), 6.86 (app d, 2H, J = 8.7 Hz, H8 and H12), 3.83 (d, 1H, J = 13.1 
Hz, H6), 3.80 (s, 3H, H13), 3.77 (dd, 1H, J = 10.8, 4.6 Hz, H2), 3.75 (s, 3H, H5), 3.67 
(d, 1H, J = 13.1 Hz, H6), 3.60 (dd, 1H, J = 10.8, 6.5 Hz, H2), 3.43 (dd, 1H, J = 6.5, 4.5 
Hz, H3). 13C NMR (126 MHz, CDCl3) δ 173.5 (C4), 158.9 (C10), 131.4 (C7), 129.5 (C9 
and C11), 113.9 (C8 and C12), 62.4 (C2), 61.6 (C3), 55.3 (C13), 52.2 (C5), 51.5 (C6). 
 
Peptide Coupling 
 
 
 
Compound 103 (0.93 g, 3.9 mmol) was subjected to the general procedure for peptide 
coupling using EDAC·HCl (0.64 g, 9.7 mmol, 2.5 equiv.), NMM (0.85 mL, 7.7 mmol, 2 
equiv.), benzyl malonic half ester (1.80 g, 7.7 mmol, 2 equiv.) and DMAP (0.10 g, 0.8 
mmol, 0.2 equiv.). The residue was purified using column chromatography on silica gel 
(light petroleum ether/ethyl acetate, 2:1). Compound 104 was isolated as a yellow oil 
(0.23 g, 14%). Compound 112 was isolated as a colourless oil (0.42 g, 31%). 
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2-{(4’-Methoxy-benzyl)-[2’-(benzyloxycarbonyl)-acetyl]-amino}-3-hydroxy-
propanoic acid methyl ester 104 
Found (NSI): [M+H]+ 416.1698; [C22H25NO7+H]+ requires 416.1704. νmax (thin 
film)/cm−1 3456, 2953, 1740 and 1651. 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.25 (m, 
5H, H18-23), 7.14 (app d, 2H, J = 8.5 Hz, H9 and H11), 6.78 (app d, 2H, J = 8.5 Hz, H8 
and H12), 5.13 – 5.04 (m, 2H, H17), 4.51 – 4.38 (m, 2H, H6), 4.04 – 3.97 (m, 2H, H2 
and H3), 3.81 – 3.74 (m, 1H, H2), 3.70 (s, 3H, H13), 3.58 (s, 3H, H5), 3.51 (d, 1H, J = 
15.8 Hz, H15), 3.41 (d, 1H, J = 15.8 Hz, H15). 13C NMR (126 MHz, CDCl3) δ 170.0, 
167.3, 159.5, 135.2 (C10), 128.7 (Ar), 128.5 (Ar), 128.5 (C9 and C11), 127.3 (C7 and 
C18), 114.4 (C8 and C12), 67.5 (C17), 61.5 (C3), 60.7 (C2), 55.3 (C13), 53.2 (C6), 52.3 
(C5), 41.4 (C15). 
 
2-{(4’-Methoxy-benzyl)-[2’-(benzyloxycarbonyl)-acetyl]-amino}-3-(2’-
(benzyloxycarbonyl)-acetyl]-oxy)-propanoic acid methyl ester 112 
Found (NSI): [M+H]+ 592.2171; [C32H33NO10+H]+ requires 592.2177. νmax (thin 
film)/cm−1 2954, 1741 and 1655. [α]D = −33.6 (c 1, CHCl3, 25 °C). 1H NMR (500 MHz, 
CDCl3) δ 7.39 – 7.29 (m, 10H, H19-23 and H29-33), 7.20 (app d, 2H, J = 8.7 Hz, H9 
and H11), 6.85 (app d, 2H, J = 8.7 Hz, H8 and H12), 5.16 (s, 4H, H17 and H27), 4.71 
(dd, 1H, J = 11.7, 4.5 Hz, H2), 4.59 (d, 1H, J = 16.6 Hz, H6), 4.57 (dd, 1H J = 11.7, 8.1 
Hz, H2), 4.43 (d, 1H, J = 16.6 Hz, H6), 4.39 (dd, 1H, J = 8.1, 4.5 Hz, H3), 3.78 (s, 3H, 
H13), 3.65 (s, 3H, H5), 3.56 – 3.45 (m, 2H, H15 or H25), 3.32 (d, 2H J = 2.1 Hz, H15 
or H25). 13C NMR (126 MHz, CDCl3) δ 168.2, 167.1, 166.9, 166.1, 165.9, 159.4, 135.3, 
135.2, 128.6 (Ar), 128.6 (Ar), 128.6 (C9 and C11), 128.5 (Ar), 128.5 (Ar), 128.4 (Ar), 
128.4 (Ar), 127.3, 114.2 (C8 and C12), 67.3 (C17 and C27), 63.2 (C2), 58.3 (C3), 55.3 
(C13), 52.7 (C6), 52.5 (C5), 41.3 (C15 or C25), 41.3 (C15 or C25). 
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2-(4’-Methoxy-benzylamino)-3-(tri-iso-propylsilanyloxy)-propanoic acid methyl 
ester 113 
 
 
 
Compound 103 (2.07 g, 8.7 mmol) was subjected to the general procedure for the silyl 
protection of the hydroxyl moiety using triisopropyl silyl chloride (2.23 mL, 10.4 mmol, 
1.2 equiv.) and imidazole (1.48 g, 21.7 mmol, 2.5 equiv.). The product 113 was 
obtained as a yellow oil (3.10 g, 90%). No further purification was carried out. 
 
Found (NSI): [M+H]+ 396.2558; [C21H37NO4Si+H]+ requires 396.2565. νmax (thin 
film)/cm−1 2943, 2866 and 1743. [α]D = −19.2 (c 1, CHCl3, 25 °C).  1H NMR (500 MHz, 
CDCl3) δ 7.25 (app d, 2H, J = 8.6 Hz, H8 and H12), 6.85 (app d, 2H, J = 8.6 Hz, H9 
and H11), 3.97 (dd, 1H, J = 9.5, 4.8 Hz, H2), 3.90 (dd, 1H, J = 9.5, 5.0 Hz, H2), 3.84 (d, 
1H, J = 12.9 Hz, H6), 3.79 (s, 3H, H13), 3.72 (s, 3H, H5), 3.66 (d, 1H, J = 12.9 Hz, 
H6), 3.41 (t, 1H, J = 4.9 Hz, H3), 1.09 – 0.99 (m, 21H, H1). 13C NMR (126 MHz, 
CDCl3) δ 173.9 (C4), 158.7 (C10), 132.0 (C7), 129.4 (C9 and C11), 113.8 (C8 and 
C12), 65.0 (C2), 62.3 (C3), 55.3 (C13), 51.7 (C5), 51.3 (C6), 17.9 (C1), 11.9 (C1). 
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2-{(4’-Methoxy-benzyl)-[2’-(benzyloxycarbonyl)-acetyl]-amino}-3-(tri-iso-
propylsilanyloxy)-propanoic acid methyl ester 114 
 
 
 
Compound 113 (2.00 g, 5.0 mmol) was subjected to the general procedure for peptide 
coupling using EDAC·HCl (2.42 g, 12.6 mmol, 2.5 equiv.), NMM (1.10 mL, 10.1 
mmol, 2 equiv.), benzyl malonic half ester (2.35 g, 10.1 mmol, 2 equiv.) and DMAP 
(0.12 g, 1.0 mmol, 0.2 equiv.). The residue was purified using column chromatography 
on silica gel (light petroleum ether/ethyl acetate, 2:1). Compound 114 was isolated as a 
yellow oil (2.65 g, 91%). 
 
Found (NSI): [M+H]+ 572.3030; [C31H45NO7Si+H]+ requires 572.3038. νmax (thin 
film)/cm−1 2944, 2866, 1743 and 1659. [α]D = +4.4 (c 1, CHCl3, 25 °C). 1H NMR (500 
MHz, CDCl3) δ 7.36 – 7.32 (m, 5H, H19-23), 7.25 (app d, 2H, J = 9.1 Hz, H8 and 
H12), 6.86 (app d, 2H, J = 9.1 Hz, H9 and H11), 5.14 (s, 2H, H17), 4.74 (s, 2H, H6), 
4.59 (dd, 1H, J = 7.4, 3.7 Hz, H3), 4.26 (dd, 1H, J = 10.7, 7.5 Hz, H2), 4.17 (dd, 1H, J = 
10.7, 3.7 Hz, H2), 3.79 (s, 3H, H13), 3.66 (s, 3H, H5), 3.52 – 3.41 (m, 2H, H15), 1.02 – 
0.98 (m, 21H, H1). 13C NMR (126 MHz, CDCl3) δ 169.4 (C16), 167.2 (C4), 167.0 
(C14), 159.1 (C10), 135.5 (C7 and C18), 128.5 (Ar), 128.3 (Ar), 128.0 (C9 and C11), 
114.2 (C8 and C12), 67.1 (C17), 62.4 (C2), 60.9, (C3) 55.3 (C13), 52.1 (C6), 52.0 (C5), 
41.4 (C15), 17.9, 17.9 (C1), 11.8 (C1). 
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Peptide Coupling 
 
 
 
Compound 102 (0.35 g, 2.2 mmol) was subjected to the general procedure for peptide 
coupling using EDAC·HCl (0.64 g, 3.4 mmol, 1.5 equiv.), NMM (0.27 mL, 2.5 mmol, 
1.1 equiv.), benzyl malonic half ester (0.57 g, 2.5 mmol, 1.1 equiv.) and DMAP (0.05 g, 
0.4 mmol, 0.2 equiv.). The residue was purified using column chromatography on silica 
gel (30% ethyl acetate in light petroleum ether). Two compounds were isolated in a 1:6 
ratio, the first eluting compound 115 (0.08 g, 8%) and the second eluting compound 116 
(0.34 g, 52%). 
 
2-(2’-(benzyloxycarbonyl)-acetyl-amino)-3-(2’-(benzyloxycarbonyl)-acetyl]-oxy)-
propanoic acid methyl ester 115 
Found (NSI): [M+H]+ 472.1593; [C24H25NO9+H]+ requires 472.1602. νmax (thin 
film)/cm−1 3354, 2955, 1739 and 1683. [α]D = +35 (c 1, CHCl3, 25 °C). 1H NMR (500 
MHz, CDCl3) δ 7.75 (d, 1H, J = 7.8 Hz, H6), 7.41 – 7.29 (m, 10H, H12-16 and H22-
26), 5.17 (d, 4H, J = 1.9 Hz, H10 and H20), 4.89 (dt, 1H, J = 7.6, 3.6 Hz, H3), 4.55 (dd, 
1H, J = 11.4, 3.5 Hz, H2), 4.50 (dd, 1H, J = 11.4, 3.7 Hz, H2), 3.75 (s, 3H, H5), 3.42 (s, 
2H, H18), 3.37 (s, 2H, H8). 13C NMR (126 MHz, CDCl3) δ 169.3, 168.5, 166.2, 165.9, 
165.0, 135.1 (C11 or C21), 135.0 (C11 or C21), 128.7 (Ar), 128.6 (Ar), 128.6 (Ar), 
128.4 (Ar), 128.3 (Ar), 67.5 (C10 or C20), 67.4 (C10 or C20), 64.4 (C2), 53.0 (C5), 
51.6 (C3), 41.2 (C8 or C18), 41.1 (C8 or C18). 
 
2-(2’-(benzyloxycarbonyl)-acetyl-amino)-3-hydoxy-propanoic acid methyl ester 116 
Found (NSI): [M+H]+ 296.1127; [C14H17NO6+H]+ requires 296.1129. νmax (thin 
film)/cm−1 3355, 2955, 1740 and 1661. [α]D = +26 (c 1, CHCl3, 25 °C). 1H NMR (500 
MHz, CDCl3) δ 7.80 (d, 1H, J = 7.6 Hz, H6), 7.38 – 7.29 (m, 5H, H12-16), 5.16 (s, 2H, 
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H10), 4.65 (dt, 1H, J = 7.4, 3.6 Hz, H3), 3.95 (dd, 1H, J = 11.4, 3.7 Hz, H2), 3.88 (dd, 
1H, J = 11.4, 3.5 Hz, H2), 3.74 (s, 3H, H5), 3.42 (s, 2H, H8), 3.13 (s, 1H, H1). 13C 
NMR (126 MHz, CDCl3) δ 170.8 (C9), 168.7 (C4), 165.7 (C7), 135.0 (C11), 128.7 
(Ar), 128.6 (Ar), 128.4 (Ar), 67.4 (C10), 62.7 (C2) 54.9 (C3), 52.7 (C5), 41.5 (C8). 
 
N-(4’-Methoxybenzyl)-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid methyl ester 
117 
 
 
 
PMB protected L-serine methyl ester 103 (0.12 g, 0.5 mmol) and camphorsulfonic acid 
(0.02 g, 0.1 mmol, 0.2 equiv.) were dissolved in toluene (5 mL). 2,2-Dimethoxypropane 
(0.3 g, 0.3 mmol, 0.5 equiv.) was added to the reaction mixture. The reaction mixture 
was heated under reflux for 45 min at which point the reaction was cooled to room 
temperature and the solvent removed under reduced pressure. The residue was re-
dissolved in toluene (5 mL) and another portion of DMP (0.3 g, 0.3 mmol, 0.5 equiv.) 
added. This process was repeated 3 times then the solvent removed and residue re-
dissolved in diethyl ether (5 mL). The solution was then partitioned with aqueous 
NaHCO3 (5%, 15 mL). The aqueous phase was then extracted with diethyl ether (2 x 10 
mL). The organic layers were combined, dried over magnesium sulfate and the solvent 
removed under reduced pressure. The resulting product 117 was isolated as an oil (0.13 
g, 97%).  No further purification was carried out. 
 
Found (NSI): [M+H]+ 280.1538; [C15H21NO4+H]+ requires 280.1543. νmax (thin 
film)/cm−1 2953 and1737. 1H NMR (500 MHz, CDCl3) δ 7.26 (app d, 2H, J = 8.7 Hz, 
H8 and H12), 6.83 (app d, 2H, J = 8.7 Hz, H9 and H11), 4.11 (dd, 1H, J = 8.4, 7.8 Hz, 
H2), 3.96 (dd, 1H, J = 8.4, 5.4 Hz, H2), 3.89 (d, 1H, J = 13.3 Hz, H6), 3.79 (s, 3H, 
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H13), 3.64 (d, 1H, J = 13.3 Hz, H6), 3.61 (dd, 1H, J = 7.8, 5.5 Hz, H3), 3.45 (s, 3H, 
H5), 1.37 (s, 3H, H15 or H16), 1.29 (s, 3H, H15 or H16). 13C NMR (126 MHz, CDCl3) 
δ 173.1 (C4), 159.1 (C10), 130.9 (C7), 129.7 (C9 and C11), 114.0 (C8 and C12), 66.7 
(C2), 55.3 (C13), 51.7 (C5), 51.4 (C6), 26.7 (C15 or C16), 22.1 (C15 or C16). 
 
3.2.2.3 Synthesis from O-Benzyl-L-Serine 
 
O-Benzyl-L-serine methyl ester hydrochloride5 
 
 
 
O-Benzyl-L-serine (0.21 g, 1.08 mmol) was subjected to the general procedure for the 
esterification of an amino acid using acetyl chloride (0.22 mL, 3.26 mmol, 3 equiv.). 
The product 119 was obtained as off-white solid (0.27 g, quant.). No further purification 
was carried out. 
 
Found (NSI): [M+H]+ 210.1122; [C11H15NO3+H]+ requires 210.1125. mp 141-145 °C, lit 
165-166 °C.5 [α]D = +9 (c 1, CH3OH, 25 °C, lit +6.9, c 1, CH3OH, 20 °C).5 1H NMR 
(500 MHz, D2O) δ 7.42 – 7.32 (m, 5H, H8-13), 4.60 (d, 1H, J = 12.0 Hz, H7), 4.52 (d, 
1H, J = 12.0 Hz, H7), 4.32 (dd, 1H, J = 4.3, 3.2 Hz, H3), 3.95 (dd, 1H, J = 11.1, 4.3 Hz, 
H2), 3.86 (dd, 1H, J = 11.1, 3.2 Hz, H2), 3.76 (S, 3H, H5). 13C NMR (126 MHz, D2O) δ 
168.68 (C4), 136.73 (C8), 128.75 (Ar), 128.48 (Ar), 128.38 (Ar), 73.11 (C7), 66.35 
(C2), 53.71 (C5), 53.15 (C3). 
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2-(4’-Methoxy-benzylamino)-3-benzyloxy-propanoic acid methyl ester 120 
 
 
 
O-Benzyl-L-serine methyl ester hydrochloride (0.20 g, 0.81 mmol, 1.1 equiv.) was 
dissolved in acetonitrile (5 mL) and 4-methoxybenzyl chloride (0.10 mL, 0.74 mmol) 
and potassium carbonate (0.11 g, 0.81 mmol, 1.1 equiv.) were added. The reaction 
mixture was heated under reflux overnight. The solvent was removed under reduced 
pressure and the residue purified using column chromatography on silica gel (light 
petroleum ether : ethyl acetate, 2:1) to yield the title compound as an oil (0.12 g, 45%).  
 
Found (NSI): [M+H]+ 330.1697; [C19H23NO4+H]+ requires 330.1700. νmax (thin 
film)/cm−1 1739. [α]D = +14 (c 1, CHCl3, 25 °C). 1H NMR (500 MHz, CDCl3) δ 7.28 – 
7.18 (m, 5H, H9-13), 7.17 (app d, 2H, J = 8.7 Hz, H17 and H19), 6.77 (app d, 2H, J = 
8.7 Hz, H16 and H20), 4.45 (d, 1H, J = 12.2 Hz, H7), 4.41 (d, 1H, J = 12.2 Hz, H7), 
3.75 (d, 1H, J = 12.7 Hz, H14), 3.71 (s, 3H, H21), 3.65 (s, 3H, H5), 3.61 (dd, 2H, J = 
8.7, 4.9 Hz, H2), 3.58 (d, 1H, J = 12.7 Hz, H14), 3.43 (t, 1H, J = 4.9 Hz, H3), 2.10 (s, 
1H, H6). 13C NMR (126 MHz, CDCl3) δ 173.6 (C4), 158.8 (C18), 137.9 (C8), 131.6 
(C15), 129.6 (C17 and C19), 128.4 (Ar), 127.7 (Ar), 127.6 (Ar), 113.8 (C16 and C20), 
73.2 (C7), 71.0 (C2), 60.4 (C3), 55.3 (C21), 52.0 (C5), 51.4 (C14). 
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2-(2’-(Benzyloxycarbonyl)-acetyl-amino)-3-benzyloxy-propanoic acid methyl ester 
121 
 
 
 
O-Benzyl-L-serine methyl ester hydrochloride 119 (0.20 g, 0.82 mmol) was subjected to 
the general procedure for peptide coupling using EDAC·HCl (0.39 g, 2.04 mmol, 2.5 
equiv.), NMM (0.18 mL, 1.63 mmol, 2 equiv.), benzyl malonic half ester (0.21 g, 0.90 
mmol, 2 equiv.), and DMAP (0.02g, 0.16 mmol, 0.2 equiv.). The residue was purified 
using column chromatography on silica gel (light petroleum ether/ethyl acetate, 2:1). 
Compound 121 was isolated as an off-white solid (0.22 g, 69%). 
 
Found (NSI): [M+H]+ 386.1588; [C19H23NO4+H]+ requires 386.1598. νmax (thin 
film)/cm−1 3353, 1744 and 1679. mp 104-109 °C. [α]D = +24 (c 1, CHCl3, 25 °C). 1H 
NMR (500 MHz, CDCl3) δ 7.74 (d, 1H, J = 7.7 Hz, H6), 7.38 – 7.27 (m, 10H, H9-13 
and H19-23), 5.19 (s, 2H, H17), 4.76 (dt, 1H, J = 7.9, 3.3 Hz, H3), 4.53 (d, 1H, J = 12.2 
Hz, H7), 4.48 (d, 1H, J = 12.2 Hz, H7), 3.89 (dd, 1H, J = 9.6, 3.3 Hz, H2), 3.73 (s, 3H, 
H5), 3.69 (dd, 1H, J = 9.6, 3.3 Hz, H2), 3.39 (d, 2H, J = 2.8 Hz, H15). 13C NMR (126 
MHz, CDCl3) δ 170.4, 168.6, 164.9, 137.5, 135.1, 128.7 (Ar), 128.6 (Ar), 128.5 (Ar), 
128.5 (Ar), 127.9 (Ar), 127.7 (Ar), 73.3 (C7), 69.4 (C2), 67.3 (C17), 52.9 (C3), 52.6 
(C5), 41.3 (C15). 
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The Dieckmann Cyclization 
 
 
 
The diester 121 (0.17 g, 0.43 mmol) was subjected to the general procedure for the one-
pot Dieckmann cyclization using TBAF (1 M in THF, 1.5 mL, 1.5 mmol, 3.5 equiv.) 
and iodomethane (0.1 mL, 1.7 mmol, 4 equiv.). The residue was purified using column 
chromatography on silica gel (light petroleum ether/ethyl acetate, 4:1). Compound 122 
was isolated as a colourless oil (0.05 g, 30%). 
 
2-(2’-(Benzyloxycarbonyl)-2’-methyl-propionyl-amino)-3-benzyloxy-propanoic 
acid methyl ester 
Found (NSI): [M+H]+ 386.1588; [C19H23NO4+H]+ requires 386.1598. νmax (thin 
film)/cm−1 3353, 1744 and 1679. [α]D = +22 (c 1, CHCl3, 25 °C). 1H NMR (500 MHz, 
CDCl3) δ 7.28 – 7.14 (m, 10H, H9-13 and H19-23), 7.03 (d, 1H, J = 7.6 Hz, H6), 5.10 
(s, 2H, H17), 4.62 (dt, 1H, J = 7.8, 3.2 Hz, H3), 4.43 – 4.34 (m, 2H, H7), 3.78 (dd, 1H, 
J = 9.5, 3.2 Hz, H2), 3.64 (s, 3H, H5), 3.54 (dd, 1H, J = 9.5, 3.3 Hz, H2), 1.43 (s, 3H, 
H24 or H25), 1.41 (s, 3H, H24 or H25). 13C NMR (126 MHz, CDCl3) δ 174.1 (C4), 
171.8 (C16), 170.6 (C14), 137.7 (C18), 135.7 (C8), 128.7 (Ar), 128.6 (Ar), 128.4 (Ar), 
128.1 (Ar), 128.0 (Ar), 127.7 (Ar), 73.3 (C7), 69.4 (C2), 67.3 (C17), 53.0 (C3), 52.6 
(C5), 50.2, 23.6 (C24 or C25), 23.5 (C24 or C25). 
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3.2.2.4 Synthesis from L-Valine 
 
L-Valine methyl ester hydrochloride 1236 
 
 
 
L-valine (10.11 g, 0.09 mol) was subjected to the general procedure for the 
esterification of an amino acid using acetyl chloride (18 mL, 0.26 mol, 3 equiv.). The 
product 123 was obtained as off-white solid (14.46 g, quant.). No further purification 
was carried out. 
 
[α]D = +12 (c 2, H2O , 25 °C, lit +15°, c 2, H2O ).6 mp 170-173 °C, lit 171-173 °C.6 1H 
NMR (500 MHz, D2O) δ 3.98 (d, 1H, J = 4.7 Hz, H4), 3.80 (s, 3H, H6), 2.30 (m, 1H, 
H3), 0.98 (d, 3H, J = 6.8 Hz, H 1 or H2), 0.96 (d, 3H, J = 6.8 Hz, H 1 or H2). 13C NMR 
(126 MHz, D2O) δ 170.4 (C5), 58.4 (C6), 53.4 (C4), 29.3 (C3), 17.3 (C1 or C2), 17.0 
(C1 or C2). 
 
2-(4’-Methoxy-benzylamino)-3-methyl-butanoic acid methyl ester 1247 
 
 
 
L-Valine methyl ester hydrochloride (1.50 g, 8.89 mmol) and 4-methoxybenzaldehyde 
(1.12 mL, 9.77 mmol, 1.1 equiv.) were dissolved in toluene (50 mL) and acetic acid 
(0.25 mL, 4.44 mmol 0.5 equiv.) added. The reaction mixture was heated under reflux 
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using a Dean-Stark apparatus overnight. The solvent was removed under reduced 
pressure and the residue re-dissolved in methanol (50 mL) and acetic acid (0.25 mL, 
4.44 mmol, 0.5 equiv.) added. The reaction mixture was cooled to 0 °C and sodium 
cyanoborohydride (1.12 g, 17.77 mmol, 2 equiv.) was added slowly in small portions. 
The reaction mixture was stirred for 30 min at 0 °C then allowed to warm to room 
temperature and stirred overnight. The reaction was quenched with water (10 mL). The 
solvents were removed under reduced pressure and the residue was dissolved in 
dichloromethane (50 mL) and washed with water (2 x 50 mL), brine (2 x 50 mL) and 
Na2CO3 (2 x 50 mL). The organic layer was dried over anhydrous magnesium sulfate, 
filtered, and evaporated to dryness under reduced pressure. The product 124 was 
obtained as a yellow oil (2.09 g, 94%). No further purification was carried out. 
 
Found (NSI): [M+H]+ 252.1595; [C14H22NO3+H]+ requires 252.1594. νmax (thin film)/cm-
1 1733. [α]D = +7 (c 1, CHCl3, 25 °C).  1H NMR (500 MHz, CDCl3) δ 7.25 (app d, 2H, J 
= 8.7 Hz, H10 and H12), 6.85 (app d, 2H, J = 8.7 Hz, H9 and H13), 3.79 (s, 3H, H14), 
3.75 (d, 1H, J = 12.9 Hz, H7), 3.71 (s, 3H, H6), 3.52 (d, 1H, J = 12.9 Hz, H7), 3.00 (d, 
1H, J = 6.1 Hz, H4), 1.90 (m, 1H, H3), 0.94 (d, 3H, J = 6.8 Hz, H1 or H2), 0.92 (d, 3H, 
J = 6.8 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 175.8 (C5), 158.7 (C11), 132.2 
(C8), 129.4 (C10 and C12), 113.7 (C9 and C13), 66.5 (C4), 55.3 (C14), 52.0 (C7), 51.4 
(C6), 32.0 (C3), 19.3 (C1 or C2), 18.7 (C1 or C2). 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 Experimental		
	 182	
2-{(4’-Methoxy-benzyl)-[2’-(benzyloxycarbonyl)-acetyl]-amino}-3-methyl-butanoic 
acid methyl ester 125 
 
 
 
Compound 124 (1.16 g, 6.20 mmol) was subjected to the general procedure for peptide 
coupling using EDAC·HCl (2.99 g, 15.49 mmol, 2.5 equiv.), NMM (1.40 mL, 12.39 
mmol, 2 equiv.), benzyl malonic half ester (3.02 g, 9.30 mmol, 1.5 equiv.) and DMAP 
(0.16 g, 1.24 mmol, 0.2 equiv.). The residue was purified using column chromatography 
on silica gel (light petroleum ether/ethyl acetate, 4:1). Compound 125 was isolated as a 
yellow oil (1.75 g, 66%). 
 
Found (NSI): [M+H]+ 428.2066; [C24H29NO6+H]+ requires 428.2068. νmax (thin 
film)/cm−11741 and 1655. [α]D = +6 (c 1, CHCl3, 25 °C).  
 
Major rotamer: 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, H20-24), 7.04 (app 
d, 2H, J = 8.6 Hz, H10 and H12), 6.83 (app d, 2H, J = 8.6 Hz, H9 and H13), 5.14 (d, 
2H, J = 2.3 Hz, H18), 4.85 (d, 1H, J = 10.4 Hz, H4), 4.59 (d, 1H, J = 17.5 Hz, H7), 4.53 
(d, 1H, J = 17.5 Hz, H7), 3.77 (s, 3H, H14), 3.48 (d, 1H, J = 15.5 Hz, H16), 3.45 (s, 3H, 
H6), 3.39 (d, 1H, J = 15.5 Hz, H16), 2.32 – 2.26 (m, 1H, H3), 0.96 (d, 3H, J = 6.7 Hz, 
H1 or H2), 0.89 (d, 3H, J = 6.7 Hz, H1 or H2). 
 
Minor rotamer: 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, H20-24), 7.17 (app 
d, 2H, J = 8.6 Hz, H10 and H12), 6.73 (app d, 2H, J = 8.6 Hz, H9 and H13), 5.21 (d, 
2H, J = 2.1 Hz, H18),	4.87 (d, 1H, J = 15.2 Hz, H7), 4.28 (d, 1H, J = 15.2 Hz, H7), 3.82 
(d, 1H, J = 10.9 Hz, H4), 3.75 (s, 3H, H14), 3.69 (d, 2H, J = 2.4 Hz, H16), 3.35 (s, 3H, 
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H6), 2.40 – 2.32 (m, 1H, H3), 0.93 (d, 3H, J = 6.6 Hz, H1 or H2), 0.77 (d, 3H, J = 6.6 
Hz, H1 or H2). 
 
13C NMR (126 MHz, CDCl3) δ 170.7, 169.8, 167.5, 167.3, 167.2, 167.2, 159.0, 158.60, 
135.4, 135.3, 129.4, 128.6, 128.6, 128.4, 128.4, 128.4, 128.2, 127.2, 114.2, 113.5, 67.2, 
66.7, 62.1, 60.4, 55.3, 52.0, 51.7, 48.4, 45.6, 42.1, 41.6, 28.1, 27.6, 19.9, 18.6. 
 
The Dieckmann Cyclization 
 
 
 
The diester 125 (1.74 g, 4.08 mmol) was subjected to the general procedure for the one-
pot Dieckmann cyclization using TBAF (1 M in THF, 14.30 mL, 14.28 mmol, 3.5 
equiv.) and iodomethane (1 mL, 16.32 mmol, 4 equiv.). The residue was purified using 
column chromatography on silica gel (20% ethyl acetate in light petroleum ether). The 
first eluting diastereoisomer (±)-132 was obtained as a yellow oil (0.43 g, 25%) and the 
second eluting diastereoisomer (±)-126 was obtained as an off-white solid (0.68 g, 
41%). 
 
(±)-(3S,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(1’-methylethyl)-pyrrolidin-2,4-
dione-3-carboxylic acid benzyl ester (±)-132 
Found (NSI): [M+H]+ 427.2225; [C24H27NO5+NH4]+ requires 427.2227. νmax (thin 
film)/cm-1 2964, 1776, 1748 and 1697. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.33 (m, 
3H, Ar), 7.25 – 7.22 (m, 2H, Ar), 6.99 (app d, 2H, J = 8.6 Hz, H10 and H14), 6.57 (app 
d, 2H, J = 8.6 Hz, H11 and H13), 5.43 (d, 1H, J = 15.0 Hz, H8), 5.21 (d, 1H, J = 12.3 
Hz, H17), 5.06 (d, 1H, J = 12.3 Hz, H17), 3.77 (d, 1H, J = 15.0 Hz, H8), 3.75 (d, 1H, J 
= 3.4 Hz, H4), 3.72 (s, 3H, H15), 2.18 – 2.14 (m, 1H, H3), 1.53 (s, 3H, H24), 1.05 (d, 
3H, J = 7.1 Hz, H1 or H2), 0.82 (d, 3H, J = 7.1 Hz, H1 or H2). 13C NMR (126 MHz, 
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CDCl3) δ 205.5, 170.0, 159.2, 134.8, 129.4 (C11 and C13), 128.8 (Ar), 128.6 (Ar), 
128.3 (Ar), 126.0, 114.2 (C10 and C14), 68.3 (C4), 68.2 (C17), 59.0 (C6), 55.2 (C15), 
42.9 (C8), 27.7 (C3), 18.2 (C1 or C2), 16.4 (C1 or C2), 15.0 (C 24). 
 
(±)-(3R,5S)-N-(4’-Methoxybenzyl)-3-methyl-5-(1’-methylethyl)-)-pyrrolidin-2,4-
dione-3-carboxylic acid benzyl ester (±)-126 
Found (NSI): [M+H]+ 410.1963; [C24H27NO5+H]+ requires 410.1962. νmax (thin film)/cm-
1 2966, 1773, 1743 and 1695. mp 96-99 °C. 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.28 
(m, 5H, H19-23), 7.13 (app d, 2H, J = 8.6 Hz, H11 and H13), 6.83 (app d, 2H, J = 8.6 
Hz, H10 and H14), 5.25 (d, 1H, J = 14.9 Hz, H8), 5.19 (d, 1H, J = 12.2 Hz, H17), 5.14 
(d, 1H, J = 12.2 Hz, H17), 3.96 (d, 1H, J = 14.9 Hz, H8), 3.78 (s, 3H, H15), 3.63 (d, 1H, 
J = 3.5 Hz, H4), 2.19 – 2.14 (m, 1H, H3), 1.54 (s, 3H, H24), 1.03 (d, 3H, J = 7.1 Hz, H1 
or H2), 0.70 (d, 3H, J = 7.1 Hz, H1 or H2). 13C NMR (126 MHz, CDCl3) δ 205.0, 
170.3, 165.6, 159.4, 134.8, 129.4 (C11 and C13), 128.5 (Ar), 128.5 (Ar), 128.4 (Ar), 
127.1, 114.4 (C10 and C14), 68.0 (C4), 68.0 (C17), 59.0 (C6), 55.3 (C15), 43.4 (C8), 
28.3 (C3), 18.6 (C1 or C2), 18.3 (C24), 16.4 (C1 or C2). 
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4.0 Biological Activity Studies 
 
4.1 Introduction 
 
Proteasome inhibition is a key strategy for anti-cancer therapy and is of great interest in 
current research. The proteasome is essential in regulating many processes within the 
cell, including cellular function and homeostasis.1 The ubiquitin proteasome pathway 
regulates the processes that are important for cell growth and survival, for both healthy 
and tumour cells. Inhibition of the proteasome stops the process of protein degradation, 
thereby inducing apoptosis. If cancer cells can be specifically targeted for proteasome 
inhibition, these cells will undergo apoptosis leaving behind only healthy cells.  
 
 
Figure 1. Bortezomib 
 
Bortezomib was the first proteasome inhibitor to be used in clinical trials for the 
treatment of multiple myeloma and is now fully approved by the Food and Drug 
Administration (FDA) in the USA.2 It was found to be successful at inducing apoptosis 
in cancer cell lines whilst having little cytotoxic effects on healthy cells.3 Unfortunately, 
in many cases, patients either failed to respond to treatment or relapse occurred (when 
using Bortezomib alone or as part of combination therapies).4 This resistance to 
Bortezomib has led to the need for second generation inhibitors. 
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Figure 2.  Structures of lactacystin 1 and its active form, omuralide 2. 
 
Lactacystin 1 is a microbial metabolite isolated from Streptomyces sp. OM-6519.5, 6 It 
has anti-tumor effects in vitro and in vivo. It has been shown to inhibit tumour growth in 
an animal model of malignant glioma,7 and prevent cell proliferation in the human 
Neuro 2A neuroblastoma cell line and the human osteosarcoma cell line.8 Lactacystin 
itself cannot permeate through cell walls, but the β-lactone derivative, also known as 
omuralide 2, can. The efficiency of lactacystin as a proteasome inhibitor is thus 
dependent on its ability to form the β-lactone 2. The 20S proteasome (Figure 3) was 
found to be the specific cellular target of lactacystin and its derivatives.9 
 
 
Figure 3. The 20S proteasome. 
 
In 1994, Fenteany et al. studied the activity of lactacystin analogues to determine which 
structural features were essential for biological activity.8 They found that the activity 
could be greatly affected by the groups on the γ-lactam ring and modifications 
(including changing the groups completely or altering the stereochemistry) at the C5, 
C6, C7 and C9 positions can result in partial or complete loss of activity. The case 
where this does not apply is in the N-acetyl-L-cysteine (NAC) moiety at C5; it was 
found to play no part in the activity and this group could be changed with no effect on 
activity. 
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Lactacystin was found to inhibit the trypsin-like (proteases that cleave peptide bonds in 
the position following a positively charged amino acid such as lysine), chymotrypsin-
like (the hydrophobic nature of the S1 pocket makes it specific for medium to large 
hydrophobic residues) and peptidylglutamyl-peptide hydrolysing (cleavage of peptide 
bonds in the position following acidic or branched-chain amino acids) activities in the 
enzyme complex.9 The trypsin- and chymotrypsin-like activities are both irreversibly 
inhibited by lactacystin. 
 
In this study, four compounds were selected to be tested for biological activity (Figure 
4); including proteasome inhibition and anti proliferative effects. These compounds 
were chosen due to their structural similarities to lactacystin and omuralide in the hope 
that they would exhibit similar biological activity. Each compound was tested to 
determine its IC50 value against the human leukemia HL-60 cell line (using an MTS cell 
viability assay) and its ability to inhibit the 20S proteasome (using an enzyme inhibition 
assay). 
 
 
Figure 4. Structures of the compounds chosen for biological activity studies. 
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4.2 Anti-Proliferative Studies 
 
4.2.1 Introduction 
 
Cell viability assays are used to screen compounds against a specific type of cell to 
determine if the compound shows direct cytotoxic effects, which can lead to cell death, 
or has an effect on cell proliferation. An MTS assay is a colourimetric method used to 
determine cell viability in proliferation or cytotoxicity assays. In living cells, MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) is bioreduced to form a formazan product that is red in colour. The 
reduction is believed to require NADH or NADPH. If the cells are killed, reduction of 
the MTS is no longer possible and formazan is not formed (i.e. the red colour of 
formazan is not seen). Cell viability is measured in terms of absorbance; formazan dye 
absorbs at 492 nm. The formation of formazan product is directly proportional to the 
number of viable cells present. 
 
 
Scheme 1. Conversion of MTS to formazan. 
 
An MTS assay is used to determine the IC50 value of a compound against a specific cell 
line. IC50 is defined as the ‘half maximal inhibitory concentration’. It is a measure of 
how effective a compound is at inhibiting a specific biological process. The IC50 value 
can be calculated using the absorbance values of a compound at varying inhibitor 
concentrations. The IC50 value will vary between cell lines; inhibitors show different 
specific effects in different cell types. 
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The HL-60 cell line is often used in cell viability assays. HL-60 cells are human 
promyelocytic leukemia cells established in 1977 from a single patient with acute 
myeloid leukemia. Proliferation of HL-60 cells occurs in suspension culture with a 
doubling time of 20 – 45 h.10 
 
4.2.2 Results and Discussion 
 
In order to confirm that our assay was working and to produce a positive control for our 
studies, we investigated the anti-proliferative activity of omuralide in HL-60 cells. 3 x 
104 cells were seeded in wells of a 96 well plate. The positive control (containing only 
media), negative control (containing only HL-60’s) and the vehicle control (containing 
HL-60’s and DMSO) were set up and the remaining wells treated with omuralide at 
varying concentrations from 0 – 20 μM. After incubation for 72 h at 37 °C, followed by 
addition of MTS and further incubation for 4 h at 37 °C, the absorbance was measured 
at 492 nm. Figure 5 shows the 96 well plate after MTS addition and incubation. An 
obvious colour difference is observed as the concentration of omuralide present 
decreases. 
 
 
Figure 5. Cell viability assay for omuralide after incubation with MTS 
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The red colour, due to the presence of formazan, cannot be seen at concentrations 20, 
10, 5, 2.5 and 1.25 μM. At these concentrations the compounds have decreased cell 
viability and the bioreduction of MTS to formazan does not occur. The change from 
yellow to red gives us an indication of where the IC50 value will be; between 1.25 and 
0.625 μM. Table 1 shows the absorbance readings obtained and from this a graph can 
be plotted. Using this graph the IC50 value for omuralide against the HL-60 cell line was 
calculated to be 1.15 μM. 
 
Table 1. MTS assay results for omuralide	 Figure 6. Determination the IC50 value of 
omuralide using GraphPad Prism	
  
		 
The next step was to test the compounds made in our laboratories to see how they 
compare to omuralide. 3 x 104 cells were seeded in wells of a 96 well plate. The positive 
control (containing only media), negative control (containing only HL-60’s) and the 
vehicle control (containing HL-60’s and DMSO) were set up and the remaining wells 
treated with compounds (±)-10, (±)-51, (±)-57 and (±)-66 at varying concentrations 
from 0 – 1000 μM. After incubation for 72 h at 37 °C, followed by addition of MTS and 
further incubation for 4 h at 37 °C, the absorbance was measured at 492 nm. 
 
Figure 7 shows the 96 well plates after MTS addition and incubation. An obvious 
colour difference is observed as the concentration decreases. In compounds (±)-51 and 
(±)-66 the red colour, due to the presence of formazan, cannot be seen at concentrations 
of 1000, 500 and 100 μM. At these concentrations the compounds have decreased cell 
viability and the bioreduction of MTS to formazan does not occur.  Again, the change 
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from yellow to red gives us an indication of where the IC50 value will be; between 100 
and 50 μM. Compound (±)-57 appears to decrease cell viability at concentrations of 
1000 and 500 μM and compound (±)-10 does not appear to decrease cell viability even 
at a concentration of 1000 μM (i.e. the IC50 value is greater than 1000 μM). The IC50 
values are calculated using a graph of absorbance (at 492 nm) vs. log concentration 
(pM). 
 
 
 
Figure 7. Cell viability assays for compounds (±)-10, (±)-51, (±)-57 and (±)-66 after 
incubation with MTS 
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Table 2. MTS assay results for compound 
(±)-51	 Figure 8. Determination the IC50 value of compound (±)-51 using GraphPad Prism		
 
 
Table 3. MTS assay results for compound 
(±)-57	 Figure 9. Determination the IC50 value of compound (±)-57 using GraphPad Prism	
 
 
 
Table 4. MTS assay results for compound 
(±)-66	 Figure 10. Determination the IC50 value of compound (±)-66 using GraphPad Prism	
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Tables 2-4 show the absorbance readings obtained for compounds (±)-51, (±)-57 and 
(±)-66: the absorbance decreases as the compound concentration increases. Looking at 
the absorbance data, and the assay, the IC50 value can be estimated to be between 50 and 
100 μM, 100 and 500 μM and 50 and 100 μM respectively. The data obtained was used 
to plot a graph for each compound from which the IC50 value was calculated to be. The 
calculated IC50 values for compounds (±)-51, (±)-57 and (±)-66 are 54.70 μM, 146.22 
μM and 53.09 μM, respectively. 
 
The results obtained for compound (±)-57 should be viewed with caution; they do not 
give the standard dose-response curve. More data points over a larger range may result 
in data more likely to give the standard dose-response curve. 
 
When we compare the data obtained for our compounds to that obtained for omuralide 
(Table 5) we can see that the IC50 values are considerably higher for our compounds; 
they do not decrease cell viability at the same level. A low IC50 value is an essential 
feature for a compound if it were to be used as a therapeutic drug; this is because the 
dosage of the drug required would also be low. 
 
Table 5. IC50 concentrations for compounds (±)-10 (±)-51, (±)-57 and (±)-66 and 
omuralide. 
Compound LogIC50 [pM] IC50 [μM] 
(±)-51 7.74 54.70 
(±)-57 8.17 146.22 
(±)-66 7.73 53.09 
(±)-10 - > 1000 
Omuralide 6.06 1.15 
 
Compound (±)-66 has a β-lactone moiety (albeit at a different position on the ring) also 
found in the natural product and so we could expect it to have a similar anti-
proliferative effect on HL-60’s as omuralide. Although not as low as omuralide 
compound (±)-66 has an IC50 value closest to that of omuralide. 
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Compound (±)-10 is the least similar in structure to omuralide and the other compounds 
tested; it contains a ketone moiety at the C6 position not found in any of the other 
compounds or the natural product. Structural differences will affect levels of activity. 
 
4.2.3 Conclusion and Future Work 
 
IC50 values were successfully calculated for compounds (±)-51, (±)-57 and (±)-66 
against the HL-60 cell line. Unfortunately, none of these were in the same order of 
magnitude as that calculated for omuralide but all showed anti-proliferative effects in 
the HL-60 cell line. Compound (±)-10 had little effect on cell viability at the 
concentrations tested. 
 
We were unable to find any literature reporting the study of the anti-proliferative effects 
of omuralide on HL-60 cells. This makes the work reported here novel and potentially 
very interesting and worthy of further investigation. Further investigation is also needed 
into structure activity relationships. It is clear from the results that structure plays a key 
role in the observed level of activity; compounds (±)-10 and (±)-66 show vastly 
different anti-proliferative effects. 
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4.2.4 Experimental 
 
4.2.4.1 Chemicals 
 
The human promyelocytic leukemia cells (HL-60’s) were purchased from the European 
Collection of Cell Cultures (ECCC, Porton Down, UK). Foetal calf serum (FCS) was 
purchased from Biosera. RPMI-1640 media and L-glutamine were purchased from 
Invitrogen. MTS was purchased from Promega. 
 
Compounds (±)-10, (±)-51, (±)-57 and (±)-66 were synthesized in our laboratories and 
dissolved in the required volume of DMSO to give a 100 mM stock solution. From the 
stock solution serial dilutions were made (in DMSO) to give 50, 10, 5, 2.5, 1.25, 0.625 
and 3.125 mM stocks to be used in the MTS assay. 
 
4.2.4.2 Cell Culture 
 
The HL-60 cells were cultured in RPMI-1640 media that contained 2mM L-glutamine, 
100 U/mL penicillin, 100 μg/mL streptomycin and 10% FCS. Cells were maintained at 
37 °C in a 5% CO2 atmosphere. HL-60 density in culture was maintained between 1 × 
105 and 9 × 105 cells / mL in 75 cm2 flasks. Every 3.5 days the cultures were split with 
fresh media and used for experimentation until passage 30. HL-60’s were diluted to 1 in 
2 using trypan blue and counted using a Malassez haemocytometer with light 
microscopy. 
 
4.2.4.3 MTS assay 
 
The MTS assays were carried out, following the manufacturer’s instructions, using the 
CellTilter 96® Aqueous One Solution Cell Proliferation Assay kit. The outer wells of a 96 
well plate were filled with 250 μl of water to aid in the prevention of evaporation of 
other wells on the plate. 100 μl of 3 x 104 cells were seeded in each well. Three sets of 
control wells made up; one containing only media (positive control), one containing 
only HL-60 cells (negative control) and one containing HL-60 cells and DMSO (vehicle 
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control). The remaining wells were seeded with HL-60 cells and either compounds (±)-
10, (±)-51, (±)-57 or (±)-66 (at varying concentrations). Each experiment was carried 
out in triplicate. The plate was incubated for 72 h at 37 °C with 5% CO2. After 
incubation 10 μl of MTS assay reagent was added to each well and the plate incubated 
for a further 4 h at 37 °C with 5% CO2. 
 
Absorbance was measured at 492 nm using a BMG Labtech POLARstarOPTIMA 
microplate reader. IC50 values were calculated from a graph of log[pM] vs. absorbance 
(492 nm) using GraphPad Prism Version 6.0. 
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4.3 Enzyme Inhibitor Studies 
 
4.3.1 Basic Enzyme Kinetics 
 
It is important to understand the ‘normal’ action of an enzyme before discussing the 
effect of an inhibitor on enzyme activity. When a substrate binds and is turned over by 
the enzyme the product is produced. This can be represented by the scheme below and 
also illustrated graphically (Figure 11). 
 
 
Scheme 2. General scheme for enzyme catalysed substrate turnover. 
 
The term KM is known as the Michaelis constant and is defined as the ‘concentration of 
substrate leading to half saturation of the enzyme active sites under steady state 
conditions’.10  Upon mixing E + S the initial equilibrium to form the enzyme-substrate 
(ES) complex is rapidly established, usually within μ seconds. The term kcat is defined as 
the rate constant for the slowest ‘rate determining’ step of the steps that then lead to 
product formation.11 
 
 
Figure 11. General graphical illustration for enzyme activity without the presence of an 
inhibitor. 
E S ES E P
kcatKM
FAST SLOW
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The deviation from linearity in the graph illustrates the substrate depletion after time; 
when all the substrate has been turned over by the enzyme, no more product can be 
formed. The rate of product formation is defined as [ES]kcat. As product is formed the 
concentration of substrate decreases so the E + S  ES equilibrium shifts to the left; 
the concentration of ES drops so the rate of product formation gradually decreases until 
all substrate is consumed. 
 
If the initial rate of product formation is measured across a range of different substrate 
concentrations, a plot of the initial rate vs. [S] gives a curve which is described by the 
Michaelis-Menten equation: 
 ! =  !!"#[!]!! + [!] 
 
From this, it is possible to obtain a value for the term Vmax. When the enzyme is 
saturated with substrate, this is the Vmax and is defined as the maximum velocity (rate) of 
product formation at infinite substrate concentration.11 
 
 
Figure 12. General graphical illustration to determine the rate of product formation. 
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4.3.1.1 The Difference Between Reversible and Time-Dependent 
Covalent Inhibitors 
 
Reversible inhibitors bind to the enzyme through non-covalent forces including, 
hydrophobic and electrostatics forces, hydrogen bonding and van der Waals 
interactions. There are three types of reversible inhibition derived from the equilibrium 
reactions described above; competitive inhibition, non-competitive inhibition and 
uncompetitive inhibition.  
 
Competitive inhibitors are those that bind to the enzyme in place of the substrate, i.e. 
they are mutually exclusive, either the substrate binds or the inhibitor binds. They 
cannot bind at the same time and so formation of the enzyme-substrate (ES) complex is 
affected.  
 
Non-competitive inhibitors are those that show binding affinity for both the free enzyme 
and the ES complex (or subsequent species). They can result in the formation of an 
enzyme-inhibitor (EI) complex and/or an enzyme-substrate-inhibitor (ESI) complex. 
 
Uncompetitive inhibitors are those that show no binding affinity for the free enzyme but 
bind exclusively to the ES complex (or subsequent species). Inhibition can only occur 
after the formation of the enzyme-substrate complex, i.e. the E + S  ES reaction is 
not affected but the ES à ES* reaction is. 
 
Competitive covalent inhibitors bond irreversibly to the enzymes active site and as a 
result, modify the enzyme and activity is permanently reduced. Many irreversible 
inhibitors first bind reversibly to the enzyme forming the EI complex, before covalent 
bonding occurs (EI*). The rate of EI formation is very fast (μ seconds) compared to that 
of EI* formation (seconds/minutes) and so these inhibitors are often referred to as slow 
binding.9 
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Competitive inhibition 
 
 
Competitive covalent inhibition 
Scheme 3. 
 
The initial curve in the presence of a time-dependent covalent inhibitor is similar to that 
of a classical reversible inhibitor (Figure 13). This is because the first (reversible) step 
is very fast and the second (irreversible) step is much slower. When the inhibitor bonds 
irreversibly the substrate is no longer turned over by the enzyme, no product is formed 
and the curve begins to level off. The formation of the EI* complex (the slow step) 
shifts the equilibrium towards EI* and so the concentration of ES drops which in turn 
results in reduced product formation. 
 
 
Figure 13. General graphical illustration to compare product formation over time in the 
presence of no inhibitor, a classical reversible inhibitor and a time-dependent covalent 
inhibitor. 
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4.3.1.2 Proteasome Inhibition by Omuralide 
 
Omuralide acts as a competitive irreversible inhibitor of trypsin- and chymotrypsin-like 
activity in the 20S proteasome.9 Cell apoptosis is induced as a result of this inhibition.12 
Omuralide acts by acylating the amino terminal threonine residue of one of the β-type 
protein subunits of the 20S proteasome, this blocks the active site and stops normal 
working of the proteasome.13 
 
 
Scheme 4. Deactivation of the 20S proteasome by acylation of a terminal threonine 
residue. 8 
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4.3.2 Results and Discussion 
 
As described above, omuralide inhibits the trypsin-like and chymotrypsin-like activity 
in the 20S proteasome. We decided to test our compounds against the chymotrypsin-
like activity using a commercially available assay kit containing the 20S proteasome 
and the chymotrypsin-like substrate (Suc-LLVY-AMC). The AMC (7-amino-4-
methylcoumarin) part of the substrate is a fluorescent tag, when the substrate binds and 
is turned over by the enzyme the AMC tag is released and fluorescence is observed and 
measured. Continuous kinetic readings were performed over 1 h using a microplate 
reader. 
 
 
Figure 14. AMC (7-amino-4-methylcoumarin). 
 
As we know the mechanism of action of omuralide, we can deduce which compounds 
may behave in a similar manner. Compound (±)-66 also has a β-lactone moiety (albeit 
at a different position on the ring) also found in the natural product and so we would 
expect a similar mode of action to omuralide. Esters are also reactive towards 
nucleophiles, although less so than lactones; the ester moiety at C5 present in all 
compounds could also be used in the reaction with threonine. 
 
 
Figure 15. The structures of the compounds being screened. 
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Two standard experiments were run to obtain data that could be used to compare the 
results for compounds (±)-10, (±)-51, (±)-57 and (±)-66. The first standard experiment 
contained only substrate and 20S proteasome, this gives us data to represent the normal 
enzyme activity without the presence of an inhibitor. The second standard was run with 
only the substrate to give a baseline reading. Compounds (±)-10, (±)-51, (±)-57 and (±)-
66 (500 μM) were then screened for inhibition of the 20S proteasome chymotrypsin 
activity, compared to 1 μM of omuralide. 
 
	
Figure 16. A graph of proteasome activity over time with no inhibitor and with 
omuralide. 
 
Figure 16 shows the standard curve obtained from the substrate with no inhibitor 
present (the purple line). Fluorescence increases over time; the substrate binds and is 
being turned over by the enzyme and the fluorescent tag is being released. Deviation 
from linearity occurs after time due to substrate depletion. 
 
In the case of omuralide (Figure 16, the green line), we can see that after about 1000 s 
the line starts to level off; the inhibitor is binding to the enzyme in the place of the 
substrate and so the fluorescent tag is not being released and no further increase in 
fluorescence is observed. Under these assay conditions the initial percentage inhibition 
can be calculated from the line gradients; the initial percentage inhibition for omuralide 
against the chymotrypsin-like activity of the 20S proteasome was calculated to be 47%. 
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Figure 17. A graph of proteasome activity over time in the presence of different 
inhibitors, compounds (±)-10, (±)-51, (±)-57, (±)-66 and omuralide. 
 
Figure 17 shows the results of screening for compounds (±)-10, (±)-51, (±)-57 and (±)-
66 against that of the standard substrate curve and that obtained for the known inhibitor 
omuralide. The curves obtained show similar linearity to that of the substrate standard 
(again with deviation from linearity due to substrate depletion) thereby indicating that 
they are not inhibiting the chymotrypsin-like activity in the 20S proteasome. The curve 
obtained for omuralide is exactly as expected from a time-dependent covalent inhibitor; 
the initial rate is similar to that where no inhibitor is present as the first step is reversible 
however after time it covalently binds to the proteasome and the curve levels off. The 
percentage activity was calculated for each compound (Table 6). 
 
Also evident from this graph is that the initial RFU values for some of the compounds 
being tested is higher than that of the substrate only standard; this is due to the 
compounds themselves fluorescing, this will have no effect on the gradient and so does 
not affect the results obtained. 
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Table 6. Calcualted activites for compounds tested against the chymotrypsin activity of 
the 20S proteasome. 
Inhibitor % Activity Time-Dependent 
None 100 - 
Omuralide 47 ± 2 Yes 
(±)-10 113 ± 2 - 
(±)-51 109 ± 1 - 
(±)-57 106 ± 1 - 
(±)-66 105 ± 2 - 
 
4.3.3 Conclusion and Future Work 
 
Compounds (±)-10, (±)-51, (±)-57 and (±)-66 do not appear to inhibit the chymotrypsin-
like activity of the 20S proteasome as in the case of omuralide. There are many factors 
to consider in what makes a compound a successful inhibitor; the functional groups 
present and the overall size of the compound are both important. The protecting group 
(PMB) present on all the compounds tested is likely to cause the lack of activity, this 
group makes the compounds much larger than the natural product and so they may not 
fit into the active site of the enzyme. It is also possible that the functional groups 
present in compounds (±)-10, (±)-51, (±)-57 and (±)-66 are not optimal for inhibition. 
 
Compound (±)-66 is the most interesting of those tested as it has the lactone motif, 
albeit at the C6-7 position rather than the C5-6 position, found in omuralide. It is 
expected that this would act chemically in the most similar way to the natural product. 
 
Future work should include the deprotection and re-screening of the compounds against 
the chymotrypsin-like activity. To achieve a full set of data the deprotected compounds 
should be screened against the trypsin- and caspase-like activity in the 20S proteasome. 
It is possible for a compound to inhibit one type of activity and not another. 
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4.3.4 Experimental 
 
The proteasome assays were carried out, following the manufacturer’s instructions, 
using the VIVAdetect™ 20S Proteasome Assay Kit PLUS. The kit contained 10x 
VIVAdetect™ proteasome assay buffer, 20S proteasome, Suc-LLVY-AMC 
(chymotrypsin-like substrate), VIVAdetect™ 96 well assay plate and VIVAdetect™ 
AMC standard. Each experiment was performed in duplicate at 25 °C. 
 
AMC standard experiment: AMC standard was diluted with the provided VIVAdetect™ 
proteasome assay buffer to give a final assay concentration of 1.6 μM. 
 
Substrate control experiment: The substrate Suc-LLVY-AMC (chymotrypsin-like 
substrate) was diluted with the provided VIVAdetect™ proteasome assay buffer and 
DMSO to give a final assay concentration of 100 μM. 
 
Substrate plus 20S proteasome control experiment: The substrate Suc-LLVY-AMC 
(chymotrypsin-like substrate) and the 20S proteasome were diluted with the provided 
VIVAdetect™ proteasome assay buffer and DMSO to give a final assay concentration 
of substrate of 100 μM and 20S proteasome of 2.5 nM. 
 
Inhibitor testing experiments: Omuralide and compounds (±)-10, (±)-51, (±)-57 and (±)-
66 were individually tested for their ability to inhibit the 20S proteasome. For each 
experiment the substrate Suc-LLVY-AMC (chymotrypsin-like substrate) and the 20S 
proteasome were diluted with the provided VIVAdetect™ proteasome assay buffer and 
DMSO to give a final assay concentration of substrate of 100 μM and 20S proteasome 
of 2.5 nM. Omuralide was tested at a final assay concentration of 1 μM, and compounds 
(±)-10, (±)-51, (±)-57 and (±)-66 were tested at a final assay concentration of 500 μM. 
The buffer solution, the substrate and the compound being tested were all added 
together then incubated at 25 °C for 15 min before the addition of the 20S proteasome. 
 
The fluorescence (measured in relative fluorescence units) was measured using a BMG 
Labtech POLARstarOPTIMA microplate reader with filters for 340 nm excitation and 
480 nm emission. A continuous kinetic analysis was performed for 1 h. Analysis of the 
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results obtained was performed by plotting graphs of fluorescence (RFU) vs. time (s) 
using GraFit Version 5.0.10. 	
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